[2025-11-01 15:02:38,640] - ==================================================
[2025-11-01 15:02:38,653] - Medical GA Prompt Optimization Starting
[2025-11-01 15:02:38,653] - ==================================================
[2025-11-01 15:02:38,653] - budget: 5
[2025-11-01 15:02:38,653] - popsize: 2
[2025-11-01 15:02:38,653] - sel_mode: tour
[2025-11-01 15:02:38,653] - ga_mode: topk
[2025-11-01 15:02:38,653] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 15:02:38,653] - output_dir: ./medical_ga_outputs
[2025-11-01 15:02:38,653] - seed: 42
[2025-11-01 15:02:38,653] - Creating Medical Evaluator...
[2025-11-01 15:02:38,653] - Creating Medical GA Evoluter...
[2025-11-01 15:02:38,653] - ==================================================
[2025-11-01 15:02:38,653] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 15:02:38,653] - ==================================================
[2025-11-01 15:02:38,653] - Starting evolution process...
[2025-11-01 15:02:38,653] - Evaluating initial user_input 1/2
[2025-11-01 15:02:38,653] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:06:38,282] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:06:38,282] - Evaluating initial user_input 2/2
[2025-11-01 15:06:38,282] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:07:26,992] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:07:26,992] - Initialized population with 2 user_inputs
[2025-11-01 15:07:26,993] - step 2, pop 0
[2025-11-01 15:07:26,993] - evolution example:
[2025-11-01 15:07:26,993] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:07:26,993] - parents:
[2025-11-01 15:07:26,993] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:07:26,994] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:08:13,402] - original child prompt: **Enhanced Crossover**:
- **Disease terminology diversification**: Integrate related conditions like Renal Osteodystrophy with Mineral and Bone Disorder, and expand genetic aspects by including Adrenal Hypoplasia congenita along with Leydig cell hypoplasia.
- **Numerical value range expansion**: Include blood calcium levels (e.g., 8.5-10.2 mg/dL) and genetic mutation frequencies (e.g., mutations in the NR0B1 gene).
- **Clinical parameter variation**: Mention varying stages of Chronic Kidney Disease (stages 1-5) and include varying dosages of medications like calcitriol or phosphate binders depending on the stage.

**Strategic Semantic Mutation**:
- **数值扰动策略**:
  - Adjust physiological parameters like blood pressure in CKD patients (±10-20% from average values).
  - Expand age range impact on the disease expression in both pediatric and geriatric populations.
  - Vary laboratory indicators like parathyroid hormone levels in different severity stages of CKD.

- **疾病术语多样化**:
  - Use ICD codes to include synonyms like "Secondary Hyperparathyroidism" for complications in CKD.
  - Vary symptom combinations—include symptoms like bone pain and muscle weakness.
  - Introduce complications like cardiovascular diseases in CKD scenarios.

- **临床场景分化**:
  - Highlight differences in emergency vs. outpatient settings for acute hypercalcemia.
  - Differentiate initial vs. follow-up visits for monitoring genetic disorders.
  - Describe screening vs. confirmed diagnosis in the context of genetic testing for Leydig cell hypoplasia.

**Final Mutated Prompt**:
<prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
</prompt>

**Divergence Focus**:
- **血钙数值细微变化** (8.5 mg/dL → 10.2 mg/dL)
- **添加治疗细节** (不同阶段钙剂和磷结合剂的剂量调整)
- **扩展疾病关联** (慢性肾病→骨矿物质病变→甲状旁腺功能亢进)
- **基因筛查与个体化治疗** (NR0B1突变 → Leydig细胞发育不良的个体化干预)
[2025-11-01 15:08:13,402] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:08:13,402] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:09:04,805] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:09:04,806] - new score: 0.0
[2025-11-01 15:09:04,806] - step 2, pop 1
[2025-11-01 15:09:04,806] - evolution example:
[2025-11-01 15:09:04,806] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:09:04,807] - parents:
[2025-11-01 15:09:04,807] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:09:04,807] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:09:38,692] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What can be done for Mineral and Bone Disorder associated with Stage 4 Chronic Kidney Disease in a 68-year-old patient?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
回答应涵盖以下内容：在钙磷代谢失衡情况下，建议每日监测血钙水平（调整后应控制在8.4到9.5 mg/dL之间），血磷水平应调整至3.5到4.5 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。此外，建议每三个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。老年人治疗需特别考虑肾功能持续下降的风险。
</prompt>

**Divergence Focus**:
- **疾病术语多样化**: 从“Mineral and Bone Disorder in Chronic Kidney Disease”扩展到具体的“钙磷代谢失衡”和“Stage 4 Chronic Kidney Disease”。
- **数值扰动策略**: 血钙和血磷的目标范围进行了具体化和调整。
- **临床场景分化**: 特别强调了老年患者治疗的复杂性和需要定期监测的参数，如甲状旁腺激素水平。
- **年龄区间扩展**: 明确指出患者为68岁，关注老年人群体。
- **实验室指标变异**: 提供了具体的血钙和血磷监控数值，强调了定期检查的重要性。
- **并发症引入**: 提及了肾功能持续下降的风险，加深了治疗方案的考量深度。
[2025-11-01 15:09:38,693] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What can be done for Mineral and Bone Disorder associated with Stage 4 Chronic Kidney Disease in a 68-year-old patient?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
回答应涵盖以下内容：在钙磷代谢失衡情况下，建议每日监测血钙水平（调整后应控制在8.4到9.5 mg/dL之间），血磷水平应调整至3.5到4.5 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。此外，建议每三个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。老年人治疗需特别考虑肾功能持续下降的风险。
[2025-11-01 15:09:38,693] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What can be done for Mineral and Bone Disorder associated with Stage 4 Chronic Kidney Disease in a 68-year-old patient?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
回答应涵盖以下内容：在钙磷代谢失衡情况下，建议每日监测血钙水平（调整后应控制在8.4到9.5 mg/dL之间），血磷水平应调整至3.5到4.5 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。此外，建议每三个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。老年人治疗需特别考虑肾功能持续下降的风险。
[2025-11-01 15:10:30,046] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What can be done for Mineral and Bone Disorder associated with Stage 4 Chronic Kidney Disease in a 68-year-old patient?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
回答应涵盖以下内容：在钙磷代谢失衡情况下，建议每日监测血钙水平（调整后应控制在8.4到9.5 mg/dL之间），血磷水平应调整至3.5到4.5 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。此外，建议每三个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。老年人治疗需特别考虑肾功能持续下降的风险。
[2025-11-01 15:10:30,046] - new score: 0.0
[2025-11-01 15:10:30,061] - step 3, pop 0
[2025-11-01 15:10:30,061] - evolution example:
[2025-11-01 15:10:30,061] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What can be done for Mineral and Bone Disorder associated with Stage 4 Chronic Kidney Disease in a 68-year-old patient?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
回答应涵盖以下内容：在钙磷代谢失衡情况下，建议每日监测血钙水平（调整后应控制在8.4到9.5 mg/dL之间），血磷水平应调整至3.5到4.5 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。此外，建议每三个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。老年人治疗需特别考虑肾功能持续下降的风险。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What can be done for Mineral and Bone Disorder associated with Stage 4 Chronic Kidney Disease in a 68-year-old patient?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
回答应涵盖以下内容：在钙磷代谢失衡情况下，建议每日监测血钙水平（调整后应控制在8.4到9.5 mg/dL之间），血磷水平应调整至3.5到4.5 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。此外，建议每三个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。老年人治疗需特别考虑肾功能持续下降的风险。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:10:30,061] - parents:
[2025-11-01 15:10:30,061] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What can be done for Mineral and Bone Disorder associated with Stage 4 Chronic Kidney Disease in a 68-year-old patient?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
回答应涵盖以下内容：在钙磷代谢失衡情况下，建议每日监测血钙水平（调整后应控制在8.4到9.5 mg/dL之间），血磷水平应调整至3.5到4.5 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。此外，建议每三个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。老年人治疗需特别考虑肾功能持续下降的风险。
[2025-11-01 15:10:30,061] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:11:16,545] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What are the recommended treatment protocols for managing Mineral and Bone Disorder in conjunction with Renal Osteodystrophy across various stages of Chronic Kidney Disease, particularly considering genetic factors such as NR0B1 mutations that may affect Adrenal Hypoplasia?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用调整后的钙剂和磷结合剂剂量（如钙400mg/日至1600mg/日，磷结合剂0.7g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于与NR0B1基因突变相关的肾上腺发育不良和Leydig细胞发育不良，应进行基因筛查并根据患者年龄和具体病情调整治疗方案，特别是在老年人中考虑肾功能持续下降的风险。此外，对于钙磷代谢失衡，推荐每日监测血钙水平（调整后应控制在8.2到10.0 mg/dL之间），血磷水平应调整至3.4到4.6 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。建议每两个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。  
回答应控制在200字以内。
</prompt>
[2025-11-01 15:11:16,545] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What are the recommended treatment protocols for managing Mineral and Bone Disorder in conjunction with Renal Osteodystrophy across various stages of Chronic Kidney Disease, particularly considering genetic factors such as NR0B1 mutations that may affect Adrenal Hypoplasia?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用调整后的钙剂和磷结合剂剂量（如钙400mg/日至1600mg/日，磷结合剂0.7g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于与NR0B1基因突变相关的肾上腺发育不良和Leydig细胞发育不良，应进行基因筛查并根据患者年龄和具体病情调整治疗方案，特别是在老年人中考虑肾功能持续下降的风险。此外，对于钙磷代谢失衡，推荐每日监测血钙水平（调整后应控制在8.2到10.0 mg/dL之间），血磷水平应调整至3.4到4.6 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。建议每两个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。  
回答应控制在200字以内。
[2025-11-01 15:11:16,545] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What are the recommended treatment protocols for managing Mineral and Bone Disorder in conjunction with Renal Osteodystrophy across various stages of Chronic Kidney Disease, particularly considering genetic factors such as NR0B1 mutations that may affect Adrenal Hypoplasia?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用调整后的钙剂和磷结合剂剂量（如钙400mg/日至1600mg/日，磷结合剂0.7g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于与NR0B1基因突变相关的肾上腺发育不良和Leydig细胞发育不良，应进行基因筛查并根据患者年龄和具体病情调整治疗方案，特别是在老年人中考虑肾功能持续下降的风险。此外，对于钙磷代谢失衡，推荐每日监测血钙水平（调整后应控制在8.2到10.0 mg/dL之间），血磷水平应调整至3.4到4.6 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。建议每两个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。  
回答应控制在200字以内。
[2025-11-01 15:12:06,455] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What are the recommended treatment protocols for managing Mineral and Bone Disorder in conjunction with Renal Osteodystrophy across various stages of Chronic Kidney Disease, particularly considering genetic factors such as NR0B1 mutations that may affect Adrenal Hypoplasia?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用调整后的钙剂和磷结合剂剂量（如钙400mg/日至1600mg/日，磷结合剂0.7g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于与NR0B1基因突变相关的肾上腺发育不良和Leydig细胞发育不良，应进行基因筛查并根据患者年龄和具体病情调整治疗方案，特别是在老年人中考虑肾功能持续下降的风险。此外，对于钙磷代谢失衡，推荐每日监测血钙水平（调整后应控制在8.2到10.0 mg/dL之间），血磷水平应调整至3.4到4.6 mg/dL。推荐使用磷酸盐结合剂以控制血磷，并定期使用维生素D补充剂以优化骨骼健康。建议每两个月检查一次甲状旁腺激素水平，并根据结果调整治疗方案。  
回答应控制在200字以内。
[2025-11-01 15:12:06,455] - new score: 0.0
[2025-11-01 15:12:06,455] - step 3, pop 1
[2025-11-01 15:12:06,456] - evolution example:
[2025-11-01 15:12:06,456] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:12:06,456] - parents:
[2025-11-01 15:12:06,456] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:12:06,456] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:12:32,253] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
</prompt>

**Divergence Focus**:
- **数值扰动策略**: 钙剂和磷结合剂的剂量调整（500mg/日至1500mg/日 → 400mg/日至1600mg/日），血钙水平监控范围调整（8.5-10.2 mg/dL → 8.2-10.5 mg/dL）
- **疾病术语多样化**: 未明显改变，但通过扩大数值范围加强了疾病管理的个体化
- **临床场景分化**: 增强了针对不同阶段慢性肾病的介入措施的细节描述，强调了随着病情进展，治疗方案的调整需求
[2025-11-01 15:12:32,254] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:12:32,254] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:13:20,183] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:13:20,183] - new score: 0.0
[2025-11-01 15:13:20,184] - step 4, pop 0
[2025-11-01 15:13:20,184] - evolution example:
[2025-11-01 15:13:20,184] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:13:20,184] - parents:
[2025-11-01 15:13:20,184] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:13:20,184] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:13:49,908] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Bone Mineral Disorder in various stages of Chronic Kidney Disease, and how do genetic variations in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1650mg/日，磷结合剂0.72g/日至3.5g/日），同时监控血钙水平（7.9-11.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案，包括儿童到成人的范围。回答应控制在200字以内。
</prompt>

**Divergence Focus**:
- 扩展疾病术语 (Renal Osteodystrophy → Bone Mineral Disorder)
- 数值范围扩展 (钙剂和磷结合剂剂量, 血钙水平)
- 引入年龄多样性 (儿童到成人)
- 临床参数变异 (监控指标的范围变化)
[2025-11-01 15:13:49,909] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Bone Mineral Disorder in various stages of Chronic Kidney Disease, and how do genetic variations in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1650mg/日，磷结合剂0.72g/日至3.5g/日），同时监控血钙水平（7.9-11.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案，包括儿童到成人的范围。回答应控制在200字以内。
[2025-11-01 15:13:49,909] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Bone Mineral Disorder in various stages of Chronic Kidney Disease, and how do genetic variations in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1650mg/日，磷结合剂0.72g/日至3.5g/日），同时监控血钙水平（7.9-11.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案，包括儿童到成人的范围。回答应控制在200字以内。
[2025-11-01 15:14:41,477] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Bone Mineral Disorder in various stages of Chronic Kidney Disease, and how do genetic variations in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），建议使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1650mg/日，磷结合剂0.72g/日至3.5g/日），同时监控血钙水平（7.9-11.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案，包括儿童到成人的范围。回答应控制在200字以内。
[2025-11-01 15:14:41,478] - new score: 0.0
[2025-11-01 15:14:41,478] - step 4, pop 1
[2025-11-01 15:14:41,478] - evolution example:
[2025-11-01 15:14:41,478] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:14:41,479] - parents:
[2025-11-01 15:14:41,479] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:14:41,479] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙500mg/日至1500mg/日，磷结合剂0.8g/日至3.2g/日），同时监控血钙水平（8.5-10.2 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:15:15,570] - original child prompt: <prompt>你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1550mg/日，磷结合剂0.85g/日至3.4g/日），同时监控血钙水平（8.3-10.4 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。此外，引入钙代谢调节剂如维生素D衍生物，以及对于高龄患者考虑合并心血管风险评估。回答应控制在200字以内。</prompt>

**Divergence Focus**:
- **Disease terminology diversification**: Introduced related terms like "钙代谢调节剂" (calcium metabolism regulators) and expanded clinical considerations to cardiovascular risk for elderly patients.
- **Numerical value range expansion**: Adjusted dosage ranges for calcium (450-1550mg/day) and phosphate binders (0.85-3.4g/day), and lab values for blood calcium (8.3-10.4 mg/dL).
- **Clinical parameter variation**: Added consideration of vitamin D derivatives, emphasizing personalized treatment adjustments, including the assessment of cardiovascular risks in older patients.
[2025-11-01 15:15:15,571] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1550mg/日，磷结合剂0.85g/日至3.4g/日），同时监控血钙水平（8.3-10.4 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。此外，引入钙代谢调节剂如维生素D衍生物，以及对于高龄患者考虑合并心血管风险评估。回答应控制在200字以内。
[2025-11-01 15:15:15,571] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1550mg/日，磷结合剂0.85g/日至3.4g/日），同时监控血钙水平（8.3-10.4 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。此外，引入钙代谢调节剂如维生素D衍生物，以及对于高龄患者考虑合并心血管风险评估。回答应控制在200字以内。
[2025-11-01 15:16:04,216] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙450mg/日至1550mg/日，磷结合剂0.85g/日至3.4g/日），同时监控血钙水平（8.3-10.4 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。此外，引入钙代谢调节剂如维生素D衍生物，以及对于高龄患者考虑合并心血管风险评估。回答应控制在200字以内。
[2025-11-01 15:16:04,217] - new score: 0.0
[2025-11-01 15:16:04,245] - ----------testing step 4 population----------
[2025-11-01 15:16:04,245] - ----------step 4 best score: 0.0, best prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。----------
[2025-11-01 15:16:04,245] - best_scores: 0.0,0.0,0.0
[2025-11-01 15:16:04,245] - avg_scores: 0.0,0.0,0.0
[2025-11-01 15:16:04,245] - ==================================================
[2025-11-01 15:16:04,245] - Medical GA Optimization Completed!
[2025-11-01 15:16:04,245] - ==================================================
[2025-11-01 15:16:04,245] - Best Score: 0.0
[2025-11-01 15:16:04,245] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。问题类别：frequency 用户问题：What interventions are recommended for managing Renal Osteodystrophy and Mineral and Bone Disorder in various stages of Chronic Kidney Disease, and how do genetic changes in NR0B1 gene relate to Adrenal Hypoplasia and Leydig cell hypoplasia? 请基于医学常识与临床实践经验给出直接、重点突出的回答。在慢性肾病不同阶段（1-5期），推荐使用不同剂量的钙剂和磷结合剂（如钙400mg/日至1600mg/日，磷结合剂0.9g/日至3.5g/日），同时监控血钙水平（8.2-10.5 mg/dL）和甲状旁腺激素水平的变化。对于Leydig细胞发育不良及相关的遗传改变，建议基因筛查NR0B1突变频率，并结合患者年龄和病情制定个体化治疗方案。回答应控制在200字以内。
[2025-11-01 15:16:04,245] - Best result saved to: ./medical_ga_outputs/best_result.txt
[2025-11-01 15:28:57,652] - ==================================================
[2025-11-01 15:28:57,652] - Medical GA Prompt Optimization Starting
[2025-11-01 15:28:57,652] - ==================================================
[2025-11-01 15:28:57,652] - budget: 5
[2025-11-01 15:28:57,652] - popsize: 2
[2025-11-01 15:28:57,652] - sel_mode: tour
[2025-11-01 15:28:57,652] - ga_mode: topk
[2025-11-01 15:28:57,652] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 15:28:57,652] - output_dir: ./medical_ga_outputs
[2025-11-01 15:28:57,652] - seed: 42
[2025-11-01 15:28:57,652] - Creating Medical Evaluator...
[2025-11-01 15:28:57,652] - Creating Medical GA Evoluter...
[2025-11-01 15:28:57,652] - ==================================================
[2025-11-01 15:28:57,652] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 15:28:57,652] - ==================================================
[2025-11-01 15:28:57,652] - Starting evolution process...
[2025-11-01 15:28:57,653] - Evaluating initial user_input 1/2
[2025-11-01 15:28:57,653] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:29:43,471] - ==================================================
[2025-11-01 15:29:43,471] - Medical GA Prompt Optimization Starting
[2025-11-01 15:29:43,471] - ==================================================
[2025-11-01 15:29:43,471] - budget: 5
[2025-11-01 15:29:43,471] - popsize: 2
[2025-11-01 15:29:43,471] - sel_mode: tour
[2025-11-01 15:29:43,471] - ga_mode: topk
[2025-11-01 15:29:43,471] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 15:29:43,471] - output_dir: ./medical_ga_outputs
[2025-11-01 15:29:43,471] - seed: 42
[2025-11-01 15:29:43,471] - Creating Medical Evaluator...
[2025-11-01 15:29:43,471] - Creating Medical GA Evoluter...
[2025-11-01 15:29:43,471] - ==================================================
[2025-11-01 15:29:43,472] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 15:29:43,472] - ==================================================
[2025-11-01 15:29:43,472] - Starting evolution process...
[2025-11-01 15:29:43,472] - Evaluating initial user_input 1/2
[2025-11-01 15:29:43,472] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:35:12,994] - Difference score: 0.9666568440344125
[2025-11-01 15:35:12,994] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Mineral and Bone Disorder in Chronic Kidney Disease is a common complica...
[2025-11-01 15:35:12,994] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:35:12,994] - Evaluating initial user_input 2/2
[2025-11-01 15:35:12,994] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:36:46,436] - Difference score: 0.7077364216011235
[2025-11-01 15:36:46,436] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Leydig cell hypoplasia is a rare disorder characterized by the absence o...
[2025-11-01 15:36:46,436] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:36:46,436] - Initialized population with 2 user_inputs
[2025-11-01 15:36:46,436] - step 2, pop 0
[2025-11-01 15:36:46,436] - evolution example:
[2025-11-01 15:36:46,436] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:36:46,436] - parents:
[2025-11-01 15:36:46,436] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:36:46,436] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:37:21,716] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议监测血钙水平（通常范围8.5-10.2 mg/dL，可能波动至7.9-10.5 mg/dL）和磷水平（正常范围2.5-4.5 mg/dL，病情加重时可达2.2-5.0 mg/dL）。年轻患者（20-40岁）可能需更频繁的监测。应考虑使用磷结合剂和维生素D补充剂，剂量根据病情严重程度调整，每日剂量可能从起始的5微克到维持15微克不等。并发症如高血压和糖尿病应得到适当管理。对于儿童和青少年患者，监测生长发育指标，并根据需要调整治疗方案。
</prompt>

**Divergence Focus**:
- **疾病术语多样化**: 使用"Renal Osteodystrophy"替换原有病名以增强专业性
- **数值扰动策略**: 血钙和磷水平的正常及病态范围扩展，体现不同严重程度的数值表现
- **临床场景分化**: 特别指出年轻患者的监测频率和剂量调整，以及儿童和青少年的特殊管理，强调不同年龄段的治疗原则和监测重点
- **并发症引入**: 高血压和糖尿病作为CKD的常见并发症，增加其在治疗计划中的考虑
[2025-11-01 15:37:21,716] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议监测血钙水平（通常范围8.5-10.2 mg/dL，可能波动至7.9-10.5 mg/dL）和磷水平（正常范围2.5-4.5 mg/dL，病情加重时可达2.2-5.0 mg/dL）。年轻患者（20-40岁）可能需更频繁的监测。应考虑使用磷结合剂和维生素D补充剂，剂量根据病情严重程度调整，每日剂量可能从起始的5微克到维持15微克不等。并发症如高血压和糖尿病应得到适当管理。对于儿童和青少年患者，监测生长发育指标，并根据需要调整治疗方案。
[2025-11-01 15:37:21,716] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议监测血钙水平（通常范围8.5-10.2 mg/dL，可能波动至7.9-10.5 mg/dL）和磷水平（正常范围2.5-4.5 mg/dL，病情加重时可达2.2-5.0 mg/dL）。年轻患者（20-40岁）可能需更频繁的监测。应考虑使用磷结合剂和维生素D补充剂，剂量根据病情严重程度调整，每日剂量可能从起始的5微克到维持15微克不等。并发症如高血压和糖尿病应得到适当管理。对于儿童和青少年患者，监测生长发育指标，并根据需要调整治疗方案。
[2025-11-01 15:39:03,046] - Difference score: 0.8685480636117688
[2025-11-01 15:39:03,046] - Response1: 在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议监测血钙水平（通常范围8.5-10.2 mg/dL，可...
[2025-11-01 15:39:03,046] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:39:03,047] - new score: 0.8685
[2025-11-01 15:39:03,047] - step 2, pop 1
[2025-11-01 15:39:03,047] - evolution example:
[2025-11-01 15:39:03,047] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:39:03,047] - parents:
[2025-11-01 15:39:03,047] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:39:03,047] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 15:39:23,159] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
</prompt>

**Divergence Focus**:
- 疾病术语扩展 (Chronic Kidney Disease → Renal Osteodystrophy)
- 数值扰动策略 (血钙、磷水平和PTH数值调整)
- 年龄和治疗剂量的具体化 (添加年龄相关剂量建议)
- 引入治疗监测和评估细节 (骨密度评估, 肾脏病专家合作)
[2025-11-01 15:39:23,160] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
[2025-11-01 15:39:23,160] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
[2025-11-01 15:40:46,526] - Difference score: 0.9793201492494388
[2025-11-01 15:40:46,527] - Response1: [2025-11-01 15:39:54,290] [INFO] [launch.py:367:main] Process 2717596 exits successfully.
[2025-11-0...
[2025-11-01 15:40:46,527] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:40:46,527] - new score: 0.9793
[2025-11-01 15:40:46,528] - step 3, pop 0
[2025-11-01 15:40:46,528] - evolution example:
[2025-11-01 15:40:46,528] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:40:46,529] - parents:
[2025-11-01 15:40:46,529] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
[2025-11-01 15:40:46,529] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
[2025-11-01 15:41:18,128] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
</prompt>

**Divergence Focus**:
- **数值扰动策略**: 血钙和磷水平的范围扩大，PTH水平稍有变化，剂量调整以适应不同年龄段。
- **疾病术语多样化**: 引入钾的控制，钙磷产品的监控，添加抗骨吸收药物和钙通道阻滞剂的治疗选项。
- **临床场景分化**: 提出在不同年龄段和临床情况下的个体化治疗方案，强调与肾脏病专家的合作。
[2025-11-01 15:41:18,128] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
[2025-11-01 15:41:18,129] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
[2025-11-01 15:43:10,832] - Difference score: 0.9793333719629359
[2025-11-01 15:43:10,833] - Response1: [2025-11-01 15:41:49,438] [INFO] [launch.py:367:main] Process 2720268 exits successfully.
[2025-11-0...
[2025-11-01 15:43:10,833] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:43:10,833] - new score: 0.9793
[2025-11-01 15:43:10,833] - step 3, pop 1
[2025-11-01 15:43:10,833] - evolution example:
[2025-11-01 15:43:10,833] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:43:10,833] - parents:
[2025-11-01 15:43:10,833] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
[2025-11-01 15:43:10,833] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（9.0-9.5 mg/dL）和磷水平（3.5-4.5 mg/dL），调整饮食以控制磷摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄和肾功能状态调整，如成年患者每餐500mg。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-300 pg/mL，调整活性维生素D的使用。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中。
[2025-11-01 15:43:42,978] - original child prompt: <prompt>
在处理慢性肾脏病（Chronic Kidney Disease, CKD）引发的矿物质和骨骼代谢异常（Metabolic Bone Disease in CKD）时，建议采取以下综合措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.0-4.8 mg/dL），适当调整饮食以限制磷的摄入，并考虑患者年龄和性别的影响。
2. 根据患者的肾功能和骨密度情况，使用磷结合剂，如羟基磷灰石（每餐600mg），或者在必要时使用其他类型的磷结合剂。
3. 定期监测PTH（副甲状腺激素）水平，尝试维持在140-320 pg/mL之间，同时根据患者具体情况调整活性维生素D剂量。
4. 特别关注有骨痛症状或高风险骨折的患者，进行详细的骨密度评估，并基于评估结果调整治疗方案。
5. 紧密与肾病专家合作，针对老年人和具有其他并发症的患者，定期进行治疗效果和潜在并发症的评估。

以上建议综合了不同年龄段和病情严重程度的患者需求，强调了在治疗过程中对生理参数的细致调整和个体化处理的重要性。
</prompt>

Divergence Focus:
- 血钙和磷水平的数值范围被扩大 (9.0-9.5 mg/dL → 8.5-10.0 mg/dL for calcium; 3.5-4.5 mg/dL → 3.0-4.8 mg/dL for phosphorus)
- 疾病术语从"矿物质和骨骼疾病"变异为"矿物质和骨骼代谢异常"
- 引入更多类型的磷结合剂和对剂量的调整 (碳酸钙或碳酸镧 → 羟基磷灰石)
- PTH水平的正常范围调整并且提供了更广的治疗调整空间 (150-300 pg/mL → 140-320 pg/mL)
- 针对特定患者群体（如老年人和有并发症的患者）的治疗方案做了更详细的描述和调整。
[2025-11-01 15:43:42,979] - child prompt: 在处理慢性肾脏病（Chronic Kidney Disease, CKD）引发的矿物质和骨骼代谢异常（Metabolic Bone Disease in CKD）时，建议采取以下综合措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.0-4.8 mg/dL），适当调整饮食以限制磷的摄入，并考虑患者年龄和性别的影响。
2. 根据患者的肾功能和骨密度情况，使用磷结合剂，如羟基磷灰石（每餐600mg），或者在必要时使用其他类型的磷结合剂。
3. 定期监测PTH（副甲状腺激素）水平，尝试维持在140-320 pg/mL之间，同时根据患者具体情况调整活性维生素D剂量。
4. 特别关注有骨痛症状或高风险骨折的患者，进行详细的骨密度评估，并基于评估结果调整治疗方案。
5. 紧密与肾病专家合作，针对老年人和具有其他并发症的患者，定期进行治疗效果和潜在并发症的评估。

以上建议综合了不同年龄段和病情严重程度的患者需求，强调了在治疗过程中对生理参数的细致调整和个体化处理的重要性。
[2025-11-01 15:43:42,979] - Evaluating user_input: 在处理慢性肾脏病（Chronic Kidney Disease, CKD）引发的矿物质和骨骼代谢异常（Metabolic Bone Disease in CKD）时，建议采取以下综合措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.0-4.8 mg/dL），适当调整饮食以限制磷的摄入，并考虑患者年龄和性别的影响。
2. 根据患者的肾功能和骨密度情况，使用磷结合剂，如羟基磷灰石（每餐600mg），或者在必要时使用其他类型的磷结合剂。
3. 定期监测PTH（副甲状腺激素）水平，尝试维持在140-320 pg/mL之间，同时根据患者具体情况调整活性维生素D剂量。
4. 特别关注有骨痛症状或高风险骨折的患者，进行详细的骨密度评估，并基于评估结果调整治疗方案。
5. 紧密与肾病专家合作，针对老年人和具有其他并发症的患者，定期进行治疗效果和潜在并发症的评估。

以上建议综合了不同年龄段和病情严重程度的患者需求，强调了在治疗过程中对生理参数的细致调整和个体化处理的重要性。
[2025-11-01 15:45:57,107] - Difference score: 0.7031978047115465
[2025-11-01 15:45:57,107] - Response1: 同时，建议在治疗过程中密切关注患者的骨骼健康状况，避免过度治疗或不当治疗，确保患者获得最优质的护理服务。

```python
# Define variables
patient_age = 65 ...
[2025-11-01 15:45:57,107] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:45:57,107] - new score: 0.7032
[2025-11-01 15:45:57,128] - step 4, pop 0
[2025-11-01 15:45:57,128] - evolution example:
[2025-11-01 15:45:57,128] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:45:57,128] - parents:
[2025-11-01 15:45:57,128] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
[2025-11-01 15:45:57,128] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
[2025-11-01 15:46:29,551] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.2-10.4 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐180mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-350 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物和其他药物干预。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制，并关注心血管健康。
</prompt>

**Divergence Focus**:
- **数值扰动策略**: 血钙和磷水平的数值调整（8.5-10.0 mg/dL → 8.2-10.4 mg/dL; 3.2-4.8 mg/dL → 3.0-5.0 mg/dL），剂量调整（儿童每餐200mg → 180mg, 成人每餐600mg → 650mg），PTH水平（140-320 pg/mL → 150-350 pg/mL）
- **疾病术语多样化**: 引入“其他药物干预”和“心血管健康”的概念，扩展治疗计划和并发症的关注点
- **临床场景分化**: 特别强调老年患者中的心血管健康监控，以及复杂的药物管理策略
[2025-11-01 15:46:29,551] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.2-10.4 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐180mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-350 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物和其他药物干预。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制，并关注心血管健康。
[2025-11-01 15:46:29,551] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.2-10.4 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐180mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-350 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物和其他药物干预。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制，并关注心血管健康。
[2025-11-01 15:48:20,410] - Difference score: 0.9794902720808891
[2025-11-01 15:48:20,410] - Response1: [2025-11-01 15:46:58,507] [INFO] [launch.py:367:main] Process 2726209 exits successfully.
[2025-11-0...
[2025-11-01 15:48:20,410] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:48:20,410] - new score: 0.9795
[2025-11-01 15:48:20,411] - step 4, pop 1
[2025-11-01 15:48:20,411] - evolution example:
[2025-11-01 15:48:20,411] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 15:48:20,411] - parents:
[2025-11-01 15:48:20,411] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
[2025-11-01 15:48:20,411] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.5-10.0 mg/dL）和磷水平（3.2-4.8 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐200mg, 成人每餐600mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在140-320 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制。
[2025-11-01 15:48:52,356] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾功能衰竭（Chronic Renal Failure, CRF）相关的矿物质代谢异常和骨病变（Metabolic Bone Disease in Renal Failure）时，建议采取以下措施：
1. 监测血钙（8.0-10.5 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以减少磷的摄入，并注意钾的摄入限制。
2. 使用磷结合剂如碳酸钙或羟基磷灰石，剂量视患者年龄（青少年每餐150mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在130-350 pg/mL，调整活性维生素D的使用，并监控钙磷比例。
4. 对于有骨痛或骨质疏松风险的患者，建议进行骨密度评估，并根据结果调整治疗方案，可能包括使用双磷酸盐类药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在中老年患者中，采用ACE抑制剂或ARBs优化血压控制。

</prompt>

Divergence Focus:
- **Disease Terminology Diversification**: 从“慢性肾病”变为“慢性肾功能衰竭”，“矿物质和骨骼疾病”变为“矿物质代谢异常和骨病变”。
- **Numerical Value Range Expansion**: 血钙监测值从8.5-10.0 mg/dL变为8.0-10.5 mg/dL，磷水平监测范围从3.2-4.8 mg/dL扩展到3.0-5.0 mg/dL，PTH范围调整从140-320 pg/mL到130-350 pg/mL。
- **Clinical Parameter Variation**: 磷结合剂剂量调整，儿童剂量从每餐200mg降至150mg，成人剂量从每餐600mg增至650mg；药物治疗从抗骨吸收药物变更为使用双磷酸盐类药物；血压控制从添加钙通道阻滞剂变为使用ACE抑制剂或ARBs。
[2025-11-01 15:48:52,356] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾功能衰竭（Chronic Renal Failure, CRF）相关的矿物质代谢异常和骨病变（Metabolic Bone Disease in Renal Failure）时，建议采取以下措施：
1. 监测血钙（8.0-10.5 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以减少磷的摄入，并注意钾的摄入限制。
2. 使用磷结合剂如碳酸钙或羟基磷灰石，剂量视患者年龄（青少年每餐150mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在130-350 pg/mL，调整活性维生素D的使用，并监控钙磷比例。
4. 对于有骨痛或骨质疏松风险的患者，建议进行骨密度评估，并根据结果调整治疗方案，可能包括使用双磷酸盐类药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在中老年患者中，采用ACE抑制剂或ARBs优化血压控制。
[2025-11-01 15:48:52,357] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾功能衰竭（Chronic Renal Failure, CRF）相关的矿物质代谢异常和骨病变（Metabolic Bone Disease in Renal Failure）时，建议采取以下措施：
1. 监测血钙（8.0-10.5 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以减少磷的摄入，并注意钾的摄入限制。
2. 使用磷结合剂如碳酸钙或羟基磷灰石，剂量视患者年龄（青少年每餐150mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在130-350 pg/mL，调整活性维生素D的使用，并监控钙磷比例。
4. 对于有骨痛或骨质疏松风险的患者，建议进行骨密度评估，并根据结果调整治疗方案，可能包括使用双磷酸盐类药物。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在中老年患者中，采用ACE抑制剂或ARBs优化血压控制。
[2025-11-01 15:50:44,944] - Difference score: 0.9786887866205518
[2025-11-01 15:50:44,944] - Response1: [2025-11-01 15:49:21,168] [INFO] [launch.py:367:main] Process 2729255 exits successfully.
[2025-11-0...
[2025-11-01 15:50:44,944] - Response2: 肚子疼的原因有哪些？
　　1. The stomach is a hollow organ, which is located in the upper abdomen, and is the mai...
[2025-11-01 15:50:44,944] - new score: 0.9787
[2025-11-01 15:50:44,954] - ----------testing step 4 population----------
[2025-11-01 15:50:44,954] - ----------step 4 best score: 0.9794902720808891, best prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.2-10.4 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐180mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-350 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物和其他药物干预。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制，并关注心血管健康。----------
[2025-11-01 15:50:44,954] - best_scores: 0.9793201492494388,0.9793333719629359,0.9794902720808891
[2025-11-01 15:50:44,954] - avg_scores: 0.973,0.9793,0.9794
[2025-11-01 15:50:44,955] - ==================================================
[2025-11-01 15:50:44,955] - Medical GA Optimization Completed!
[2025-11-01 15:50:44,955] - ==================================================
[2025-11-01 15:50:44,955] - Best Score: 0.9794902720808891
[2025-11-01 15:50:44,955] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在处理慢性肾病（Chronic Kidney Disease, CKD）相关的矿物质和骨骼疾病（Renal Osteodystrophy）时，建议采取以下措施：
1. 监测血钙（8.2-10.4 mg/dL）和磷水平（3.0-5.0 mg/dL），调整饮食以控制磷摄入，并考虑限制钾的摄入。
2. 使用磷结合剂如碳酸钙或碳酸镧，剂量视患者年龄（儿童每餐180mg, 成人每餐650mg）和肾功能状态调整。
3. 定期检查PTH（副甲状腺激素）水平，维持在150-350 pg/mL，调整活性维生素D的使用，并监控钙磷产品。
4. 对于有骨痛或骨折风险的患者，考虑进行骨密度评估，并根据结果调整治疗计划，可能包括抗骨吸收药物和其他药物干预。
5. 与肾脏病专家合作，定期评估治疗效果和潜在并发症，特别是在老年患者中，加入钙通道阻滞剂以优化血压控制，并关注心血管健康。
[2025-11-01 15:50:44,955] - Best result saved to: ./medical_ga_outputs/best_result.txt
[2025-11-01 16:08:34,447] - ==================================================
[2025-11-01 16:08:34,448] - Medical GA Prompt Optimization Starting
[2025-11-01 16:08:34,448] - ==================================================
[2025-11-01 16:08:34,448] - budget: 5
[2025-11-01 16:08:34,448] - popsize: 2
[2025-11-01 16:08:34,448] - sel_mode: tour
[2025-11-01 16:08:34,448] - ga_mode: topk
[2025-11-01 16:08:34,448] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 16:08:34,448] - output_dir: ./medical_ga_outputs
[2025-11-01 16:08:34,448] - seed: 42
[2025-11-01 16:08:34,448] - Creating Medical Evaluator...
[2025-11-01 16:08:34,448] - Creating Medical GA Evoluter...
[2025-11-01 16:08:34,448] - ==================================================
[2025-11-01 16:08:34,448] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 16:08:34,448] - ==================================================
[2025-11-01 16:08:34,448] - Starting evolution process...
[2025-11-01 16:08:34,448] - Evaluating initial user_input 1/2
[2025-11-01 16:08:34,449] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:09:35,202] - Difference score: 0.465948499776086
[2025-11-01 16:09:35,202] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Mineral and Bone Disorder in Chronic Kidney Disease is a common complica...
[2025-11-01 16:09:35,202] - Response2: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Mineral and Bone Disorder in Chronic Kidney Disease is a common complica...
[2025-11-01 16:09:35,202] - Evaluating initial user_input 2/2
[2025-11-01 16:09:35,202] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:10:51,764] - Difference score: 0.15546353545783773
[2025-11-01 16:10:51,764] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Leydig cell hypoplasia is a rare disorder characterized by the absence o...
[2025-11-01 16:10:51,765] - Response2: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Leydig cell hypoplasia is a rare disorder characterized by the absence o...
[2025-11-01 16:10:51,765] - Initialized population with 2 user_inputs
[2025-11-01 16:10:51,765] - step 2, pop 0
[2025-11-01 16:10:51,765] - evolution example:
[2025-11-01 16:10:51,765] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 16:10:51,765] - parents:
[2025-11-01 16:10:51,765] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:10:51,765] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:11:17,826] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在慢性肾脏病(Chronic Kidney Disease, CKD)相关的矿物质和骨骼紊乱（也称为肾性骨病或Renal Osteodystrophy）中，首先建议根据患者的年龄、病程阶段及伴随症状调整治疗策略。成人患者（例如，40-60岁）的血钙可能低于8.5 mg/dL，而儿童患者的血钙值可能低至7 mg/dL。建议调整饮食摄入，限制磷的摄入，并可能需使用钙补充剂和维生素D来调整钙磷平衡。对于血磷超过5.5 mg/dL的患者，可以考虑使用磷结合剂。此外，定期监测血清钙、磷和副甲状腺激素水平，根据这些指标调整用药剂量和治疗计划。在治疗过程中，监测肾功能的变化至关重要，以预防病情进一步恶化。
</prompt>

**Divergence Focus**:
- 引入年龄相关的数值变异（成人40-60岁血钙8.5 mg/dL，儿童血钙低至7 mg/dL）
- 详细化血磷数值和治疗措施（血磷超过5.5 mg/dL使用磷结合剂）
- 引入具体的监测和调整治疗策略（监测血清钙、磷和副甲状腺激素水平，调整用药剂量）
- 疾病术语的多样化和临床参数的细化（肾性骨病或Renal Osteodystrophy，补充维生素D调整钙磷平衡）
[2025-11-01 16:11:17,826] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在慢性肾脏病(Chronic Kidney Disease, CKD)相关的矿物质和骨骼紊乱（也称为肾性骨病或Renal Osteodystrophy）中，首先建议根据患者的年龄、病程阶段及伴随症状调整治疗策略。成人患者（例如，40-60岁）的血钙可能低于8.5 mg/dL，而儿童患者的血钙值可能低至7 mg/dL。建议调整饮食摄入，限制磷的摄入，并可能需使用钙补充剂和维生素D来调整钙磷平衡。对于血磷超过5.5 mg/dL的患者，可以考虑使用磷结合剂。此外，定期监测血清钙、磷和副甲状腺激素水平，根据这些指标调整用药剂量和治疗计划。在治疗过程中，监测肾功能的变化至关重要，以预防病情进一步恶化。
[2025-11-01 16:11:17,826] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在慢性肾脏病(Chronic Kidney Disease, CKD)相关的矿物质和骨骼紊乱（也称为肾性骨病或Renal Osteodystrophy）中，首先建议根据患者的年龄、病程阶段及伴随症状调整治疗策略。成人患者（例如，40-60岁）的血钙可能低于8.5 mg/dL，而儿童患者的血钙值可能低至7 mg/dL。建议调整饮食摄入，限制磷的摄入，并可能需使用钙补充剂和维生素D来调整钙磷平衡。对于血磷超过5.5 mg/dL的患者，可以考虑使用磷结合剂。此外，定期监测血清钙、磷和副甲状腺激素水平，根据这些指标调整用药剂量和治疗计划。在治疗过程中，监测肾功能的变化至关重要，以预防病情进一步恶化。
[2025-11-01 16:12:59,401] - Difference score: 0.12463235936487937
[2025-11-01 16:12:59,401] - Response1: 同时，建议患者保持良好的生活习惯，包括适当的运动和饮食，避免过度疲劳和压力，以促进骨骼健康。

在慢性肾脏病(Chronic Kidney Disease, CKD)相关的矿物质和骨骼紊乱（也称为肾性...
[2025-11-01 16:12:59,401] - Response2: 同时，建议患者保持良好的生活习惯，包括适当的运动和饮食，避免过度疲劳和压力，以促进骨骼健康。

在慢性肾脏病(Chronic Kidney Disease, CKD)相关的矿物质和骨骼紊乱（也称为肾性...
[2025-11-01 16:12:59,401] - new score: 0.1246
[2025-11-01 16:12:59,401] - step 2, pop 1
[2025-11-01 16:12:59,401] - evolution example:
[2025-11-01 16:12:59,401] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 16:12:59,401] - parents:
[2025-11-01 16:12:59,402] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:12:59,402] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:13:25,183] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

In managing Mineral and Bone Disorder (MBD) associated with Chronic Kidney Disease (CKD), it is crucial to consider a multifaceted approach:
1. **Monitoring and Adjustments**: Regular monitoring of serum calcium (Ca), phosphorus (P), and Parathyroid Hormone (PTH) levels is essential. For adults, aim to maintain Ca levels at 8.5-10.2 mg/dL, P levels at 2.5-4.5 mg/dL, and PTH levels typically between 150-300 pg/mL, adapting these targets based on the severity and stage of CKD.
2. **Dietary Management**: Adjust dietary intake to manage mineral levels, including reducing foods high in phosphorus and maintaining adequate calcium intake. In pediatric patients, ensure dietary adjustments are age-appropriate.
3. **Medication**: Use phosphate binders to control hyperphosphatemia, and calcitriol or vitamin D analogs to manage hypocalcemia. Dosage adjustments may be necessary based on ongoing lab results and patient response.
4. **Complication Awareness**: Be vigilant for complications such as vascular calcification and bone pain, adjusting treatment plans accordingly.
5. **Patient Education**: Educate patients about the importance of medication adherence and dietary restrictions to prevent fluctuations in disease parameters.

This approach should be tailored to individual patient needs, considering variations such as age (children vs. adults), severity of CKD, and presence of symptoms or complications.
</prompt>
[2025-11-01 16:13:25,183] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

In managing Mineral and Bone Disorder (MBD) associated with Chronic Kidney Disease (CKD), it is crucial to consider a multifaceted approach:
1. **Monitoring and Adjustments**: Regular monitoring of serum calcium (Ca), phosphorus (P), and Parathyroid Hormone (PTH) levels is essential. For adults, aim to maintain Ca levels at 8.5-10.2 mg/dL, P levels at 2.5-4.5 mg/dL, and PTH levels typically between 150-300 pg/mL, adapting these targets based on the severity and stage of CKD.
2. **Dietary Management**: Adjust dietary intake to manage mineral levels, including reducing foods high in phosphorus and maintaining adequate calcium intake. In pediatric patients, ensure dietary adjustments are age-appropriate.
3. **Medication**: Use phosphate binders to control hyperphosphatemia, and calcitriol or vitamin D analogs to manage hypocalcemia. Dosage adjustments may be necessary based on ongoing lab results and patient response.
4. **Complication Awareness**: Be vigilant for complications such as vascular calcification and bone pain, adjusting treatment plans accordingly.
5. **Patient Education**: Educate patients about the importance of medication adherence and dietary restrictions to prevent fluctuations in disease parameters.

This approach should be tailored to individual patient needs, considering variations such as age (children vs. adults), severity of CKD, and presence of symptoms or complications.
[2025-11-01 16:13:25,184] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

In managing Mineral and Bone Disorder (MBD) associated with Chronic Kidney Disease (CKD), it is crucial to consider a multifaceted approach:
1. **Monitoring and Adjustments**: Regular monitoring of serum calcium (Ca), phosphorus (P), and Parathyroid Hormone (PTH) levels is essential. For adults, aim to maintain Ca levels at 8.5-10.2 mg/dL, P levels at 2.5-4.5 mg/dL, and PTH levels typically between 150-300 pg/mL, adapting these targets based on the severity and stage of CKD.
2. **Dietary Management**: Adjust dietary intake to manage mineral levels, including reducing foods high in phosphorus and maintaining adequate calcium intake. In pediatric patients, ensure dietary adjustments are age-appropriate.
3. **Medication**: Use phosphate binders to control hyperphosphatemia, and calcitriol or vitamin D analogs to manage hypocalcemia. Dosage adjustments may be necessary based on ongoing lab results and patient response.
4. **Complication Awareness**: Be vigilant for complications such as vascular calcification and bone pain, adjusting treatment plans accordingly.
5. **Patient Education**: Educate patients about the importance of medication adherence and dietary restrictions to prevent fluctuations in disease parameters.

This approach should be tailored to individual patient needs, considering variations such as age (children vs. adults), severity of CKD, and presence of symptoms or complications.
[2025-11-01 16:14:14,115] - Difference score: 0.0
[2025-11-01 16:14:14,115] - Response1: [2025-11-01 16:13:54,013] [INFO] [launch.py:367:main] Process 2749130 exits successfully.
[2025-11-0...
[2025-11-01 16:14:14,115] - Response2: ...
[2025-11-01 16:14:14,115] - new score: 0.0
[2025-11-01 16:14:14,116] - step 3, pop 0
[2025-11-01 16:14:14,116] - evolution example:
[2025-11-01 16:14:14,116] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 16:14:14,116] - parents:
[2025-11-01 16:14:14,116] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:14:14,117] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:14:42,805] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  
</prompt>

**Enhanced Crossover with Disease-Numerical Divergence Focus**:
- **Disease Terminology Diversification**: Substitute "Mineral and Bone Disorder in Chronic Kidney Disease" with "Renal Osteodystrophy in Chronic Kidney Disease Stage 4".
- **Numerical Value Range Expansion**: Introduce specifics such as "patients aged between 60-70 years".
- **Clinical Parameter Variation**: Mention different treatment recommendations depending on the severity of the kidney disease.

**Strategic Semantic Mutation Emphasizing Parameter Variability**:
- **数值扰动策略**: Adjust the age range slightly (±10 years), indicating patients aged 50-80 years showing symptoms.
- **疾病术语多样化**: Expand the diagnosis term and introduce a symptom combination variant such as "secondary hyperparathyroidism".
- **临床场景分化**: Differentiate between initial diagnosis and follow-up treatment options, such as the introduction of specific phosphorus binders or calcium supplements based on serum calcium levels.

**Final Mutated Prompt with Explicit Clinical Value Differences**:
<prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
</prompt>

**Divergence Focus**:
- **Age Range and Symptom Combination**: Expanded the age range to 50-80 years and included secondary hyperparathyroidism as a specific symptom.
- **Treatment Recommendations Variation**: Introduced variability in treatment depending on the initial diagnosis vs. follow-up, tailored to serum calcium levels.
- **Disease Terminology Expansion**: Used more specific terms like "Renal Osteodystrophy" and differentiated stages of Chronic Kidney Disease.
[2025-11-01 16:14:42,805] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
[2025-11-01 16:14:42,806] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
[2025-11-01 16:15:31,500] - Difference score: 0.9392690150351442
[2025-11-01 16:15:31,501] - Response1: 回答：  

[2025-11-01 16:15:13,728] [INFO] [launch.py:367:main] Process 2751456 exits successfully.
[20...
[2025-11-01 16:15:31,501] - Response2: 回答：...
[2025-11-01 16:15:31,501] - new score: 0.9393
[2025-11-01 16:15:31,501] - step 3, pop 1
[2025-11-01 16:15:31,501] - evolution example:
[2025-11-01 16:15:31,501] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 16:15:31,501] - parents:
[2025-11-01 16:15:31,501] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:15:31,501] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:16:11,179] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

**变异后问题**: What are the recommended interventions for Renal Osteodystrophy in patients with Chronic Renal Failure?
请根据医学知识与实际临床经验，提供详细的管理策略。回答应包括年龄相关的治疗方案，血钙和磷的实验室数值调整提示，并说明监测频率。

**疾病术语多样化**: 
- 疾病名称从"Mineral and Bone Disorder"变异为"Renal Osteodystrophy"
- 疾病状态从"Chronic Kidney Disease"扩展为"Chronic Renal Failure"

**数值扰动策略**:
- 引入具体的实验室数值调整提示，如调整血钙至8.5-10.2 mg/dL，血磷至3.5-4.5 mg/dL
- 提出不同年龄段的治疗策略，例如儿童使用更低剂量的磷结合剂

**临床场景分化**:
- 强调监测频率，如每三个月监测一次血钙和磷水平，以及年度的骨密度评估
</prompt>

**Divergence Focus**:
- **疾病术语**: 通过使用不同的疾病名称提高了诊断的精确性和多样性
- **数值变化**: 明确指出了具体的血液测试值和不同年龄段的处理建议，增加了回答的细节和深度
- **监测与治疗策略**: 引入了更频繁的监测与针对性的治疗建议，根据患者情况调整治疗方案，使得答案更具个体化和实用性
[2025-11-01 16:16:11,180] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

**变异后问题**: What are the recommended interventions for Renal Osteodystrophy in patients with Chronic Renal Failure?
请根据医学知识与实际临床经验，提供详细的管理策略。回答应包括年龄相关的治疗方案，血钙和磷的实验室数值调整提示，并说明监测频率。

**疾病术语多样化**: 
- 疾病名称从"Mineral and Bone Disorder"变异为"Renal Osteodystrophy"
- 疾病状态从"Chronic Kidney Disease"扩展为"Chronic Renal Failure"

**数值扰动策略**:
- 引入具体的实验室数值调整提示，如调整血钙至8.5-10.2 mg/dL，血磷至3.5-4.5 mg/dL
- 提出不同年龄段的治疗策略，例如儿童使用更低剂量的磷结合剂

**临床场景分化**:
- 强调监测频率，如每三个月监测一次血钙和磷水平，以及年度的骨密度评估
[2025-11-01 16:16:11,180] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

**变异后问题**: What are the recommended interventions for Renal Osteodystrophy in patients with Chronic Renal Failure?
请根据医学知识与实际临床经验，提供详细的管理策略。回答应包括年龄相关的治疗方案，血钙和磷的实验室数值调整提示，并说明监测频率。

**疾病术语多样化**: 
- 疾病名称从"Mineral and Bone Disorder"变异为"Renal Osteodystrophy"
- 疾病状态从"Chronic Kidney Disease"扩展为"Chronic Renal Failure"

**数值扰动策略**:
- 引入具体的实验室数值调整提示，如调整血钙至8.5-10.2 mg/dL，血磷至3.5-4.5 mg/dL
- 提出不同年龄段的治疗策略，例如儿童使用更低剂量的磷结合剂

**临床场景分化**:
- 强调监测频率，如每三个月监测一次血钙和磷水平，以及年度的骨密度评估
[2025-11-01 16:17:56,390] - Difference score: 0.09995043317979999
[2025-11-01 16:17:56,390] - Response1: **问题类别**:frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与...
[2025-11-01 16:17:56,390] - Response2: **问题类别**:frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与...
[2025-11-01 16:17:56,390] - new score: 0.1
[2025-11-01 16:17:56,409] - step 4, pop 0
[2025-11-01 16:17:56,409] - evolution example:
[2025-11-01 16:17:56,409] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 16:17:56,409] - parents:
[2025-11-01 16:17:56,409] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
[2025-11-01 16:17:56,410] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
[2025-11-01 16:19:05,656] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 45-85 years displaying secondary hyperparathyroidism?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用，同时考虑患者可能伴有的高血压或心血管疾病。初诊时，对于血清钙水平较低（8.5-9.0 mg/dL）的患者，建议使用含钙的磷结合剂；对于血清钙水平正常或偏高的患者（9.1-10.5 mg/dL），推荐使用不含钙的磷结合剂。复诊时，根据患者的血清钙及磷水平调整治疗方案，增加或减少药物剂量，并密切监测心血管健康状况。回答应控制在200字以内。
</prompt>

**Divergence Focus**:
- **年龄区间扩展** (50-80 → 45-85)
- **血清钙水平的细微调整** (未指定 → 8.5-9.0 mg/dL 和 9.1-10.5 mg/dL)
- **并发症引入** (添加高血压或心血管疾病考量)
- **治疗细节增加** (根据血清钙及磷水平调整治疗方案，监测心血管健康)
[2025-11-01 16:19:05,656] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 45-85 years displaying secondary hyperparathyroidism?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用，同时考虑患者可能伴有的高血压或心血管疾病。初诊时，对于血清钙水平较低（8.5-9.0 mg/dL）的患者，建议使用含钙的磷结合剂；对于血清钙水平正常或偏高的患者（9.1-10.5 mg/dL），推荐使用不含钙的磷结合剂。复诊时，根据患者的血清钙及磷水平调整治疗方案，增加或减少药物剂量，并密切监测心血管健康状况。回答应控制在200字以内。
[2025-11-01 16:19:05,657] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 45-85 years displaying secondary hyperparathyroidism?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用，同时考虑患者可能伴有的高血压或心血管疾病。初诊时，对于血清钙水平较低（8.5-9.0 mg/dL）的患者，建议使用含钙的磷结合剂；对于血清钙水平正常或偏高的患者（9.1-10.5 mg/dL），推荐使用不含钙的磷结合剂。复诊时，根据患者的血清钙及磷水平调整治疗方案，增加或减少药物剂量，并密切监测心血管健康状况。回答应控制在200字以内。
[2025-11-01 16:19:52,970] - Difference score: 0.938395698427382
[2025-11-01 16:19:52,970] - Response1: 生成结束
[2025-11-01 16:19:36,385] [INFO] [launch.py:367:main] Process 2757299 exits successfully.
[2025...
[2025-11-01 16:19:52,970] - Response2: 生成结束...
[2025-11-01 16:19:52,970] - new score: 0.9384
[2025-11-01 16:19:52,971] - step 4, pop 1
[2025-11-01 16:19:52,971] - evolution example:
[2025-11-01 16:19:52,971] - You are an expert at generating medical prompt variants that maximize disease terminology and numerical value divergence across distributed inference scenarios. Please follow the instruction step-by-step to create semantic mutations with enhanced numerical and diagnostic variability.

1. **Enhanced Crossover** with disease-numerical focus:
Prompt 1: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
Prompt 2: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。

Cross-pollinate these prompts while emphasizing:
- Disease terminology diversification (同义词替换, 相关疾病扩展, 严重程度变化)
- Numerical value range expansion (年龄, 血压, 血糖, 心率, 实验室数值等)
- Clinical parameter variation (检查指标, 用药剂量, 时间周期)

2. **Apply strategic semantic mutation** using these enhanced transformation strategies:

**数值扰动策略**:
- 生理参数随机化: 在合理医学范围内调整数值 (±10-20%)
- 年龄区间扩展: 儿童/成人/老年不同年龄段的疾病表现
- 实验室指标变异: 同一疾病的不同严重程度数值表现

**疾病术语多样化**:
- 诊断名称扩展: 使用ICD编码相关的同义诊断术语
- 症状组合变异: 同一疾病的不同症状组合表达
- 并发症引入: 添加合理的伴随疾病描述

**临床场景分化**:
- 急诊vs门诊: 同一疾病在不同场景下的数值阈值差异
- 初诊vs复诊: 不同就诊阶段的数据表达变化
- 筛查vs确诊: 不同诊断确信度的描述方式

3. **Generate the final mutated prompt** with explicit disease-numerical divergence, bracketed with <prompt> and </prompt>.

**Enhanced Example**:
原始: 患者血压150/95mmHg，建议降压治疗
变异: 中年患者收缩压148mmHg舒张压96mmHg，伴有轻度头痛，推荐起始剂量降压药物干预，监测肾功能指标变化

**Divergence Focus**:
- 血压数值细微变化 (150/95 → 148/96)
- 添加症状描述 (轻度头痛)  
- 引入治疗细节 (起始剂量, 肾功能监测)
- 扩展疾病关联 (高血压→降压治疗→肾功能关联)

Now apply this enhanced process:
1. Crossover 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。 and 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。 with disease-numerical divergence focus
2. Apply strategic semantic mutation emphasizing parameter variability
3. Generate final result with explicit clinical value differences:
[2025-11-01 16:19:52,971] - parents:
[2025-11-01 16:19:52,971] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
[2025-11-01 16:19:52,971] - 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
[2025-11-01 16:20:36,827] - original child prompt: <prompt>
你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：对于慢性肾病第四期的肾性骨病患者（尤其是显示继发性甲状旁腺功能亢进的50-90岁患者），推荐哪些干预措施？
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平在8.8-10.5 mg/dL的磷结合剂或血清钙水平在8.2-9.4 mg/dL时的钙补充剂的使用。同时考虑到患者可能伴有轻微肾功能衰竭或心血管疾病，并根据这些临床参数调整治疗方案。回答应控制在200字以内。
</prompt>

**Divergence Focus**:
- **年龄区间扩展**：50-80岁 → 50-90岁
- **实验室指标变异**：血清钙水平普遍调整，细分不同治疗建议的水平范围
- **并发症引入**：考虑患者可能的轻微肾功能衰竭或心血管疾病
- **临床场景分化**：针对不同血清钙水平的治疗建议，以及并发症的调整方案

This mutation strategically enhances the prompt by diversifying clinical parameters and expanding the disease's complexity and the related numerical values to cater to a broader and more variable patient profile. This method increases the response's applicability and precision in real-world medical scenarios.
[2025-11-01 16:20:36,828] - child prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：对于慢性肾病第四期的肾性骨病患者（尤其是显示继发性甲状旁腺功能亢进的50-90岁患者），推荐哪些干预措施？
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平在8.8-10.5 mg/dL的磷结合剂或血清钙水平在8.2-9.4 mg/dL时的钙补充剂的使用。同时考虑到患者可能伴有轻微肾功能衰竭或心血管疾病，并根据这些临床参数调整治疗方案。回答应控制在200字以内。
[2025-11-01 16:20:36,828] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：对于慢性肾病第四期的肾性骨病患者（尤其是显示继发性甲状旁腺功能亢进的50-90岁患者），推荐哪些干预措施？
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平在8.8-10.5 mg/dL的磷结合剂或血清钙水平在8.2-9.4 mg/dL时的钙补充剂的使用。同时考虑到患者可能伴有轻微肾功能衰竭或心血管疾病，并根据这些临床参数调整治疗方案。回答应控制在200字以内。
[2025-11-01 16:21:24,715] - Difference score: 0.938395698427382
[2025-11-01 16:21:24,716] - Response1: 生成结束
[2025-11-01 16:21:06,128] [INFO] [launch.py:367:main] Process 2760617 exits successfully.
[2025...
[2025-11-01 16:21:24,716] - Response2: 生成结束...
[2025-11-01 16:21:24,716] - new score: 0.9384
[2025-11-01 16:21:24,734] - ----------testing step 4 population----------
[2025-11-01 16:21:24,734] - ----------step 4 best score: 0.9392690150351442, best prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。----------
[2025-11-01 16:21:24,734] - best_scores: 0.465948499776086,0.9392690150351442,0.9392690150351442
[2025-11-01 16:21:24,734] - avg_scores: 0.3107,0.7026,0.9388
[2025-11-01 16:21:24,735] - ==================================================
[2025-11-01 16:21:24,735] - Medical GA Optimization Completed!
[2025-11-01 16:21:24,735] - ==================================================
[2025-11-01 16:21:24,735] - Best Score: 0.9392690150351442
[2025-11-01 16:21:24,735] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What interventions are recommended for Renal Osteodystrophy in Chronic Kidney Disease Stage 4, particularly in patients aged 50-80 years displaying secondary hyperparathyroidism?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含初诊与复诊时的不同治疗建议，特别是针对血清钙水平不同的磷结合剂或钙补充剂的使用。回答应控制在200字以内。
[2025-11-01 16:21:24,735] - Best result saved to: ./medical_ga_outputs/best_result.txt
[2025-11-01 16:26:35,951] - ==================================================
[2025-11-01 16:26:35,951] - Medical GA Prompt Optimization Starting
[2025-11-01 16:26:35,951] - ==================================================
[2025-11-01 16:26:35,951] - budget: 5
[2025-11-01 16:26:35,951] - popsize: 2
[2025-11-01 16:26:35,951] - sel_mode: tour
[2025-11-01 16:26:35,951] - ga_mode: topk
[2025-11-01 16:26:35,951] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 16:26:35,952] - output_dir: ./medical_ga_outputs
[2025-11-01 16:26:35,952] - seed: 42
[2025-11-01 16:26:35,952] - Creating Medical Evaluator...
[2025-11-01 16:26:35,952] - Creating Medical GA Evoluter...
[2025-11-01 16:26:35,952] - ==================================================
[2025-11-01 16:26:35,952] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 16:26:35,952] - ==================================================
[2025-11-01 16:26:35,952] - Starting evolution process...
[2025-11-01 16:26:35,952] - Evaluating initial user_input 1/2
[2025-11-01 16:26:35,952] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:27:14,474] - Error during optimization: look-behind requires fixed-width pattern
[2025-11-01 16:27:14,477] - Traceback (most recent call last):
  File "/VisCom-HDD-1/wyf/D3/llm/run_medical_ga.py", line 94, in main
    evoluter.evolute()
  File "/VisCom-HDD-1/wyf/D3/llm/GA.py", line 143, in evolute
    self.evaluated_prompts, cur_budget = self.init_pop()
  File "/VisCom-HDD-1/wyf/D3/llm/GA.py", line 129, in init_pop
    scores = self.evaluator.evaluate_prompt(user_input)
  File "/VisCom-HDD-1/wyf/D3/llm/medical_evaluator.py", line 173, in evaluate_prompt
    response1 = self.run_model(self.location1_path)
  File "/VisCom-HDD-1/wyf/D3/llm/medical_evaluator.py", line 41, in run_model
    pattern = re.compile(r"(?<=Pipeline生成的新文字:\s*)(.*?)(?=\s*生成结束)", re.S)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/re.py", line 251, in compile
    return _compile(pattern, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/re.py", line 303, in _compile
    p = sre_compile.compile(pattern, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/sre_compile.py", line 792, in compile
    code = _code(p, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/sre_compile.py", line 631, in _code
    _compile(code, p.data, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/sre_compile.py", line 198, in _compile
    raise error("look-behind requires fixed-width pattern")
re.error: look-behind requires fixed-width pattern

[2025-11-01 16:30:42,695] - ==================================================
[2025-11-01 16:30:42,695] - Medical GA Prompt Optimization Starting
[2025-11-01 16:30:42,696] - ==================================================
[2025-11-01 16:30:42,696] - budget: 5
[2025-11-01 16:30:42,696] - popsize: 2
[2025-11-01 16:30:42,696] - sel_mode: tour
[2025-11-01 16:30:42,696] - ga_mode: topk
[2025-11-01 16:30:42,696] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 16:30:42,696] - output_dir: ./medical_ga_outputs
[2025-11-01 16:30:42,696] - seed: 42
[2025-11-01 16:30:42,696] - Creating Medical Evaluator...
[2025-11-01 16:30:42,696] - Creating Medical GA Evoluter...
[2025-11-01 16:30:42,696] - ==================================================
[2025-11-01 16:30:42,696] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 16:30:42,696] - ==================================================
[2025-11-01 16:30:42,696] - Starting evolution process...
[2025-11-01 16:30:42,696] - Evaluating initial user_input 1/2
[2025-11-01 16:30:42,696] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:31:22,057] - Error during optimization: look-behind requires fixed-width pattern
[2025-11-01 16:31:22,058] - Traceback (most recent call last):
  File "/VisCom-HDD-1/wyf/D3/llm/run_medical_ga.py", line 94, in main
    evoluter.evolute()
  File "/VisCom-HDD-1/wyf/D3/llm/GA.py", line 143, in evolute
    self.evaluated_prompts, cur_budget = self.init_pop()
  File "/VisCom-HDD-1/wyf/D3/llm/GA.py", line 129, in init_pop
    scores = self.evaluator.evaluate_prompt(user_input)
  File "/VisCom-HDD-1/wyf/D3/llm/medical_evaluator.py", line 173, in evaluate_prompt
    response1 = self.run_model(self.location1_path)
  File "/VisCom-HDD-1/wyf/D3/llm/medical_evaluator.py", line 41, in run_model
    pattern = re.compile(r"(?<=Pipeline生成的新文字:\s*)(.*?)(?=\s*生成结束)", re.S)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/re.py", line 251, in compile
    return _compile(pattern, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/re.py", line 303, in _compile
    p = sre_compile.compile(pattern, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/sre_compile.py", line 792, in compile
    code = _code(p, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/sre_compile.py", line 631, in _code
    _compile(code, p.data, flags)
  File "/home/ta/anaconda3/wyf_llm/lib/python3.10/sre_compile.py", line 198, in _compile
    raise error("look-behind requires fixed-width pattern")
re.error: look-behind requires fixed-width pattern

[2025-11-01 16:32:06,008] - ==================================================
[2025-11-01 16:32:06,008] - Medical GA Prompt Optimization Starting
[2025-11-01 16:32:06,008] - ==================================================
[2025-11-01 16:32:06,008] - budget: 5
[2025-11-01 16:32:06,008] - popsize: 2
[2025-11-01 16:32:06,008] - sel_mode: tour
[2025-11-01 16:32:06,008] - ga_mode: topk
[2025-11-01 16:32:06,008] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 16:32:06,008] - output_dir: ./medical_ga_outputs
[2025-11-01 16:32:06,008] - seed: 42
[2025-11-01 16:32:06,008] - Creating Medical Evaluator...
[2025-11-01 16:32:06,008] - Creating Medical GA Evoluter...
[2025-11-01 16:32:06,009] - ==================================================
[2025-11-01 16:32:06,009] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 16:32:06,009] - ==================================================
[2025-11-01 16:32:06,009] - Starting evolution process...
[2025-11-01 16:32:06,009] - Evaluating initial user_input 1/2
[2025-11-01 16:32:06,009] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:33:09,708] - Difference score: 0.0
[2025-11-01 16:33:09,708] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Mineral and Bone Disorder in Chronic Kidney Disease is a common complication of chronic kidney disease. It is characterized by abnormal mineral metabolism, including hyperphosphatemia, hypocalcemia, and hyperparathyroidism. The main treatment for Mineral and Bone Disorder in Chronic Kidney Disease is to control the levels of phosphorus, calcium, and parathyroid hormone. This can be done through a combination of dietary modifications, medications, and dialysis. In addition, it is important to monitor the patient's kidney function and adjust the treatment plan as needed.
[2025-11-01 16:33:09,708] - Response2: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Mineral and Bone Disorder in Chronic Kidney Disease is a common complication of chronic kidney disease. It is characterized by abnormal mineral metabolism, including hyperphosphatemia, hypocalcemia, and hyperparathyroidism. The main treatment for Mineral and Bone Disorder in Chronic Kidney Disease is to control the levels of phosphorus, calcium, and parathyroid hormone. This can be done through a combination of dietary modifications, medications, and dialysis. In addition, it is important to monitor the patient's kidney function and adjust the treatment plan as needed.
[2025-11-01 16:33:09,708] - Evaluating initial user_input 2/2
[2025-11-01 16:33:09,708] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:34:37,651] - Difference score: 0.0
[2025-11-01 16:34:37,651] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Leydig cell hypoplasia is a rare disorder characterized by the absence of Leydig cells in the testes. Leydig cells are the cells that produce testosterone in the testes. The absence of Leydig cells results in low levels of testosterone, which can lead to a variety of symptoms, including delayed puberty, infertility, and reduced muscle mass. The genetic changes associated with Leydig cell hypoplasia are not well understood, but it is believed to be caused by mutations in the LHCGR gene, which encodes the luteinizing hormone receptor. This gene is responsible for the production of luteinizing hormone, which is a hormone that stimulates the production of testosterone in the testes. Mutations in this gene can lead to a reduction in the number of Leydig cells in the testes, resulting in low levels of testosterone. In addition to the LHCGR gene, other genes may also be involved in the development of Leydig cell hypoplasia. For example, mutations in the NR5A1 gene, which encodes the steroidogenic factor 1 protein, have been associated with Leydig cell hypoplasia. This protein is involved in the regulation of testosterone production in the testes. Other genes that may be involved in the development of Leydig cell hypoplasia include the DAX1 gene, which encodes the dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome gene, and the INSL3 gene, which encodes the insulin-like 3 protein. It is important to note that the genetic changes associated with Leydig cell hypoplasia are not fully understood, and further research is needed to fully understand the underlying mechanisms of this disorder.
[2025-11-01 16:34:37,651] - Response2: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Leydig cell hypoplasia is a rare disorder characterized by the absence of Leydig cells in the testes. Leydig cells are the cells that produce testosterone in the testes. The absence of Leydig cells results in low levels of testosterone, which can lead to a variety of symptoms, including delayed puberty, infertility, and reduced muscle mass. The genetic changes associated with Leydig cell hypoplasia are not well understood, but it is believed to be caused by mutations in the LHCGR gene, which encodes the luteinizing hormone receptor. This gene is responsible for the production of luteinizing hormone, which is a hormone that stimulates the production of testosterone in the testes. Mutations in this gene can lead to a reduction in the number of Leydig cells in the testes, resulting in low levels of testosterone. In addition to the LHCGR gene, other genes may also be involved in the development of Leydig cell hypoplasia. For example, mutations in the NR5A1 gene, which encodes the steroidogenic factor 1 protein, have been associated with Leydig cell hypoplasia. This protein is involved in the regulation of testosterone production in the testes. Other genes that may be involved in the development of Leydig cell hypoplasia include the DAX1 gene, which encodes the dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome gene, and the INSL3 gene, which encodes the insulin-like 3 protein. It is important to note that the genetic changes associated with Leydig cell hypoplasia are not fully understood, and further research is needed to fully understand the underlying mechanisms of this disorder.
[2025-11-01 16:34:37,652] - Initialized population with 2 user_inputs
[2025-11-01 16:34:37,652] - step 2, pop 0
[2025-11-01 16:34:57,173] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How can Leydig cell hypoplasia impact mineral and bone health in pediatric patients with varying stages of Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

Leydig cell hypoplasia can indirectly affect mineral and bone disorders, especially in pediatric patients with chronic kidney disease (CKD). In early CKD stages (stage 1-2), the impact might be minimal with blood calcium levels slightly below normal range (8.9-9.5 mg/dL), whereas in more advanced stages (stage 3-5), these levels can significantly drop (6.5-8.0 mg/dL), exacerbating bone demineralization. It is crucial to monitor these levels along with other markers such as parathyroid hormone (150-600 pg/mL in moderate stages) and vitamin D (20-30 ng/mL). Treatment should include calcium and vitamin D supplementation, adjusted according to the severity and progression of CKD and the child's developmental needs. Regular endocrinologic and nephrologic evaluations are recommended to manage the interplay between Leydig cell function, bone health, and kidney disease effectively.
[2025-11-01 16:35:44,582] - Difference score: 0.0
[2025-11-01 16:35:44,583] - Response1: 
[2025-11-01 16:35:44,583] - Response2: 
[2025-11-01 16:35:44,583] - new score: 0.0
[2025-11-01 16:35:44,583] - step 2, pop 1
[2025-11-01 16:36:29,402] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

**变异应用**：  
- 对于慢性肾病（Chronic Kidney Disease, CKD）引起的矿物质和骨骼紊乱（又称肾性骨病），建议监测血钙水平（通常在8.5-10.2 mg/dL），磷水平（建议维持在2.5-4.5 mg/dL），以及副甲状腺激素（PTH）水平（目标范围因CKD阶段而异）。  
- 根据患者年龄和具体病情，成人患者可能需要口服磷结合剂（如碳酸钙或碳酸镧），以减少磷吸收，同时可能需补充活性维生素D（如钙泊三醇）以调节钙磷代谢，剂量需个体化调整。  
- 对于儿童和青少年患者，应特别注意生长发育影响，适时调整治疗计划，密切监测生长激素及其相关指标的变化。  
- 在紧急情况下，如血钙显著低于正常值（低于7.0 mg/dL），应立即进行钙剂补充治疗，并密切监测心电图和肌肉功能，以预防可能的心脏和神经并发症。  

**疾病术语多样化与数值扰动策略**：  
- 疾病名称扩展：使用"肾性骨病"替代"矿物质和骨骼紊乱"  
- 数值范围调整：血钙正常值调整至8.5-10.2 mg/dL，磷的维持范围调整至2.5-4.5 mg/dL  
- 年龄区间扩展与临床场景分化：成人和儿童的治疗计划差异化，紧急情况下的处理策略  

**临床参数变异与疾病术语多样化**：  
- 引入并发症描述：心脏和神经并发症的预防  
- 检查指标变异：监测副甲状腺激素水平，根据CKD的不同阶段调整目标范围  
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量调整
[2025-11-01 16:37:57,806] - Difference score: 0.0008674222736192543
[2025-11-01 16:37:57,806] - Response1: - 生长发育的影响：儿童和青少年患者的特殊关注  

**多样化策略总结**：  
- 疾病术语多样化：扩展疾病名称，增加并发症描述  
- 临床参数变异：调整血钙和磷的正常值范围，监测副甲状腺激素水平，调整药物剂量和时间周期  
- 生长发育的影响：儿童和青少年患者的特殊关注  
- 整体上，多样化策略增加了回答的可读性和可靠性，提高了用户的满意度和信任感。  

**参考文献**：  
1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76:S1-S130. doi:10.1038/ki.2009.188  
2. National Kidney Foundation. KDOQI clinical practice guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201. doi:10.1016/s0272-6386(03)00832-0  
3. National Kidney Foundation. KDOQI clinical practice guideline for nutrition in chronic kidney disease. Am J Kidney Dis. 2000;35(6 Suppl 2):S1-S140. doi:10.1016/s0272-6386(00)70080-2  
4. National Kidney Foundation. KDOQI clinical practice guideline for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530. doi:10.1053/j.ajkd.2007.06.015  
5. National Kidney Foundation. KDOQI clinical practice guideline for vascular access: 2006 update. Am J Kidney Dis. 2006;48(5):S1-S179. doi:10.1053/j.ajkd.2006.07.027  
6. National Kidney Foundation. KDOQI clinical practice guideline for
[2025-11-01 16:37:57,806] - Response2: - 生长发育的影响：儿童和青少年患者的特殊关注  

**多样化策略总结**：  
- 疾病术语多样化：扩展疾病名称，增加并发症描述  
- 临床参数变异：调整血钙和磷的正常值范围，监测副甲状腺激素水平，调整药物剂量和时间周期  
- 生长发育的影响：儿童和青少年患者的特殊关注  
- 整体上，多样化策略增加了回答的可读性和可靠性，提高了用户的满意度和信任感。  

**参考文献**：  
1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;76:S1-S130. doi:10.1038/ki.2009.188  
2. National Kidney Foundation. KDOQI clinical practice guideline for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-S201. doi:10.1016/s0272-6386(03)00832-0  
3. National Kidney Foundation. KDOQI clinical practice guideline for nutrition in chronic kidney disease. Am J Kidney Dis. 2000;35(6 Suppl 2):S1-S140. doi:10.1016/s0272-6386(00)70080-2  
4. National Kidney Foundation. KDOQI clinical practice guideline for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50(3):471-530. doi:10.1053/j.ajkd.2007.06.015  
5. National Kidney Foundation. KDOQI clinical practice guideline for vascular access: 2006 update. Am J Kidney Dis. 2006;48(5):S1-S179. doi:10.1053/j.ajkd.2006.07.015  
6. National Kidney Foundation. KDOQI clinical practice guideline for
[2025-11-01 16:37:57,806] - new score: 0.0009
[2025-11-01 16:37:57,807] - step 3, pop 0
[2025-11-01 16:38:42,066] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

**变异应用**：
- 对于慢性肾脏疾病（Chronic Kidney Disease, CKD）引起的肾性骨病，建议监测血钙水平（通常在8.3-10.5 mg/dL），磷水平（建议维持在2.3-4.7 mg/dL），以及副甲状腺激素（PTH）水平（目标范围因CKD阶段而有所不同）。
- 根据患者具体病情及年龄阶段，成人患者可能需口服磷结合剂（如碳酸钙或碳酸镧），减少磷的吸收，并可能需补充活性维生素D（如钙泊三醇）以调节钙磷代谢，剂量应根据个体需要调整。
- 对于儿童和青少年患者，关注其生长发育，及时调整治疗计划，监测生长激素及相关生化指标的变化。
- 在血钙严重低于正常值（低于6.8 mg/dL）的紧急情况下，应立即补充钙剂，并密切监测心电图及肌肉功能，以防止心脏和神经系统并发症。

**疾病术语多样化与数值扰动策略**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**临床参数变异与疾病术语多样化**：
- 描述心脏和神经并发症的预防措施
- 调整副甲状腺激素（PTH）的监测指标，根据CKD的不同阶段设定不同的目标范围
- 个体化调整活性维生素D和磷结合剂的剂量和治疗周期
[2025-11-01 16:40:07,550] - Difference score: 0.0
[2025-11-01 16:40:07,550] - Response1: **多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病
[2025-11-01 16:40:07,550] - Response2: **多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病术语与临床参数变异**：
- 使用"肾性骨疾病"替代"矿物质和骨骼紊乱"
- 调整血钙和磷的正常维持范围，扩大数值波动范围
- 区分成人和儿童治疗策略，应对不同临床场景

**多样化的疾病
[2025-11-01 16:40:07,550] - new score: 0.0
[2025-11-01 16:40:07,550] - step 3, pop 1
[2025-11-01 16:40:46,868] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

**变异应用**：  
- 在慢性肾功能衰竭（Chronic Kidney Failure, CKF）中出现的肾性骨营养不良症（又名肾性骨病），建议监测血钙水平（通常在8.1-10.4 mg/dL），磷水平（维持在2.4-4.6 mg/dL），及副甲状腺激素（PTH）水平（目标范围取决于CKF的进展）。  
- 针对成人患者，可能需要服用磷结合剂（如碳酸钙或碳酸镧）来减少磷的吸收，并可能需要补充活性维生素D（例如钙泊三醇）以调整钙磷平衡，剂量应根据个体情况调整。
- 对于儿童和青少年患者，应重视其生长发育的影响，及时调整治疗方案，密切监测生长激素及其相关指标的波动。
- 在急性低血钙事件（血钙低于6.8 mg/dL）中，应迅速补充钙剂，并严密监测心电图和神经肌肉功能，以防止心脏和神经系统的并发症。

**疾病术语多样化与数值扰动策略**：  
- 扩展疾病名称：使用“肾性骨营养不良症”替代“肾性骨病”
- 数值范围调整：血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化：成人和儿童的治疗策略差异化，急性情况下的处理策略

**临床参数变异与疾病术语多样化**：  
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
[2025-11-01 16:42:28,861] - Difference score: 0.04557163748980174
[2025-11-01 16:42:28,861] - Response1: **多样化的医学术语**：  
- 血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整

**多样化的医学术语**：  
- 血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整

**多样化的医学术语**：  
- 血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整

**多样化
[2025-11-01 16:42:28,862] - Response2: - 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
- 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
- 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
-
[2025-11-01 16:42:28,862] - new score: 0.0456
[2025-11-01 16:42:28,874] - step 4, pop 0
[2025-11-01 16:43:08,246] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

**变异应用**：  
- 在慢性肾脏病（Chronic Kidney Disease, CKD）阶段3-4中的肾源性骨病变（Renal Osteodystrophy），建议监测血钙水平（通常在7.9-10.6 mg/dL），磷水平（维持在2.3-4.8 mg/dL），及副甲状腺激素（PTH）水平（目标范围取决于CKD的具体阶段）。  
- 针对成人患者，可能需要服用磷结合剂（如碳酸钙或碳酸镧）来减少磷的吸收，并可能需要补充活性维生素D（例如钙泊三醇）以调整钙磷平衡，剂量应根据个体情况调整。
- 对于儿童和青少年患者，应重视其生长发育的影响，及时调整治疗方案，密切监测生长激素及其相关指标的波动。
- 在急性低血钙事件（血钙低于6.5 mg/dL）中，应迅速补充钙剂，并严密监测心电图和神经肌肉功能，以防止心脏和神经系统的并发症。

**疾病术语多样化与数值扰动策略**：  
- 扩展疾病名称：使用“肾源性骨病变”替代“肾性骨营养不良症”
- 数值范围调整：血钙正常值调整至7.9-10.6 mg/dL，磷的维持范围调整至2.3-4.8 mg/dL
- 针对不同年龄层的临床场景分化：成人和儿童的治疗策略差异化，急性情况下的处理策略

**临床参数变异与疾病术语多样化**：  
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKD不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
[2025-11-01 16:44:54,142] - Difference score: 0.0
[2025-11-01 16:44:54,143] - Response1: - 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至7.9-10.6 mg/dL，磷的维持范围调整至2.3-4.8 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKD不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
- 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至7.9-10.6 mg/dL，磷的维持范围调整至2.3-4.8 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKD不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
- 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至7.9-10.6 mg/dL，磷的维持范围调整至2.3-4.8 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入
[2025-11-01 16:44:54,143] - Response2: - 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至7.9-10.6 mg/dL，磷的维持范围调整至2.3-4.8 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKD不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
- 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至7.9-10.6 mg/dL，磷的维持范围调整至2.3-4.8 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKD不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
- 针对儿童和青少年的生长发育监测：生长激素和相关指标的监测

**多样化的医学术语**：  
- 血钙正常值调整至7.9-10.6 mg/dL，磷的维持范围调整至2.3-4.8 mg/dL
- 针对不同年龄层的临床场景分化，成人和儿童的治疗策略差异化，急性情况下的处理策略
- 引入
[2025-11-01 16:44:54,143] - new score: 0.0
[2025-11-01 16:44:54,143] - step 4, pop 1
[2025-11-01 16:45:26,125] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

**变异应用**：
- 在慢性肾病（CKD）中，肾性骨矿物质代谢紊乱（又称肾性骨营养不良症或肾性骨病）常见。建议定期监测血钙水平（目标范围扩展至7.9-10.6 mg/dL），磷水平（调整至2.2-4.8 mg/dL），及副甲状腺激素（PTH）水平（根据CKD阶段调整目标范围）。
- 成人患者可能需使用磷结合剂（如硝酸钙或碳酸镧）降低磷吸收，并补充活性维生素D（如阿尔法钙泊三醇）以优化钙磷平衡，剂量依个体差异调整。
- 儿童和青少年患者的治疗需考虑其特殊的生长需求，调整治疗计划，关注生长激素及其波动。
- 在急性低血钙事件（如血钙低至6.5 mg/dL）时，应立即静脉补钙，并监测ECG及神经肌肉状态，预防心脏和神经并发症。

**疾病术语多样化与数值扰动策略**：
- 病名使用多样化：使用“肾性骨矿物质代谢紊乱”替代“肾性骨营养不良症”
- 调整数值范围：血钙和磷的正常值范围微调
- 针对不同年龄层的临床场景差异化处理：成人与儿童的治疗策略区别

**临床参数变异与疾病术语多样化**：
- 描述并发症：防范心脏和神经系统并发症
- 检查指标变异：根据CKD阶段调整副甲状腺激素监测范围
- 药物剂量与治疗周期个性化：根据患者情况调整活性维生素D和磷结合剂剂量
[2025-11-01 16:47:11,645] - Difference score: 0.0
[2025-11-01 16:47:11,645] - Response1: **多样化的医学术语**：
- “肾性骨矿物质代谢紊乱”替代“肾性骨营养不良症”
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的疾病术语**：
- “肾性骨矿物质代谢紊乱”替代“肾性骨营养不良症”
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的临床参数**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”
- “磷结合剂”替代“硝酸钙或碳酸镧”

**多样化的药物名称**：
- “磷结合剂”替代“硝酸钙或碳酸镧”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多
[2025-11-01 16:47:11,645] - Response2: **多样化的医学术语**：
- “肾性骨矿物质代谢紊乱”替代“肾性骨营养不良症”
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的疾病术语**：
- “肾性骨矿物质代谢紊乱”替代“肾性骨营养不良症”
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的临床参数**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”
- “磷结合剂”替代“硝酸钙或碳酸镧”

**多样化的药物名称**：
- “磷结合剂”替代“硝酸钙或碳酸镧”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多样化的检查指标**：
- “副甲状腺激素”替代“PTH”
- “活性维生素D”替代“阿尔法钙泊三醇”

**多
[2025-11-01 16:47:11,645] - new score: 0.0
[2025-11-01 16:47:11,646] - ----------testing step 4 population----------
[2025-11-01 16:47:11,646] - ----------step 4 best score: 0.04557163748980174, best prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

**变异应用**：  
- 在慢性肾功能衰竭（Chronic Kidney Failure, CKF）中出现的肾性骨营养不良症（又名肾性骨病），建议监测血钙水平（通常在8.1-10.4 mg/dL），磷水平（维持在2.4-4.6 mg/dL），及副甲状腺激素（PTH）水平（目标范围取决于CKF的进展）。  
- 针对成人患者，可能需要服用磷结合剂（如碳酸钙或碳酸镧）来减少磷的吸收，并可能需要补充活性维生素D（例如钙泊三醇）以调整钙磷平衡，剂量应根据个体情况调整。
- 对于儿童和青少年患者，应重视其生长发育的影响，及时调整治疗方案，密切监测生长激素及其相关指标的波动。
- 在急性低血钙事件（血钙低于6.8 mg/dL）中，应迅速补充钙剂，并严密监测心电图和神经肌肉功能，以防止心脏和神经系统的并发症。

**疾病术语多样化与数值扰动策略**：  
- 扩展疾病名称：使用“肾性骨营养不良症”替代“肾性骨病”
- 数值范围调整：血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化：成人和儿童的治疗策略差异化，急性情况下的处理策略

**临床参数变异与疾病术语多样化**：  
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整----------
[2025-11-01 16:47:11,646] - best_scores: 0.0008674222736192543,0.04557163748980174,0.04557163748980174
[2025-11-01 16:47:11,646] - avg_scores: 0.0004,0.0232,0.0232
[2025-11-01 16:47:11,646] - ==================================================
[2025-11-01 16:47:11,646] - Medical GA Optimization Completed!
[2025-11-01 16:47:11,646] - ==================================================
[2025-11-01 16:47:11,646] - Best Score: 0.04557163748980174
[2025-11-01 16:47:11,646] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。  
问题类别：frequency  
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease?  
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。  

**变异应用**：  
- 在慢性肾功能衰竭（Chronic Kidney Failure, CKF）中出现的肾性骨营养不良症（又名肾性骨病），建议监测血钙水平（通常在8.1-10.4 mg/dL），磷水平（维持在2.4-4.6 mg/dL），及副甲状腺激素（PTH）水平（目标范围取决于CKF的进展）。  
- 针对成人患者，可能需要服用磷结合剂（如碳酸钙或碳酸镧）来减少磷的吸收，并可能需要补充活性维生素D（例如钙泊三醇）以调整钙磷平衡，剂量应根据个体情况调整。
- 对于儿童和青少年患者，应重视其生长发育的影响，及时调整治疗方案，密切监测生长激素及其相关指标的波动。
- 在急性低血钙事件（血钙低于6.8 mg/dL）中，应迅速补充钙剂，并严密监测心电图和神经肌肉功能，以防止心脏和神经系统的并发症。

**疾病术语多样化与数值扰动策略**：  
- 扩展疾病名称：使用“肾性骨营养不良症”替代“肾性骨病”
- 数值范围调整：血钙正常值调整至8.1-10.4 mg/dL，磷的维持范围调整至2.4-4.6 mg/dL
- 针对不同年龄层的临床场景分化：成人和儿童的治疗策略差异化，急性情况下的处理策略

**临床参数变异与疾病术语多样化**：  
- 引入并发症描述：预防心脏和神经系统并发症
- 检查指标变异：根据CKF的不同阶段调整副甲状腺激素的监测范围
- 用药剂量和时间周期的个体化调整：活性维生素D和磷结合剂的剂量根据个体差异调整
[2025-11-01 16:47:11,646] - Best result saved to: ./medical_ga_outputs/best_result.txt
[2025-11-01 16:53:13,154] - ==================================================
[2025-11-01 16:53:13,154] - Medical GA Prompt Optimization Starting
[2025-11-01 16:53:13,154] - ==================================================
[2025-11-01 16:53:13,154] - budget: 5
[2025-11-01 16:53:13,154] - popsize: 2
[2025-11-01 16:53:13,154] - sel_mode: tour
[2025-11-01 16:53:13,154] - ga_mode: topk
[2025-11-01 16:53:13,154] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 16:53:13,154] - output_dir: ./medical_ga_outputs
[2025-11-01 16:53:13,154] - seed: 42
[2025-11-01 16:53:13,154] - Creating Medical Evaluator...
[2025-11-01 16:53:13,154] - Creating Medical GA Evoluter...
[2025-11-01 16:53:13,154] - ==================================================
[2025-11-01 16:53:13,154] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 16:53:13,154] - ==================================================
[2025-11-01 16:53:13,155] - Starting evolution process...
[2025-11-01 16:53:13,155] - Evaluating initial user_input 1/2
[2025-11-01 16:53:13,155] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:54:09,968] - Difference score: 0.0
[2025-11-01 16:54:09,969] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Mineral and Bone Disorder in Chronic Kidney Disease is a common complication of chronic kidney disease. It is characterized by abnormal mineral metabolism, including hyperphosphatemia, hypocalcemia, and hyperparathyroidism. The main treatment for Mineral and Bone Disorder in Chronic Kidney Disease is to control the levels of phosphorus, calcium, and parathyroid hormone. This can be done through a combination of dietary modifications, medications, and dialysis. In addition, it is important to monitor the patient's kidney function and adjust the treatment plan as needed.
[2025-11-01 16:54:09,969] - Response2: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Mineral and Bone Disorder in Chronic Kidney Disease is a common complication of chronic kidney disease. It is characterized by abnormal mineral metabolism, including hyperphosphatemia, hypocalcemia, and hyperparathyroidism. The main treatment for Mineral and Bone Disorder in Chronic Kidney Disease is to control the levels of phosphorus, calcium, and parathyroid hormone. This can be done through a combination of dietary modifications, medications, and dialysis. In addition, it is important to monitor the patient's kidney function and adjust the treatment plan as needed.
[2025-11-01 16:54:09,969] - Evaluating initial user_input 2/2
[2025-11-01 16:54:09,969] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 16:55:26,332] - Difference score: 0.0
[2025-11-01 16:55:26,332] - Response1: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Leydig cell hypoplasia is a rare disorder characterized by the absence of Leydig cells in the testes. Leydig cells are the cells that produce testosterone in the testes. The absence of Leydig cells results in low levels of testosterone, which can lead to a variety of symptoms, including delayed puberty, infertility, and reduced muscle mass. The genetic changes associated with Leydig cell hypoplasia are not well understood, but it is believed to be caused by mutations in the LHCGR gene, which encodes the luteinizing hormone receptor. This gene is responsible for the production of luteinizing hormone, which is a hormone that stimulates the production of testosterone in the testes. Mutations in this gene can lead to a reduction in the number of Leydig cells in the testes, resulting in low levels of testosterone. In addition to the LHCGR gene, other genes may also be involved in the development of Leydig cell hypoplasia. For example, mutations in the NR5A1 gene, which encodes the steroidogenic factor 1 protein, have been associated with Leydig cell hypoplasia. This protein is involved in the regulation of testosterone production in the testes. Other genes that may be involved in the development of Leydig cell hypoplasia include the DAX1 gene, which encodes the dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome gene, and the INSL3 gene, which encodes the insulin-like 3 protein. It is important to note that the genetic changes associated with Leydig cell hypoplasia are not fully understood, and further research is needed to fully understand the underlying mechanisms of this disorder.
[2025-11-01 16:55:26,332] - Response2: 请注意，用户可能会根据你的回答进行进一步的询问。
回答：Leydig cell hypoplasia is a rare disorder characterized by the absence of Leydig cells in the testes. Leydig cells are the cells that produce testosterone in the testes. The absence of Leydig cells results in low levels of testosterone, which can lead to a variety of symptoms, including delayed puberty, infertility, and reduced muscle mass. The genetic changes associated with Leydig cell hypoplasia are not well understood, but it is believed to be caused by mutations in the LHCGR gene, which encodes the luteinizing hormone receptor. This gene is responsible for the production of luteinizing hormone, which is a hormone that stimulates the production of testosterone in the testes. Mutations in this gene can lead to a reduction in the number of Leydig cells in the testes, resulting in low levels of testosterone. In addition to the LHCGR gene, other genes may also be involved in the development of Leydig cell hypoplasia. For example, mutations in the NR5A1 gene, which encodes the steroidogenic factor 1 protein, have been associated with Leydig cell hypoplasia. This protein is involved in the regulation of testosterone production in the testes. Other genes that may be involved in the development of Leydig cell hypoplasia include the DAX1 gene, which encodes the dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome gene, and the INSL3 gene, which encodes the insulin-like 3 protein. It is important to note that the genetic changes associated with Leydig cell hypoplasia are not fully understood, and further research is needed to fully understand the underlying mechanisms of this disorder.
[2025-11-01 16:55:26,332] - Initialized population with 2 user_inputs
[2025-11-01 16:55:26,333] - step 2, pop 0
[2025-11-01 16:55:51,510] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How can we manage bone mineralization abnormalities and related cardiovascular complications in advanced renal disease scenarios?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
- 为应对慢性肾病（CKD）引起的矿物质和骨骼紊乱（MBD），建议定期监测血钙（9.0-10.1 mg/dL）、磷（3.5-4.5 mg/dL）和副甲状腺激素（150-300 pg/mL）。此外，针对CKD晚期患者的心血管并发症，可考虑使用降脂和抗高血压药物治疗，以及定期心电图检查。推荐用药包括磷酸盐结合剂和维他命D类似物，以优化骨骼矿化并减少心血管风险。
- 增加关注于年龄因素对治疗的影响，儿童与成人患者的剂量需调整，特别是在使用钙补充剂和维他命D类似物时。
[2025-11-01 16:57:16,551] - Difference score: 0.0
[2025-11-01 16:57:16,551] - Response1: 对于儿童患者，建议使用维他命D类似物（如维他命D3）和磷酸盐结合剂（如磷酸钙）以优化骨骼矿化。对于成人患者，建议使用维他命D类似物（如维他命D3）和磷酸盐结合剂（如磷酸钙）以优化骨骼矿化，并考虑使用降脂和抗高血压药物治疗，以及定期心电图检查。
- 针对慢性肾病（CKD）引起的矿物质和骨骼紊乱（MBD），建议定期监测血钙（9.0-10.1 mg/dL）、磷（3.5-4.5 mg/dL）和副甲状腺激素（150-300 pg/mL）。此外，针对CKD晚期患者的心血管并发症，可考虑使用降脂和抗高血压药物治疗，以及定期心电图检查。推荐用药包括磷酸盐结合剂和维他命D类似物，以优化骨骼矿化并减少心血管风险。
- 针对慢性肾病（CKD）引起的矿物质和骨骼紊乱（MBD），建议定期监测血钙（9.0-10.1 mg/dL）、磷（3.5-4.5 mg/dL）和副甲状腺激素（150-300 pg/mL）。此外，针对CKD晚期患者的心血管并发症，可考虑使用降脂和抗高血压药物治疗，以及定期心电图检查。推荐用药包括磷酸盐结合剂和维他命D类似物，以优化骨骼矿化并减少心血管风险。
- 针对慢性肾病（CKD）引起的矿物质和骨骼紊乱（MBD），建议定期监测血钙（9.0-10.1 mg/dL）、磷（3.5-4.5 mg/dL）和副甲状腺激素（150-300 pg/mL）。此外，针对CKD晚期患者的心血管并发症，可考虑
[2025-11-01 16:57:16,551] - Response2: 对于儿童患者，建议使用维他命D类似物（如维他命D3）和磷酸盐结合剂（如磷酸钙）以优化骨骼矿化。对于成人患者，建议使用维他命D类似物（如维他命D3）和磷酸盐结合剂（如磷酸钙）以优化骨骼矿化，并考虑使用降脂和抗高血压药物治疗，以及定期心电图检查。
- 针对慢性肾病（CKD）引起的矿物质和骨骼紊乱（MBD），建议定期监测血钙（9.0-10.1 mg/dL）、磷（3.5-4.5 mg/dL）和副甲状腺激素（150-300 pg/mL）。此外，针对CKD晚期患者的心血管并发症，可考虑使用降脂和抗高血压药物治疗，以及定期心电图检查。推荐用药包括磷酸盐结合剂和维他命D类似物，以优化骨骼矿化并减少心血管风险。
- 针对慢性肾病（CKD）引起的矿物质和骨骼紊乱（MBD），建议定期监测血钙（9.0-10.1 mg/dL）、磷（3.5-4.5 mg/dL）和副甲状腺激素（150-300 pg/mL）。此外，针对CKD晚期患者的心血管并发症，可考虑使用降脂和抗高血压药物治疗，以及定期心电图检查。推荐用药包括磷酸盐结合剂和维他命D类似物，以优化骨骼矿化并减少心血管风险。
- 针对慢性肾病（CKD）引起的矿物质和骨骼紊乱（MBD），建议定期监测血钙（9.0-10.1 mg/dL）、磷（3.5-4.5 mg/dL）和副甲状腺激素（150-300 pg/mL）。此外，针对CKD晚期患者的心血管并发症，可考虑
[2025-11-01 16:57:16,551] - new score: 0.0
[2025-11-01 16:57:16,552] - step 2, pop 1
[2025-11-01 16:57:34,999] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：如何处理慢性肾脏疾病中的矿物质与骨骼疾患（CKD-MBD）？
针对成人患者（年龄范围40-60岁），建议定期监测血钙（目标范围8.5-10.2 mg/dL）和磷水平（目标范围2.5-4.5 mg/dL），并根据结果调整磷结合剂和维生素D类药物的剂量。建议每3至6个月评估骨密度，并考虑根据骨转换标志物水平调整治疗。并发症包括心血管疾病和软组织钙化，应密切监控这些情况的发展。
[2025-11-01 16:58:57,770] - Difference score: 0.0
[2025-11-01 16:58:57,770] - Response1: 对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类
[2025-11-01 16:58:57,770] - Response2: 对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类药物的剂量。对于儿童患者，建议定期监测血钙和磷水平，并根据结果调整磷结合剂和维生素D类
[2025-11-01 16:58:57,771] - new score: 0.0
[2025-11-01 16:58:57,771] - step 3, pop 0
[2025-11-01 17:00:35,819] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How can we manage bone mineralization abnormalities and related cardiovascular complications in advanced renal disease scenarios?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
- 针对终末期肾病（End-stage Renal Disease, ESRD）引发的矿物质和骨代谢异常（Mineral and Bone Disorder, MBD），建议扩大监测范围，包括血钙（8.1-10.4 mg/dL）、磷（3.0-4.7 mg/dL）和副甲状腺激素（130-350 pg/mL）。考虑到ESRD患者心血管风险增加，应用降脂和降压药物，并定期进行心脏超声和心电图检查。建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 考虑不同年龄段（儿童、成人、老年）患者的治疗需求差异，特别是在钙和维生素D补充上的剂量调整。
[2025-11-01 17:02:16,638] - Difference score: 0.0
[2025-11-01 17:02:16,638] - Response1: 儿童患者应避免过量补充钙和维生素D，老年患者则应避免过量补充磷酸盐。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
[2025-11-01 17:02:16,638] - Response2: 儿童患者应避免过量补充钙和维生素D，老年患者则应避免过量补充磷酸盐。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
- 针对ESRD患者的骨矿化异常，建议使用改良型磷酸盐结合剂和活性维生素D制剂，调整剂量以改善骨矿化并降低心血管事件风险。
[2025-11-01 17:02:16,638] - new score: 0.0
[2025-11-01 17:02:16,638] - step 3, pop 1
[2025-11-01 17:03:00,596] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：如何管理慢性肾功能衰退中的电解质紊乱与骨质疏松（Chronic Renal Failure with Electrolyte Imbalance and Osteoporosis）？
针对不同年龄段患者（年龄范围30-70岁），建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些情况的变化。
[2025-11-01 17:04:40,574] - Difference score: 0.0
[2025-11-01 17:04:40,574] - Response1: 对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些情况的变化。
对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些情况的变化。
对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些情况的变化。
对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些
[2025-11-01 17:04:40,574] - Response2: 对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些情况的变化。
对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些情况的变化。
对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些情况的变化。
对于年龄在30-70岁之间的患者，建议定期监测血钙（目标范围7.6-11.2 mg/dL）和磷水平（目标范围2.3-4.9 mg/dL），并根据结果调整使用磷结合剂和更高剂量的维生素D类药物。建议每2至5个月评估骨密度，并考虑根据骨代谢标志物的水平调整治疗方案。并发症包括加速的心血管衰退和肌肉软化，应密切监控这些
[2025-11-01 17:04:40,574] - new score: 0.0
[2025-11-01 17:04:40,575] - step 4, pop 0
[2025-11-01 17:05:13,550] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How can we manage bone mineralization abnormalities and related cardiovascular complications in advanced renal disease scenarios?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
- 针对晚期肾功能衰竭（Advanced Kidney Failure）所诱发的骨质疏松（Osteoporosis）和心脏病并发症，建议监测血钙（7.3-11.6 mg/dL）、血磷（2.7-5.2 mg/dL）以及甲状旁腺激素（117-385 pg/mL）。鉴于这些患者的心血管风险较高，建议使用降脂药和ACE抑制剂，并定期进行心脏MRI和动态心电图。推荐使用钙基磷结合剂和维生素D3，以优化治疗剂量，减少骨折及心血管问题的风险。
- 需考虑不同年龄段患者（青少年、中年、高龄）的治疗方案，特别是在钙剂和维生素D3的剂量调整上。
[2025-11-01 17:06:10,634] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How can we manage bone mineralization abnormalities and related cardiovascular complications in advanced renal disease scenarios?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
- 针对晚期肾功能衰竭（Advanced Kidney Failure）所诱发的骨质疏松（Osteoporosis）和心脏病并发症，建议监测血钙（7.3-11.6 mg/dL）、血磷（2.7-5.2 mg/dL）以及甲状旁腺激素（117-385 pg/mL）。鉴于这些患者的心血管风险较高，建议使用降脂药和ACE抑制剂，并定期进行心脏MRI和动态心电图。推荐使用钙基磷结合剂和维生素D3，以优化治疗剂量，减少骨折及心血管问题的风险。
- 需考虑不同年龄段患者（青少年、中年、高龄）的治疗方案，特别是在钙剂和维生素D3的剂量调整上。
[2025-11-01 17:06:10,635] - new score: 0.0
[2025-11-01 17:06:10,635] - step 4, pop 1
[2025-11-01 17:06:53,699] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：如何处理在晚期肾功能衰竭中遇到的骨骼矿化异常和相关心血管并发症？
针对不同年龄段的患者（年龄范围35-75岁），建议定期监测血钙（目标范围8.0-10.5 mg/dL）和磷水平（目标范围2.8-4.8 mg/dL），以及副甲状腺激素（120-380 pg/mL）。鉴于晚期肾功能衰竭（End-stage Renal Failure, ESRF）患者心血管疾病的高发性，应定期进行心血管系统的综合评估，包括心电图和心脏超声。建议使用新型磷酸盐结合剂和高活性维生素D制剂，根据骨代谢指标调整剂量，以优化骨矿化并减少心血管事件的风险。关注患者的并发症，如动脉硬化或软组织钙化，并调整治疗策略以应对这些挑战。
[2025-11-01 17:07:47,488] - Failed to get responses for user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：如何处理在晚期肾功能衰竭中遇到的骨骼矿化异常和相关心血管并发症？
针对不同年龄段的患者（年龄范围35-75岁），建议定期监测血钙（目标范围8.0-10.5 mg/dL）和磷水平（目标范围2.8-4.8 mg/dL），以及副甲状腺激素（120-380 pg/mL）。鉴于晚期肾功能衰竭（End-stage Renal Failure, ESRF）患者心血管疾病的高发性，应定期进行心血管系统的综合评估，包括心电图和心脏超声。建议使用新型磷酸盐结合剂和高活性维生素D制剂，根据骨代谢指标调整剂量，以优化骨矿化并减少心血管事件的风险。关注患者的并发症，如动脉硬化或软组织钙化，并调整治疗策略以应对这些挑战。
[2025-11-01 17:07:47,488] - new score: 0.0
[2025-11-01 17:07:47,499] - ----------testing step 4 population----------
[2025-11-01 17:07:47,499] - ----------step 4 best score: 0.0, best prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：如何处理慢性肾脏疾病中的矿物质与骨骼疾患（CKD-MBD）？
针对成人患者（年龄范围40-60岁），建议定期监测血钙（目标范围8.5-10.2 mg/dL）和磷水平（目标范围2.5-4.5 mg/dL），并根据结果调整磷结合剂和维生素D类药物的剂量。建议每3至6个月评估骨密度，并考虑根据骨转换标志物水平调整治疗。并发症包括心血管疾病和软组织钙化，应密切监控这些情况的发展。----------
[2025-11-01 17:07:47,499] - best_scores: 0.0,0.0,0.0
[2025-11-01 17:07:47,499] - avg_scores: 0.0,0.0,0.0
[2025-11-01 17:07:47,499] - ==================================================
[2025-11-01 17:07:47,499] - Medical GA Optimization Completed!
[2025-11-01 17:07:47,499] - ==================================================
[2025-11-01 17:07:47,499] - Best Score: 0.0
[2025-11-01 17:07:47,499] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：如何处理慢性肾脏疾病中的矿物质与骨骼疾患（CKD-MBD）？
针对成人患者（年龄范围40-60岁），建议定期监测血钙（目标范围8.5-10.2 mg/dL）和磷水平（目标范围2.5-4.5 mg/dL），并根据结果调整磷结合剂和维生素D类药物的剂量。建议每3至6个月评估骨密度，并考虑根据骨转换标志物水平调整治疗。并发症包括心血管疾病和软组织钙化，应密切监控这些情况的发展。
[2025-11-01 17:07:47,500] - Best result saved to: ./medical_ga_outputs/best_result.txt
[2025-11-01 17:27:20,571] - ==================================================
[2025-11-01 17:27:20,572] - Medical GA Prompt Optimization Starting
[2025-11-01 17:27:20,572] - ==================================================
[2025-11-01 17:27:20,572] - budget: 5
[2025-11-01 17:27:20,572] - popsize: 2
[2025-11-01 17:27:20,572] - sel_mode: tour
[2025-11-01 17:27:20,572] - ga_mode: topk
[2025-11-01 17:27:20,572] - qwen_model_path: ./Qwen2.5-7B-Instruct
[2025-11-01 17:27:20,572] - output_dir: ./medical_ga_outputs
[2025-11-01 17:27:20,572] - seed: 42
[2025-11-01 17:27:20,572] - Creating Medical Evaluator...
[2025-11-01 17:27:20,572] - Creating Medical GA Evoluter...
[2025-11-01 17:27:20,572] - ==================================================
[2025-11-01 17:27:20,572] - 
	budget = 5
	popsize = 2
	sel_mode = tour
	ga_mode = topk
	qwen_model_path = ./Qwen2.5-7B-Instruct
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 17:27:20,572] - ==================================================
[2025-11-01 17:27:20,572] - Starting evolution process...
[2025-11-01 17:27:20,572] - Evaluating initial user_input 1/2
[2025-11-01 17:27:20,572] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:28:07,505] - Difference score: 0.0
[2025-11-01 17:28:07,505] - Response1: 
[2025-11-01 17:28:07,505] - Response2: 
[2025-11-01 17:28:07,505] - Evaluating initial user_input 2/2
[2025-11-01 17:28:07,505] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:28:57,153] - Difference score: 0.0
[2025-11-01 17:28:57,153] - Response1: 
[2025-11-01 17:28:57,153] - Response2: 
[2025-11-01 17:28:57,153] - Initialized population with 2 user_inputs
[2025-11-01 17:28:57,153] - step 2, pop 0
[2025-11-01 17:29:17,166] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How can one manage osteodystrophy related to advanced nephropathy in elderly populations?
在老年人群中，高级肾病性骨营养不良的管理包括维持血钙和磷的平衡，通常建议血钙6.8-7.2 mg/dL, 血磷2.5-4.5 mg/dL。应定期监测血清钙、磷和副甲状腺激素水平，并可能需要使用磷结合剂或维生素D类药物调整。此外，适当的饮食调整和定期的骨密度测试也是必要的。年长患者可能还需考虑并发症如心血管疾病的风险。
[2025-11-01 17:30:43,888] - Difference score: 0.0
[2025-11-01 17:30:43,888] - Response1: 总之，通过综合治疗方案来有效地管理骨营養不良是关键。
回答者：Dr. Saurabh Gupta
Osteodystrophic changes are common in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). These include bone loss, decreased mineralization of the skeleton, increased risk for fractures, and secondary hyperparathyroidism.
The management of these complications is important because they contribute significantly to morbidity and mortality among CKD/ESRD patients. The goal of therapy should be to maintain serum calcium levels between 9.0–10.0 mg/dl and phosphorus levels below 3.5mg/dl while avoiding significant hypocalcemia or hyperphosphatemia. In addition to dietary modifications such as limiting phosphate intake from food sources like dairy products; medications may also play a role in managing these conditions effectively:
Calcium-based binders: Calcium carbonate or acetate tablets taken orally before meals help reduce absorption of dietary phosphates into the bloodstream by binding them together so that they cannot enter cells where they could cause damage over time due to their high acidity level when dissolved within body fluids like blood plasma etc.. This type of treatment has been shown effective at reducing both total serum PTH concentrations as well as urinary excretion rates which helps prevent further deterioration caused by excessive amounts being released from bones during resorption processes associated with aging process itself! Additionally there’s evidence suggesting long term use might even slow down progression towards more severe forms like dialysis dependence later on down road too!
Vitamin D analogues: Calcitriol (active form), alfacalcidol (inactive precursor converted into active form inside cell nucleus upon exposure sunlight rays); these two drugs work synergistically alongside each other since calcitriols main action lies primarily around increasing intestinal absorption rate whereas AlfaCalcidol acts mainly through stimulating production/release hormones responsible maintaining normal levels throughout entire body system including kidneys themselves! Both types available either alone or combined formulations depending individual needs & preferences though generally speaking most people prefer taking single dose once daily rather than multiple times per day especially those who suffer side effects such as nausea vomiting diarrhea constipation muscle cramps weakness fatigue dizziness confusion headache blurred vision dry mouth thirst metallic taste bad breath difficulty swallowing sore throat cough chest pain shortness breath rapid heartbeat irregular heart rhythm palpitations tingling numbness burning sensation pins needles sensations ringing ears hearing loss vertigo lightheadedness fainting seizures coma death etc… So always consult doctor first before starting any new medication
[2025-11-01 17:30:43,888] - Response2: 总之，通过综合治疗方案来有效地管理骨营養不良是关键。
回答者：Dr. Saurabh Gupta
Osteodystrophic changes are common in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). These include bone loss, decreased mineralization of the skeleton, increased risk for fractures, and secondary hyperparathyroidism.
The management of these complications is important because they contribute significantly to morbidity and mortality among CKD/ESRD patients. The goal of therapy should be to maintain serum calcium levels between 9.0–10.0 mg/dl and phosphorus levels below 3.5mg/dl while avoiding significant hypocalcemia or hyperphosphatemia. In addition to dietary modifications such as limiting phosphate intake from food sources like dairy products; medications may also play a role in managing these conditions effectively:
Calcium-based binders: Calcium carbonate or acetate tablets taken orally before meals help reduce absorption of dietary phosphates into the bloodstream by binding them together so that they cannot enter cells where they could cause damage over time due to their high acidity level when dissolved within body fluids like blood plasma etc.. This type of treatment has been shown effective at reducing both total serum PTH concentrations as well as urinary excretion rates which helps prevent further deterioration caused by excessive amounts being released from bones during resorption processes associated with aging process itself! Additionally there’s evidence suggesting long term use might even slow down progression towards more severe forms like dialysis dependence later on down road too!
Vitamin D analogues: Calcitriol (active form), alfacalcidol (inactive precursor converted into active form inside cell nucleus upon exposure sunlight rays); these two drugs work synergistically alongside each other since calcitriols main action lies primarily around increasing intestinal absorption rate whereas AlfaCalcidol acts mainly through stimulating production/release hormones responsible maintaining normal levels throughout entire body system including kidneys themselves! Both types available either alone or combined formulations depending individual needs & preferences though generally speaking most people prefer taking single dose once daily rather than multiple times per day especially those who suffer side effects such as nausea vomiting diarrhea constipation muscle cramps weakness fatigue dizziness confusion headache blurred vision dry mouth thirst metallic taste bad breath difficulty swallowing sore throat cough chest pain shortness breath rapid heartbeat irregular heart rhythm palpitations tingling numbness burning sensation pins needles sensations ringing ears hearing loss vertigo lightheadedness fainting seizures coma death etc… So always consult doctor first before starting any new medication
[2025-11-01 17:30:43,888] - new score: 0.0
[2025-11-01 17:30:43,888] - step 2, pop 1
[2025-11-01 17:30:58,208] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How should Osteodystrophy associated with End-Stage Renal Disease be managed?
请根据医学常识与临床经验，给出针对性建议。在20至70岁的成人中，建议监测血钙水平（正常范围8.6-10.2 mg/dL，可能波动±10%），血磷水平（正常3.5-5.5 mg/dL，可能波动±20%），并定期评估PTH（甲状旁腺激素）水平。针对检测结果，调整磷酸盐结合剂的剂量，考虑补充维生素D，以及可能的钙剂。此外，建议定期进行骨密度扫描以监测骨质疏松的进展，并在急诊和门诊场景中适当调整治疗策略。
[2025-11-01 17:31:46,427] - Difference score: 0.0
[2025-11-01 17:31:46,428] - Response1: 
[2025-11-01 17:31:46,428] - Response2: 
[2025-11-01 17:31:46,428] - new score: 0.0
[2025-11-01 17:31:46,448] - step 3, pop 0
[2025-11-01 17:31:59,742] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
在慢性肾病患者中，处理矿物质和骨骼紊乱包括调节血钙和磷的水平，建议的血钙通常为6.5-7.5 mg/dL，血磷为2.3-4.7 mg/dL。应定期监测血钙、磷水平及副甲状腺激素，根据需要使用磷结合剂和维他命D衍生物进行调整。饮食调整和骨密度测量也很关键，特别是在中老年患者中，还应注意心血管并发症的风险。
[2025-11-01 17:32:45,836] - Difference score: 0.0
[2025-11-01 17:32:45,836] - Response1: 
[2025-11-01 17:32:45,836] - Response2: 
[2025-11-01 17:32:45,836] - new score: 0.0
[2025-11-01 17:32:45,837] - step 3, pop 1
[2025-11-01 17:33:15,724] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the management strategies for renal osteodystrophy in the geriatric population with severe nephropathy?
针对老年人群中严重肾病性骨病的治理，建议维持血钙7.0-7.5 mg/dL和血磷3.0-5.0 mg/dL的水平。定期监测指标应包括血钙、磷水平及副甲状腺激素，可能需要加用磷结合剂或更高剂量的维生素D衍生物。同时，应调整饮食，增加骨密度测量频率，并注意心血管并发症如高血压和动脉硬化的风险管理。
[2025-11-01 17:34:01,955] - Difference score: 0.0
[2025-11-01 17:34:01,955] - Response1: 
[2025-11-01 17:34:01,955] - Response2: 
[2025-11-01 17:34:01,955] - new score: 0.0
[2025-11-01 17:34:01,977] - step 4, pop 0
[2025-11-01 17:34:20,452] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the latest strategies for managing renal osteodystrophy in the advanced stages of kidney disease among the elderly?
在老年人群中，晚期肾病性骨病的管理策略包括平衡血钙（建议范围6.5-7.5 mg/dL）和血磷（建议范围2.3-4.7 mg/dL）。定期监测血钙、磷以及副甲状腺激素水平至关重要，可能需要调整使用磷结合剂或增加维生素D补充剂的剂量。饮食调整和增加骨密度监测频率也是关键措施。应特别关注老年人可能出现的心血管并发症和糖尿病风险。
[2025-11-01 17:34:34,097] - ==================================================
[2025-11-01 17:34:34,097] - Medical GA Prompt Optimization Starting
[2025-11-01 17:34:34,097] - ==================================================
[2025-11-01 17:34:34,097] - budget: 5
[2025-11-01 17:34:34,097] - popsize: 6
[2025-11-01 17:34:34,097] - sel_mode: tour
[2025-11-01 17:34:34,098] - ga_mode: topk
[2025-11-01 17:34:34,098] - output_dir: ./medical_ga_outputs
[2025-11-01 17:34:34,098] - seed: 42
[2025-11-01 17:34:34,098] - Creating Medical Evaluator...
[2025-11-01 17:34:34,098] - Creating Medical GA Evoluter...
[2025-11-01 17:34:34,098] - ==================================================
[2025-11-01 17:34:34,098] - 
	budget = 5
	popsize = 6
	sel_mode = tour
	ga_mode = topk
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 17:34:34,098] - ==================================================
[2025-11-01 17:34:34,098] - Starting evolution process...
[2025-11-01 17:34:34,098] - Evaluating initial user_input 1/6
[2025-11-01 17:34:34,098] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:35:22,092] - Difference score: 0.0
[2025-11-01 17:35:22,093] - Response1: 
[2025-11-01 17:35:22,093] - Response2: 
[2025-11-01 17:35:22,093] - Evaluating initial user_input 2/6
[2025-11-01 17:35:22,093] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:36:12,594] - Difference score: 0.0
[2025-11-01 17:36:12,594] - Response1: 
[2025-11-01 17:36:12,595] - Response2: 
[2025-11-01 17:36:12,595] - Evaluating initial user_input 3/6
[2025-11-01 17:36:12,595] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:37:02,027] - Difference score: 0.0
[2025-11-01 17:37:02,028] - Response1: 
[2025-11-01 17:37:02,028] - Response2: 
[2025-11-01 17:37:02,028] - Evaluating initial user_input 4/6
[2025-11-01 17:37:02,028] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What is (are) Chromosome 8p deletion ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:37:48,798] - Difference score: 0.0
[2025-11-01 17:37:48,798] - Response1: 
[2025-11-01 17:37:48,798] - Response2: 
[2025-11-01 17:37:48,799] - Evaluating initial user_input 5/6
[2025-11-01 17:37:48,799] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to branchiootorenal/branchiootic syndrome ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:38:36,019] - Difference score: 0.0
[2025-11-01 17:38:36,019] - Response1: 
[2025-11-01 17:38:36,019] - Response2: 
[2025-11-01 17:38:36,019] - Evaluating initial user_input 6/6
[2025-11-01 17:38:36,019] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Hirschsprung disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:39:26,780] - Difference score: 0.0
[2025-11-01 17:39:26,780] - Response1: 
[2025-11-01 17:39:26,780] - Response2: 
[2025-11-01 17:39:26,781] - Initialized population with 6 user_inputs
[2025-11-01 17:39:26,781] - best_scores: 
[2025-11-01 17:39:26,781] - avg_scores: 
[2025-11-01 17:39:26,813] - ==================================================
[2025-11-01 17:39:26,813] - Medical GA Optimization Completed!
[2025-11-01 17:39:26,813] - ==================================================
[2025-11-01 17:39:26,813] - Best Score: 0.0
[2025-11-01 17:39:26,813] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:39:26,813] - Best result saved to: ./medical_ga_outputs/best_result.txt
[2025-11-01 17:41:48,511] - ==================================================
[2025-11-01 17:41:48,512] - Medical GA Prompt Optimization Starting
[2025-11-01 17:41:48,512] - ==================================================
[2025-11-01 17:41:48,512] - budget: 5
[2025-11-01 17:41:48,512] - popsize: 6
[2025-11-01 17:41:48,512] - sel_mode: tour
[2025-11-01 17:41:48,512] - ga_mode: topk
[2025-11-01 17:41:48,512] - output_dir: ./medical_ga_outputs
[2025-11-01 17:41:48,512] - seed: 42
[2025-11-01 17:41:48,512] - Creating Medical Evaluator...
[2025-11-01 17:41:48,512] - Creating Medical GA Evoluter...
[2025-11-01 17:41:48,512] - ==================================================
[2025-11-01 17:41:48,512] - 
	budget = 5
	popsize = 6
	sel_mode = tour
	ga_mode = topk
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 17:41:48,512] - ==================================================
[2025-11-01 17:41:48,512] - Starting evolution process...
[2025-11-01 17:41:48,512] - Evaluating initial user_input 1/6
[2025-11-01 17:41:48,512] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:42:59,256] - Difference score: 0.4982302681505335
[2025-11-01 17:42:59,256] - Response1: 请注意避免使用复杂的术语和专业词汇，以便普通人也能理解。
答案：Mineral and bone disorder (MBD) is a common complication of chronic kidney disease (CKD). It refers to the abnormal levels of minerals, such as calcium, phosphorus, magnesium, and parathyroid hormone (PTH), which can lead to various health problems. The most common type of MBD seen in CKD patients is hyperphosphatemia, or high blood phosphate levels.
To manage MBD in CKDs, it's important to follow a healthy diet that includes limiting intake of foods high in phosphates, such sodium-rich processed meats, dairy products, and soft drinks. Additionally, taking medications like sevelamer hydrochloride or lanthanum carbonate may help reduce serum phosphorous levels. In severe cases where dietary modifications are not enough, hemodialysis or peritoneal dialysis may be necessary to remove excess phosphates from the body.
It’s also crucial to maintain adequate vitamin D levels through supplements or exposure to sunlight since this helps regulate PTH production by the kidneys. Finally, regular monitoring of mineral and electrolyte levels via laboratory tests will allow your doctor to adjust treatment accordingly based on individual needs.
In conclusion, managing MBD effectively requires close collaboration between patient and healthcare provider involving proper nutrition management alongside appropriate use of medication when needed along with periodic lab testing to ensure optimal outcomes over time.
[2025-11-01 17:42:59,256] - Response2: 请注意避免使用复杂的术语和专业词汇，以便普通人也能理解。
答案：Mineral and bone disorder (MBD) is a common complication of chronic kidney disease (CKD). It refers to the abnormal levels of minerals, such as calcium, phosphorus, magnesium, and parathyroid hormone (PTH), which can lead to various health problems. The most common type of MBD seen in CKD patients is hyperphosphatemia, or high blood phosphate levels.
To manage MBD in CKDs, it's important to follow your doctor's recommendations regarding diet, medications, and lifestyle changes. Here are some general tips:
1. Follow a low-phosphate diet: This means limiting foods that contain high amounts of phosphates, such sodium-rich processed meats, soft drinks, and dairy products like milk and cheese. Instead, focus on eating more fruits, vegetables, whole grains, lean proteins, and healthy fats.
2. Take prescribed medications: Your doctor may prescribe medications to help control mineral levels, including phosphate binders, vitamin D supplements, and calcimimetics.
3. Get regular exercise: Exercise helps maintain strong bones and muscles, which can reduce the risk of fractures and other complications associated with MBD.
4. Avoid smoking and excessive alcohol consumption: These habits can increase the risk for osteoporosis and other bone-related issues.
5. Monitor symptoms closely: If you experience any unusual symptoms related to MBD, such
[2025-11-01 17:42:59,257] - Evaluating initial user_input 2/6
[2025-11-01 17:42:59,257] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:44:05,907] - Difference score: 0.18142750299935845
[2025-11-01 17:44:05,907] - Response1: 请注意避免使用非正式语气和不必要的信息。
Leydig cell agenesis is a rare cause of male pseudohermaphroditism. It results from an absence or severe deficiency in testicular testosterone production due to lack of Leydig cells, which leads to failure of virilization during fetal development.
The most common form of this disorder (type 1) is caused by mutations in the LHCGR gene and accounts for approximately half of all cases. This gene encodes the luteinizing hormone receptor (LHR), which mediates the action of LH on Leydigcells. Mutations in thisgene leadto loss offunctional receptorsand impaired signaling throughthe MAPK pathway,resulting in decreased testosterone synthesis.
Other forms of Leydiggcellagenesissuch as type2arecausedbymutationsinthegene encoding steroidogenic acute regulatory protein(SA R).Thisproteinisrequiredfortransportofcholesterolinto mitochondria where it servesasapre-cursorformetabolites such astestosterone. Mutant proteins fail to bind cholesterol properly, leading to reduced levels of intracellularsteroid hormones includingtestosterone.
In addition to these two genes, other potential causes include defects in transcription factors involved in regulating expression of both LHC GR and SAR genes, as well as abnormalities in enzymes required for conversion of pregnenolone into progesterone and then further down the steroidogenesis pathway towards testosterone production.
[2025-11-01 17:44:05,907] - Response2: 请注意避免使用非正式语气和不必要的信息。
Leydig cell agenesis is a rare cause of male pseudohermaphroditism. It results from an absence or severe deficiency in testicular testosterone production due to lack of Leydig cells, which leads to failure of virilization during fetal development.
The condition can be caused by mutations in several genes that encode proteins involved in steroidogenesis and/or regulation of Leydic cell function:
CYP11A1 (cytochrome P450 family 11 subfamily A member 1): encodes cytochrome p450 side chain cleavage enzyme, which catalyzes the first step in cholesterol biosynthesis leading to pregnenolone synthesis;
STAR (steroidogenic acute regulatory protein): regulates intracellular transport of cholesterol into mitochondria for conversion to pregnanolone;
HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta-and delta-isomerase type II): converts pregnanediol to progesterone;
[2025-11-01 17:44:05,908] - Evaluating initial user_input 3/6
[2025-11-01 17:44:05,908] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:45:16,482] - Difference score: 0.5195890924803089
[2025-11-01 17:45:16,483] - Response1: 请注意避免使用非正式语气和不必要的信息。
Acanthameba keratits is a rare but serious infection of the cornea caused by an amoebic organism. It can be treated with topical and systemic anti-fungal medications, as well as surgical removal of infected tissue.
The treatment of acanthameba granulomatosis amebic encephalitisis (GAAE) depends on the severity of symptoms and may include:
Antibiotics: Antibiotics such as metronidazole or sulfamethoxazole/trimethoprim may be used to treat GAAE.
Surgery: Surgery may be necessary in severe cases to remove any affected areas of brain tissue.
Steroids: Steroid therapy may help reduce inflammation associated with GAAEs.
Other Treatments: Other treatments that have been tried include hyperbaric oxygen therapy, plasmapheresis, and immunosuppressive drugs like cyclosporine or tacrolimus.
It's important to note that there is no cure for GAAES at this time; however, early diagnosis and prompt treatment can improve outcomes significantly.
[2025-11-01 17:45:16,483] - Response2: 请注意避免使用非正式语气和不必要的信息。
Acanthameba keratits is a rare but serious infection of the cornea caused by an amoebic organism. It can be treated with topical and systemic anti-fungal medications, as well as surgical removal of infected tissue.
The treatment of acanthameba granulomatosis amebic encephalitisis (GAAE) depends on the severity of symptoms and may include:
Antibiotics: These drugs help fight off bacterial infections that can occur along with GAAE.
Anti-inflammatory medicines: These reduce inflammation in the brain and spinal cord.
Surgery: In some cases, surgery may be needed to remove damaged or infected tissues from around the eyes or other parts of your body where they have spread due to this condition.
Radiation therapy: This type of radiation uses high-energy X-rays or gamma rays to kill cancer cells without damaging healthy ones nearby; it’s often used when there isn’t enough time left before death occurs because chemotherapy hasn’t worked yet either way though!
Acanthagamia granulomatis ameobic encephaloencephalomyelitis (AGAE), also known as “granuloma annulare” or simply “GA,” is a chronic inflammatory disease characterized by multiple nodules on the skin and mucosal surfaces. The most common sites affected are the face, neck, chest wall, back, arms, legs, hands, feet, scalp, ears, nose, mouth, throat, tongue, lips, gums, teeth, nails, hair follicles, sweat glands, sebaceous glands, lymph nodes, liver, spleen, kidneys, lungs, heart muscle fibers (myocardium), blood vessels (arteries), nerves (neurons).
The cause of AGAE remains unknown despite extensive research over many years into its etiology which includes genetic factors such as mutations within certain genes involved in immune function regulation pathways like TLR4 signaling pathway leading up towards development of autoimmune disorders including rheumatoid arthritis RA). Other possible causes could involve environmental exposures during childhood such as exposure through contact sports involving head trauma resulting from falls onto hard surfaces while playing soccer football etc., although no direct link has been established between these two events so far!
[2025-11-01 17:45:16,483] - Evaluating initial user_input 4/6
[2025-11-01 17:45:16,483] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What is (are) Chromosome 8p deletion ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:46:25,483] - Difference score: 0.09335543459996501
[2025-11-01 17:46:25,483] - Response1: 请注意避免使用非正式语气和不必要的信息。
Chromosome 8 p deletion syndrome, also known as monosomy 8 or partial monosmy of the short arm of chromosome 8, is a rare genetic disorder that affects many parts of the body. It occurs when there are missing genes on one copy of chromosome number 8 in each cell.
The signs and symptoms associated with this condition vary widely among affected individuals. Some people have mild features such as learning disabilities, while others may be more severely affected and experience intellectual disability, delayed development, seizures, heart defects, and other medical problems.
This condition can occur randomly for no apparent reason (sporadically). In some cases, it results from an error during the formation of reproductive cells (eggs or sperm), which leads to abnormal chromosomes being passed down to offspring. This type of inheritance pattern is called autosomal dominant because only one copy (not two copies) of the gene needs to be altered for someone to develop the condition.
In other cases, chromosomal abnormalities involving chromosome 7 may cause deletions at different locations along its length; these types of changes tend not to run in families but instead happen spontaneously due to random errors during cell division processes like mitosis or meiosis. These events usually result in multiple copies rather than single ones so they’re referred to as “mosaicism” since there’s variation between cells within an individual person who carries them out over time depending upon how much DNA has been lost through recombination processes during gamete production stages prior conception taking place leading up towards birth itself!
[2025-11-01 17:46:25,483] - Response2: 请注意避免使用非正式语气和不必要的信息。
Chromosome 8 p deletion syndrome, also known as monosomy 8 or partial monosmy of the short arm of chromosome 8, is a rare genetic disorder that affects many parts of the body. It occurs when there are missing genes on one copy of chromosome number 8 in each cell.
The signs and symptoms associated with this condition vary widely among affected individuals, even within the same family. Some people have mild features such as learning disabilities, while others may be more severely affected and experience intellectual disability, delayed development, seizures, heart defects, and other medical problems.
This condition can occur randomly for unknown reasons (sporadically). In some cases, it results from an error during the formation of reproductive cells (eggs or sperm), which leads to abnormal chromosomes being passed down to offspring. This type of inheritance pattern is called autosomal dominant because only one copy (from either parent) needs to contain the mutation for the child to develop the condition.
In other cases, chromosomal abnormalities involving chromosome 7 may cause deletions at different locations along its length; these types of rearrangements usually involve both copies of chromosome seven (autosomal recessive).
https://rarediseases.org/rare-diseases/chromosome-8-p-deletion-syndrome/
https://www.ncbi.nlm.nih.gov/books/NBK546537/
[2025-11-01 17:46:25,483] - Evaluating initial user_input 5/6
[2025-11-01 17:46:25,483] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to branchiootorenal/branchiootic syndrome ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:47:42,175] - Difference score: 0.0
[2025-11-01 17:47:42,175] - Response1: 请勿引用外部资料或链接。
The BOR gene is located on chromosome 1q31.3 and encodes a protein called EYA4, which plays an important role in embryonic development of the ear, face, neck, and kidneys.
Mutations in this gene can cause branchio-oto-renal (BOR) or branchiootic (BO) syndromes, both of which involve abnormalities of the ears, eyes, nose, throat, and/or kidneys.
In addition to these two conditions, mutations in other genes have also been linked with similar symptoms:
• Mutations in SIX5 gene: Branchiooculofacial syndrome (BOFS)
• Mutational analysis of GATA3 gene: Hypoparathyroidism-deafness-renal dysplasia syndrome (HDRD)
• Mutation in SALL1 gene: Townes-Brocks Syndrome (TBS).
These three disorders share some features but differ from each other based upon their specific clinical manifestations.
For instance, while all three may present with hearing loss due to malformations of the inner ear structures such as semicircular canal defects; only HDRS patients will develop hypocalcemia secondary to parathyroid gland dysfunction leading to seizures and coma if left untreated.
Similarly, although BOFS shares many similarities with BOR including facial clefts and preauricular pits; it does not affect renal function unlike TBS where affected individuals often suffer from kidney failure requiring dialysis early in life.
Therefore, when evaluating someone suspected of having one of these rare diseases, it’s essential to consider multiple factors beyond just physical examination findings alone since there isn’t always going to be clear cut answers right away!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089766/#:~:text=Branchio%2Dto%2Do%2Drenal%20syndrome%20(BORS)%20is,affecting%20the%20ear%2C%20face%2
[2025-11-01 17:47:42,175] - Response2: 请勿引用外部资料或链接。
The BOR gene is located on chromosome 1q31.3 and encodes a protein called EYA4, which plays an important role in embryonic development of the ear, face, neck, and kidneys.
Mutations in this gene can cause branchio-oto-renal (BOR) or branchiootic (BO) syndromes, both of which involve abnormalities of the ears, eyes, nose, throat, and/or kidneys.
In addition to these two conditions, mutations in other genes have also been linked with similar symptoms:
• Mutations in SIX5 gene: Branchiooculofacial syndrome (BOFS)
• Mutational analysis of GATA3 gene: Hypoparathyroidism-deafness-renal dysplasia syndrome (HDRD)
• Mutation in SALL1 gene: Townes-Brocks Syndrome (TBS).
These three disorders share some features but differ from each other based upon their specific clinical manifestations.
For instance, while all three may present with hearing loss due to malformations of the inner ear structures such as semicircular canal defects; only HDRS patients will develop hypocalcemia secondary to parathyroid gland dysfunction leading to seizures and coma if left untreated.
Similarly, although BOFS shares many similarities with BOR including facial clefts and preauricular pits; it does not affect renal function unlike TBS where affected individuals often suffer from kidney failure requiring dialysis early in life.
Therefore, when evaluating someone suspected of having one of these rare diseases, it’s essential to consider multiple factors beyond just physical examination findings alone since there isn’t always going to be clear cut answers right away!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089766/#:~:text=Branchio%2Dto%2Do%2Drenal%20syndrome%20(BORS)%20is,affecting%20the%20ear%2C%20face%2
[2025-11-01 17:47:42,176] - Evaluating initial user_input 6/6
[2025-11-01 17:47:42,176] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Hirschsprung disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:48:53,702] - Difference score: 0.0
[2025-11-01 17:48:53,702] - Response1: 请注意避免使用非正式语气和不必要的信息。
Hirschsprug's disease is a congenital disorder of the enteric nervous system. It results in an absence of ganglion cells within the myenteric and submucosal plexus, which leads to aganglionosis.
The most common mutation associated with this condition is RET proto-oncogene (RET) mutations. The RET gene encodes for a receptor tyrosine kinase that plays a role in neural crest cell development. Mutations in this gene can lead to abnormal migration or differentiation of these cells during embryonic development, resulting in aganglionic segments of bowel.
Other genes involved include EDNRB, ECE1, SOX10, PHOX2B, GDNF, NRTN, SLC6A8, and KIAA1279.
It should be noted that not all cases of Hirschprung’s Disease have been linked to specific genetic mutations; some may occur due to environmental factors such as exposure to certain chemicals or drugs during pregnancy.
In conclusion, there are several known genetic causes behind Hirschprungs’ Disease including RET Proto-Oncogene mutations but other genes like EDNRb, Ece1 etc also play important roles in its pathogenesis. Environmental exposures could potentially contribute too although more research needs done here.
参考答案：Hirschspurgs' disease is caused by mutations in multiple genes including RET proto oncogenes,EDNRB,ECE1,SOX10,GDNF,NRTN,KIAA 1279 and others. These mutations cause defects in neural creast cell development leading to absent ganglia along affected segment of intestine.
[2025-11-01 17:48:53,702] - Response2: 请注意避免使用非正式语气和不必要的信息。
Hirschsprug's disease is a congenital disorder of the enteric nervous system. It results in an absence of ganglion cells within the myenteric and submucosal plexus, which leads to aganglionosis.
The most common mutation associated with this condition is RET proto-oncogene (RET) mutations. The RET gene encodes for a receptor tyrosine kinase that plays a role in neural crest cell development. Mutations in this gene can lead to abnormal migration or differentiation of these cells during embryonic development, resulting in aganglionic segments of bowel.
Other genes involved include EDNRB, ECE1, SOX10, PHOX2B, GDNF, NRTN, SLC6A8, and KIAA1279.
It should be noted that not all cases of Hirschprung’s Disease have been linked to specific genetic mutations; some may occur due to environmental factors such as exposure to certain chemicals or drugs during pregnancy.
In conclusion, there are several known genetic causes behind Hirschprungs’ Disease including RET Proto-Oncogene mutations but other genes like EDNRb, Ece1 etc also play important roles in its pathogenesis. Environmental exposures could potentially contribute too although more research needs done here.
参考答案：Hirschspurgs' disease is caused by mutations in multiple genes including RET proto oncogenes,EDNRB,ECE1,SOX10,GDNF,NRTN,KIAA 1279 and others. These mutations cause defects in neural creast cell development leading to absent ganglia along affected segment of intestine.
[2025-11-01 17:48:53,703] - Initialized population with 6 user_inputs
[2025-11-01 17:48:53,703] - best_scores: 
[2025-11-01 17:48:53,703] - avg_scores: 
[2025-11-01 17:48:53,703] - ==================================================
[2025-11-01 17:48:53,703] - Medical GA Optimization Completed!
[2025-11-01 17:48:53,703] - ==================================================
[2025-11-01 17:48:53,703] - Best Score: 0.5195890924803089
[2025-11-01 17:48:53,703] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 17:48:53,703] - Best result saved to: ./medical_ga_outputs/best_result.txt
[2025-11-01 18:20:28,783] - ==================================================
[2025-11-01 18:20:28,783] - Medical GA Prompt Optimization Starting
[2025-11-01 18:20:28,783] - ==================================================
[2025-11-01 18:20:28,783] - budget: 10
[2025-11-01 18:20:28,783] - popsize: 6
[2025-11-01 18:20:28,783] - sel_mode: tour
[2025-11-01 18:20:28,783] - ga_mode: topk
[2025-11-01 18:20:28,783] - output_dir: ./medical_ga_outputs
[2025-11-01 18:20:28,783] - seed: 42
[2025-11-01 18:20:28,783] - Creating Medical Evaluator...
[2025-11-01 18:20:28,783] - Creating Medical GA Evoluter...
[2025-11-01 18:20:28,783] - ==================================================
[2025-11-01 18:20:28,783] - 
	budget = 10
	popsize = 6
	sel_mode = tour
	ga_mode = topk
	output_dir = ./medical_ga_outputs
	seed = 42
[2025-11-01 18:20:28,783] - ==================================================
[2025-11-01 18:20:28,783] - Starting evolution process...
[2025-11-01 18:20:28,783] - Evaluating initial user_input 1/6
[2025-11-01 18:20:28,783] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What to do for Mineral and Bone Disorder in Chronic Kidney Disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 18:21:37,634] - Difference score: 0.4982302681505335
[2025-11-01 18:21:37,634] - Response1: 请注意避免使用复杂的术语和专业词汇，以便普通人也能理解。
答案：Mineral and bone disorder (MBD) is a common complication of chronic kidney disease (CKD). It refers to the abnormal levels of minerals, such as calcium, phosphorus, magnesium, and parathyroid hormone (PTH), which can lead to various health problems. The most common type of MBD seen in CKD patients is hyperphosphatemia, or high blood phosphate levels.
To manage MBD in CKDs, it's important to follow a healthy diet that includes limiting intake of foods high in phosphates, such sodium-rich processed meats, dairy products, and soft drinks. Additionally, taking medications like sevelamer hydrochloride or lanthanum carbonate may help reduce serum phosphorous levels. In severe cases where dietary modifications are not enough, hemodialysis or peritoneal dialysis may be necessary to remove excess phosphates from the body.
It’s also crucial to maintain adequate vitamin D levels through supplements or exposure to sunlight since this helps regulate PTH production by the kidneys. Finally, regular monitoring of mineral and electrolyte levels via laboratory tests will allow your doctor to adjust treatment accordingly based on individual needs.
In conclusion, managing MBD effectively requires close collaboration between patient and healthcare provider involving proper nutrition management alongside appropriate use of medication when needed along with periodic lab testing to ensure optimal outcomes over time.
[2025-11-01 18:21:37,635] - Response2: 请注意避免使用复杂的术语和专业词汇，以便普通人也能理解。
答案：Mineral and bone disorder (MBD) is a common complication of chronic kidney disease (CKD). It refers to the abnormal levels of minerals, such as calcium, phosphorus, magnesium, and parathyroid hormone (PTH), which can lead to various health problems. The most common type of MBD seen in CKD patients is hyperphosphatemia, or high blood phosphate levels.
To manage MBD in CKDs, it's important to follow your doctor's recommendations regarding diet, medications, and lifestyle changes. Here are some general tips:
1. Follow a low-phosphate diet: This means limiting foods that contain high amounts of phosphates, such sodium-rich processed meats, soft drinks, and dairy products like milk and cheese. Instead, focus on eating more fruits, vegetables, whole grains, lean proteins, and healthy fats.
2. Take prescribed medications: Your doctor may prescribe medications to help control mineral levels, including phosphate binders, vitamin D supplements, and calcimimetics.
3. Get regular exercise: Exercise helps maintain strong bones and muscles, which can reduce the risk of fractures and other complications associated with MBD.
4. Avoid smoking and excessive alcohol consumption: These habits can increase the risk for osteoporosis and other bone-related issues.
5. Monitor symptoms closely: If you experience any unusual symptoms related to MBD, such
[2025-11-01 18:21:37,635] - Evaluating initial user_input 2/6
[2025-11-01 18:21:37,635] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Leydig cell hypoplasia ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 18:22:45,966] - Difference score: 0.18142750299935845
[2025-11-01 18:22:45,966] - Response1: 请注意避免使用非正式语气和不必要的信息。
Leydig cell agenesis is a rare cause of male pseudohermaphroditism. It results from an absence or severe deficiency in testicular testosterone production due to lack of Leydig cells, which leads to failure of virilization during fetal development.
The most common form of this disorder (type 1) is caused by mutations in the LHCGR gene and accounts for approximately half of all cases. This gene encodes the luteinizing hormone receptor (LHR), which mediates the action of LH on Leydigcells. Mutations in thisgene leadto loss offunctional receptorsand impaired signaling throughthe MAPK pathway,resulting in decreased testosterone synthesis.
Other forms of Leydiggcellagenesissuch as type2arecausedbymutationsinthegene encoding steroidogenic acute regulatory protein(SA R).Thisproteinisrequiredfortransportofcholesterolinto mitochondria where it servesasapre-cursorformetabolites such astestosterone. Mutant proteins fail to bind cholesterol properly, leading to reduced levels of intracellularsteroid hormones includingtestosterone.
In addition to these two genes, other potential causes include defects in transcription factors involved in regulating expression of both LHC GR and SAR genes, as well as abnormalities in enzymes required for conversion of pregnenolone into progesterone and then further down the steroidogenesis pathway towards testosterone production.
[2025-11-01 18:22:45,966] - Response2: 请注意避免使用非正式语气和不必要的信息。
Leydig cell agenesis is a rare cause of male pseudohermaphroditism. It results from an absence or severe deficiency in testicular testosterone production due to lack of Leydig cells, which leads to failure of virilization during fetal development.
The condition can be caused by mutations in several genes that encode proteins involved in steroidogenesis and/or regulation of Leydic cell function:
CYP11A1 (cytochrome P450 family 11 subfamily A member 1): encodes cytochrome p450 side chain cleavage enzyme, which catalyzes the first step in cholesterol biosynthesis leading to pregnenolone synthesis;
STAR (steroidogenic acute regulatory protein): regulates intracellular transport of cholesterol into mitochondria for conversion to pregnanolone;
HSD3B2 (hydroxy-delta-5-steroid dehydrogenase, 3 beta-and delta-isomerase type II): converts pregnanediol to progesterone;
[2025-11-01 18:22:45,966] - Evaluating initial user_input 3/6
[2025-11-01 18:22:45,966] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 18:23:57,298] - Difference score: 0.5195890924803089
[2025-11-01 18:23:57,298] - Response1: 请注意避免使用非正式语气和不必要的信息。
Acanthameba keratits is a rare but serious infection of the cornea caused by an amoebic organism. It can be treated with topical and systemic anti-fungal medications, as well as surgical removal of infected tissue.
The treatment of acanthameba granulomatosis amebic encephalitisis (GAAE) depends on the severity of symptoms and may include:
Antibiotics: Antibiotics such as metronidazole or sulfamethoxazole/trimethoprim may be used to treat GAAE.
Surgery: Surgery may be necessary in severe cases to remove any affected areas of brain tissue.
Steroids: Steroid therapy may help reduce inflammation associated with GAAEs.
Other Treatments: Other treatments that have been tried include hyperbaric oxygen therapy, plasmapheresis, and immunosuppressive drugs like cyclosporine or tacrolimus.
It's important to note that there is no cure for GAAES at this time; however, early diagnosis and prompt treatment can improve outcomes significantly.
[2025-11-01 18:23:57,298] - Response2: 请注意避免使用非正式语气和不必要的信息。
Acanthameba keratits is a rare but serious infection of the cornea caused by an amoebic organism. It can be treated with topical and systemic anti-fungal medications, as well as surgical removal of infected tissue.
The treatment of acanthameba granulomatosis amebic encephalitisis (GAAE) depends on the severity of symptoms and may include:
Antibiotics: These drugs help fight off bacterial infections that can occur along with GAAE.
Anti-inflammatory medicines: These reduce inflammation in the brain and spinal cord.
Surgery: In some cases, surgery may be needed to remove damaged or infected tissues from around the eyes or other parts of your body where they have spread due to this condition.
Radiation therapy: This type of radiation uses high-energy X-rays or gamma rays to kill cancer cells without damaging healthy ones nearby; it’s often used when there isn’t enough time left before death occurs because chemotherapy hasn’t worked yet either way though!
Acanthagamia granulomatis ameobic encephaloencephalomyelitis (AGAE), also known as “granuloma annulare” or simply “GA,” is a chronic inflammatory disease characterized by multiple nodules on the skin and mucosal surfaces. The most common sites affected are the face, neck, chest wall, back, arms, legs, hands, feet, scalp, ears, nose, mouth, throat, tongue, lips, gums, teeth, nails, hair follicles, sweat glands, sebaceous glands, lymph nodes, liver, spleen, kidneys, lungs, heart muscle fibers (myocardium), blood vessels (arteries), nerves (neurons).
The cause of AGAE remains unknown despite extensive research over many years into its etiology which includes genetic factors such as mutations within certain genes involved in immune function regulation pathways like TLR4 signaling pathway leading up towards development of autoimmune disorders including rheumatoid arthritis RA). Other possible causes could involve environmental exposures during childhood such as exposure through contact sports involving head trauma resulting from falls onto hard surfaces while playing soccer football etc., although no direct link has been established between these two events so far!
[2025-11-01 18:23:57,298] - Evaluating initial user_input 4/6
[2025-11-01 18:23:57,298] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What is (are) Chromosome 8p deletion ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 18:25:05,339] - Difference score: 0.09335543459996501
[2025-11-01 18:25:05,339] - Response1: 请注意避免使用非正式语气和不必要的信息。
Chromosome 8 p deletion syndrome, also known as monosomy 8 or partial monosmy of the short arm of chromosome 8, is a rare genetic disorder that affects many parts of the body. It occurs when there are missing genes on one copy of chromosome number 8 in each cell.
The signs and symptoms associated with this condition vary widely among affected individuals. Some people have mild features such as learning disabilities, while others may be more severely affected and experience intellectual disability, delayed development, seizures, heart defects, and other medical problems.
This condition can occur randomly for no apparent reason (sporadically). In some cases, it results from an error during the formation of reproductive cells (eggs or sperm), which leads to abnormal chromosomes being passed down to offspring. This type of inheritance pattern is called autosomal dominant because only one copy (not two copies) of the gene needs to be altered for someone to develop the condition.
In other cases, chromosomal abnormalities involving chromosome 7 may cause deletions at different locations along its length; these types of changes tend not to run in families but instead happen spontaneously due to random errors during cell division processes like mitosis or meiosis. These events usually result in multiple copies rather than single ones so they’re referred to as “mosaicism” since there’s variation between cells within an individual person who carries them out over time depending upon how much DNA has been lost through recombination processes during gamete production stages prior conception taking place leading up towards birth itself!
[2025-11-01 18:25:05,339] - Response2: 请注意避免使用非正式语气和不必要的信息。
Chromosome 8 p deletion syndrome, also known as monosomy 8 or partial monosmy of the short arm of chromosome 8, is a rare genetic disorder that affects many parts of the body. It occurs when there are missing genes on one copy of chromosome number 8 in each cell.
The signs and symptoms associated with this condition vary widely among affected individuals, even within the same family. Some people have mild features such as learning disabilities, while others may be more severely affected and experience intellectual disability, delayed development, seizures, heart defects, and other medical problems.
This condition can occur randomly for unknown reasons (sporadically). In some cases, it results from an error during the formation of reproductive cells (eggs or sperm), which leads to abnormal chromosomes being passed down to offspring. This type of inheritance pattern is called autosomal dominant because only one copy (from either parent) needs to contain the mutation for the child to develop the condition.
In other cases, chromosomal abnormalities involving chromosome 7 may cause deletions at different locations along its length; these types of rearrangements usually involve both copies of chromosome seven (autosomal recessive).
https://rarediseases.org/rare-diseases/chromosome-8-p-deletion-syndrome/
https://www.ncbi.nlm.nih.gov/books/NBK546537/
[2025-11-01 18:25:05,339] - Evaluating initial user_input 5/6
[2025-11-01 18:25:05,339] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to branchiootorenal/branchiootic syndrome ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 18:26:21,240] - Difference score: 0.0
[2025-11-01 18:26:21,240] - Response1: 请勿引用外部资料或链接。
The BOR gene is located on chromosome 1q31.3 and encodes a protein called EYA4, which plays an important role in embryonic development of the ear, face, neck, and kidneys.
Mutations in this gene can cause branchio-oto-renal (BOR) or branchiootic (BO) syndromes, both of which involve abnormalities of the ears, eyes, nose, throat, and/or kidneys.
In addition to these two conditions, mutations in other genes have also been linked with similar symptoms:
• Mutations in SIX5 gene: Branchiooculofacial syndrome (BOFS)
• Mutational analysis of GATA3 gene: Hypoparathyroidism-deafness-renal dysplasia syndrome (HDRD)
• Mutation in SALL1 gene: Townes-Brocks Syndrome (TBS).
These three disorders share some features but differ from each other based upon their specific clinical manifestations.
For instance, while all three may present with hearing loss due to malformations of the inner ear structures such as semicircular canal defects; only HDRS patients will develop hypocalcemia secondary to parathyroid gland dysfunction leading to seizures and coma if left untreated.
Similarly, although BOFS shares many similarities with BOR including facial clefts and preauricular pits; it does not affect renal function unlike TBS where affected individuals often suffer from kidney failure requiring dialysis early in life.
Therefore, when evaluating someone suspected of having one of these rare diseases, it’s essential to consider multiple factors beyond just physical examination findings alone since there isn’t always going to be clear cut answers right away!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089766/#:~:text=Branchio%2Dto%2Do%2Drenal%20syndrome%20(BORS)%20is,affecting%20the%20ear%2C%20face%2
[2025-11-01 18:26:21,240] - Response2: 请勿引用外部资料或链接。
The BOR gene is located on chromosome 1q31.3 and encodes a protein called EYA4, which plays an important role in embryonic development of the ear, face, neck, and kidneys.
Mutations in this gene can cause branchio-oto-renal (BOR) or branchiootic (BO) syndromes, both of which involve abnormalities of the ears, eyes, nose, throat, and/or kidneys.
In addition to these two conditions, mutations in other genes have also been linked with similar symptoms:
• Mutations in SIX5 gene: Branchiooculofacial syndrome (BOFS)
• Mutational analysis of GATA3 gene: Hypoparathyroidism-deafness-renal dysplasia syndrome (HDRD)
• Mutation in SALL1 gene: Townes-Brocks Syndrome (TBS).
These three disorders share some features but differ from each other based upon their specific clinical manifestations.
For instance, while all three may present with hearing loss due to malformations of the inner ear structures such as semicircular canal defects; only HDRS patients will develop hypocalcemia secondary to parathyroid gland dysfunction leading to seizures and coma if left untreated.
Similarly, although BOFS shares many similarities with BOR including facial clefts and preauricular pits; it does not affect renal function unlike TBS where affected individuals often suffer from kidney failure requiring dialysis early in life.
Therefore, when evaluating someone suspected of having one of these rare diseases, it’s essential to consider multiple factors beyond just physical examination findings alone since there isn’t always going to be clear cut answers right away!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089766/#:~:text=Branchio%2Dto%2Do%2Drenal%20syndrome%20(BORS)%20is,affecting%20the%20ear%2C%20face%2
[2025-11-01 18:26:21,240] - Evaluating initial user_input 6/6
[2025-11-01 18:26:21,240] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic changes related to Hirschsprung disease ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 18:27:33,126] - Difference score: 0.0
[2025-11-01 18:27:33,127] - Response1: 请注意避免使用非正式语气和不必要的信息。
Hirschsprug's disease is a congenital disorder of the enteric nervous system. It results in an absence of ganglion cells within the myenteric and submucosal plexus, which leads to aganglionosis.
The most common mutation associated with this condition is RET proto-oncogene (RET) mutations. The RET gene encodes for a receptor tyrosine kinase that plays a role in neural crest cell development. Mutations in this gene can lead to abnormal migration or differentiation of these cells during embryonic development, resulting in aganglionic segments of bowel.
Other genes involved include EDNRB, ECE1, SOX10, PHOX2B, GDNF, NRTN, SLC6A8, and KIAA1279.
It should be noted that not all cases of Hirschprung’s Disease have been linked to specific genetic mutations; some may occur due to environmental factors such as exposure to certain chemicals or drugs during pregnancy.
In conclusion, there are several known genetic causes behind Hirschprungs’ Disease including RET Proto-Oncogene mutations but other genes like EDNRb, Ece1 etc also play important roles in its pathogenesis. Environmental exposures could potentially contribute too although more research needs done here.
参考答案：Hirschspurgs' disease is caused by mutations in multiple genes including RET proto oncogenes,EDNRB,ECE1,SOX10,GDNF,NRTN,KIAA 1279 and others. These mutations cause defects in neural creast cell development leading to absent ganglia along affected segment of intestine.
[2025-11-01 18:27:33,127] - Response2: 请注意避免使用非正式语气和不必要的信息。
Hirschsprug's disease is a congenital disorder of the enteric nervous system. It results in an absence of ganglion cells within the myenteric and submucosal plexus, which leads to aganglionosis.
The most common mutation associated with this condition is RET proto-oncogene (RET) mutations. The RET gene encodes for a receptor tyrosine kinase that plays a role in neural crest cell development. Mutations in this gene can lead to abnormal migration or differentiation of these cells during embryonic development, resulting in aganglionic segments of bowel.
Other genes involved include EDNRB, ECE1, SOX10, PHOX2B, GDNF, NRTN, SLC6A8, and KIAA1279.
It should be noted that not all cases of Hirschprung’s Disease have been linked to specific genetic mutations; some may occur due to environmental factors such as exposure to certain chemicals or drugs during pregnancy.
In conclusion, there are several known genetic causes behind Hirschprungs’ Disease including RET Proto-Oncogene mutations but other genes like EDNRb, Ece1 etc also play important roles in its pathogenesis. Environmental exposures could potentially contribute too although more research needs done here.
参考答案：Hirschspurgs' disease is caused by mutations in multiple genes including RET proto oncogenes,EDNRB,ECE1,SOX10,GDNF,NRTN,KIAA 1279 and others. These mutations cause defects in neural creast cell development leading to absent ganglia along affected segment of intestine.
[2025-11-01 18:27:33,127] - Initialized population with 6 user_inputs
[2025-11-01 18:27:33,127] - step 6, pop 0
[2025-11-01 18:27:56,094] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the updated therapeutic approaches for Protozoan - Acanthamoeba Cerebral Infection; Corneal Inflammation?
请根据医学常识与临床实践经验给出直接、重点突出的回答。在治疗Acanthamoeba引起的脑炎和角膜炎时，推荐使用以下方案：对于年轻患者（20-30岁），建议使用每日两次的局部氯己定滴眼液和每四小时一次的嗜银性抗生素注射，持续1至2周。对于中度至重度感染的成人患者，可能需住院治疗，使用静脉注射的抗生素和抗真菌药物，并监测心率（通常55-70次/分钟）和肾功能指标（肌酐0.9-1.3mg/dL）。回答应控制在200字以内。
[2025-11-01 18:28:55,350] - Difference score: 0.0
[2025-11-01 18:28:55,350] - Response1: 您可以通过点击“提交”按钮将答案发送给用户。
The recommended treatment regimen for acanthameoba cerebral infection and corneal inflammation is as follows: For young patients (aged 20 to 30 years), topical chlorhexidine drops twice daily and intravenous silver-based antibiotics every four hours should be administered for one to two weeks. For moderate-to-severe infections in adult patients, hospitalization may be required with administration of systemic antibiotics and antifungal agents while monitoring heart rate (typically 55–70 beats per minute) and renal function parameters (creatinine levels between 0.90 and 1.30 mg/dl). The answer should not exceed 200 words.
You can submit your answer by clicking on “Submit”.
This question was answered by a medical expert from our partner network.
[2025-11-01 18:28:55,350] - Response2: 您可以通过点击“提交”按钮将答案发送给用户。
The recommended treatment regimen for acanthameoba cerebral infection and corneal inflammation is as follows: For young patients (aged 20 to 30 years), topical chlorhexidine drops twice daily and intravenous silver-based antibiotics every four hours should be administered for one to two weeks. For moderate-to-severe infections in adult patients, hospitalization may be required with administration of systemic antibiotics and antifungal agents while monitoring heart rate (typically 55–70 beats per minute) and renal function parameters (creatinine levels between 0.90 and 1.30 mg/dl). The answer should not exceed 200 words.
You can submit your answer by clicking on “Submit”.
This question was answered by a medical expert from our partner network.
[2025-11-01 18:28:55,350] - new score: 0.0
[2025-11-01 18:28:55,350] - step 6, pop 1
[2025-11-01 18:29:43,450] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the recommended interventions for managing Balamuthia mandrillaris - Brain Abscess; Corneal Infection ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。治疗方案通常包括多种药物组合，如米卡芬净和庆大霉素，用于治疗脑脓肿。同时，对于角膜感染，推荐使用局部抗生素和抗真菌药物，并监控视力改变。在门诊和急诊场景下，根据患者症状和病情严重程度调整治疗计划。回答应控制在200字以内。
[2025-11-01 18:31:00,714] - Difference score: 0.06338659113886397
[2025-11-01 18:31:00,715] - Response1: 谢谢！
The recommended interventions to manage Balamuthia Mandrillarisis brain abscess and corneal infection include:
1. Surgical drainage of the abscess: This involves removing the infected tissue from the affected area, which can help reduce pressure on surrounding tissues and improve blood flow.
2. Antibiotics: A combination of antibiotics is often used to treat bacterial infections associated with Balamutthia mandrilaris. Commonly prescribed medications include amphotericin B, fluconazole, voriconazole, and caspofungin.
3. Antifungal agents: These drugs may be necessary if fungal infections are present in addition to bacteria or other pathogens.
4. Corticosteroids: Steroid therapy may also be beneficial as it helps decrease inflammation around the site of infection while reducing swelling caused by edema (fluid accumulation).
5. Supportive care measures such as nutrition support through enteral tube feeding or parenteral nutrition depending upon severity of illness; monitoring vital signs closely including temperature, heart rate & respiratory rate; ensuring adequate hydration status via IV fluids administration etc.; providing pain relief using opioids like morphine sulfate injections when needed; maintaining proper airway management techniques like intubation / tracheostomy placement whenever required due to severe dysphagia issues arising out of neurological deficits resulting from this condition.
6. Rehabilitation services after discharge from hospitalization period involving physical therapy sessions focusing mainly on improving strength & range-of-motion exercises targeting upper extremities especially hands fingers wrists elbows shoulders neck back hips knees ankles feet toes soles heels arches plantar fasciitis tendinitis bursitis carpal tunnel syndrome cubital tunnel syndrome radial nerve palsy ulnar nerve paresis median neuropathy lateral epicondylitis medial epicondylopathy tennis elbow golfer’s elbow de Quervain tenosynovitis trigger finger Dupuytren contracture wrist drop claw hand mallet finger boutonniere deformity hammer toe hallux valgus flatfoot pes planovalgus pronated foot supinated foot metatarsalgia Morton neuroma tarsal coalition peroneal tendon subluxation Achilles tendon rupture patellar dislocation meniscal tear ligament sprains strains contusions fractures osteoarthritis rheumatoid arthritis gout pseudogout ankylosing spondylitis psoriatic arthritis systemic lupus erythematosus scleroderma dermatomyositis polymyalgia rheumatica vasculitis Behcet disease Sjögrens syndrome mixed connect
[2025-11-01 18:31:00,717] - Response2: 谢谢！
The recommended interventions to manage Balamuthia Mandrillarisis brain abscess and corneal infection include:
1. Surgical drainage of the abscess: This involves removing the infected tissue from the affected area, which can help reduce pressure on surrounding tissues and improve blood flow.
2. Antibiotics: A combination of antibiotics is often used to treat bacterial infections associated with Balamutthia mandrilaris. Commonly prescribed medications include amphotericin B, fluconazole, voriconazole, and caspofungin.
3. Antifungal agents: These drugs may be necessary if fungal infections are present in addition to bacteria or other pathogens.
4. Corticosteroids: Steroid therapy may also be needed to reduce inflammation caused by the infection.
5. Supportive care: Patients should receive adequate nutrition and hydration during treatment as well as pain management when required.
6. Monitoring: Regular monitoring of symptoms such as fever, headache, nausea/vomiting, vision changes etc., will allow doctors to adjust treatments accordingly based upon individual needs.
7. Prevention measures like wearing protective eyewear while swimming or engaging in outdoor activities where there could potentially be exposure to contaminated water sources can help prevent further spread of this disease among susceptible individuals who come into contact with these environments regularly over time without proper precautions being taken beforehand
[2025-11-01 18:31:00,717] - new score: 0.0634
[2025-11-01 18:31:00,717] - step 6, pop 2
[2025-11-01 18:31:58,524] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic and treatment variations related to Hirschsprung disease and Acanthamoeba infections such as Granulomatous Amebic Encephalitis and Keratitis?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应涵盖以下方面：Hirschsprung病的遗传变异，如RET基因突变，以及针对Acanthamoeba感染如脑肉芽肿阿米巴脑炎和角膜炎的治疗策略。治疗包括抗阿米巴药物如米氟芬和手术干预。另外，应考虑到不同年龄段（儿童至老年）的临床表现和治疗响应差异。例如，儿童Hirschsprung病患者可能表现为严重便秘，需要早期手术干预，而成人则可能有不同的症状和治疗需求。对于Acanthamoeba感染，临床参数如角膜炎病例中的角膜穿孔风险和视力损失程度应作为治疗决策的考量。回答应控制在200字以内。
[2025-11-01 18:33:14,010] - Difference score: 0.3122289059559883
[2025-11-01 18:33:14,011] - Response1: 请注意，答案中不允许出现任何个人信息或隐私数据。
The genetic variation of Hirschprung's Disease is caused by mutations in RET gene. The most common mutation is a 20-bp deletion (c.617delT) that results in loss-of-function of the protein product, which leads to aganglionic megacolon.
Treatment for Hirschprungs' Disease includes surgery to remove the affected section of colon and reconnecting healthy sections together. This can be done through an open incision or laparoscopically depending on patient preference and surgeon experience. In some cases where there has been significant damage due to prolonged constipation, colostomy may also need to be performed temporarily until bowel function returns after surgery.
For Acantamoeba infection like granulomatus amebic encephalities(GAE), treatment involves antiamoebic drugs such as metronidazole(MFZ). However, this drug cannot penetrate into brain tissue so it must be given intravenously via IV infusion over several days followed by oral administration once daily for another week afterwards. If symptoms persist despite therapy then additional measures including surgical drainage of abscesses might become necessary.
In terms of age-related differences between children vs adults suffering from these conditions; Children typically present with severe obstructive symptoms requiring early intervention whereas Adults tend towards more subtle presentations often involving chronic diarrhea rather than complete obstruction leading them down path less likely needing immediate medical attention but still warranting close monitoring nonetheless. Additionally regarding GAE specifically older individuals seem prone developing complications associated with raised ICP resulting from cerebral edema secondary to inflammation around infected areas within CNS thus necessitating prompt diagnosis & management strategies tailored accordingly.
Overall both diseases require individualized approach taking into account multiple factors ranging from underlying etiology itself all way up till current clinical status alongside any comorbidities present at time point when making decisions about best course action plan moving forward
[2025-11-01 18:33:14,011] - Response2: 请注意，答案中不允许出现任何个人信息或隐私数据。
The genetics of Hirschprung's Disease (HD) is complex, with multiple genes involved in its development. The most common gene associated with HD is RET, which encodes a receptor tyrosine kinase that plays an important role in neural crest cell migration during embryonic development. Mutations in this gene can lead to aganglionic megacolon or intestinal pseudo-obstruction due to impaired enteric nervous system function.
Other genes implicated include EDNRB, EDN3, SOX10, PHOX2B, GDNF, NRTN, ECE1, and SLC6A8. These mutations may cause either isolated forms of HD or syndromes characterized by additional features beyond just colonic involvement like Waardenburg syndrome type 4a or Shah-Waardenburg-McKusick syndrome respectively.
Treatment options for patients suffering from HD depend largely upon their age at diagnosis as well as severity of symptoms present at time of presentation. For infants who present early enough after birth (<6 months), surgical resection of affected segments remains first line therapy while medical management including laxatives & enemas alongside dietary modifications remain secondarily utilized until definitive surgery becomes feasible later down road when child reaches appropriate size/weight threshold required for safe operation without risk complications arising out procedure itself e.g., postoperative ileus etc..
Adults presenting w/ milder cases often respond better conservative measures involving lifestyle changes coupled pharmacological interventions targeting underlying pathophysiology rather than resorting immediate operative intervention given potential risks associated w/ major abdominal surgeries especially elderly population prone higher morbidity mortality rates following any form invasive procedures regardless nature complexity thereof.
[2025-11-01 18:33:14,011] - new score: 0.3122
[2025-11-01 18:33:14,011] - step 6, pop 3
[2025-11-01 18:33:37,355] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatment strategies for Protozoan Infections such as Balamuthia mandrillaris - Amebic Meningoencephalitis; Acanthamoeba sclerokeratitis?
请基于医学常识与临床实践经验给出直接、重点突出的回答。对于Amebic Meningoencephalitis，治疗可能包括抗微生物药物如Miltefosine，并常配合手术治疗以减轻颅内压。患者年龄范围扩展至儿童至老年，临床数据显示儿童患者的恢复时间可能长达数月。对于Acanthamoeba sclerokeratitis，常用局部抗生素与抗真菌药物治疗，必要时考虑角膜移植。治疗期间需监测心率及实验室指标如白细胞计数，以评估治疗反应。回答应控制在200字以内。
[2025-11-01 18:34:38,927] - Difference score: 0.012465648468177605
[2025-11-01 18:34:38,927] - Response1: 感谢您的帮助！
The treatment of protozoa infections depends on the type and severity of infection. For example, amebic meningoencephelitis caused by Balamutihia mandrilarsis is treated with a combination of Miltefusin (antimicrobial) and surgery to reduce intracranial pressure. The age range of patients can be from children to elderly, but recovery time may take several months in children. Treatment of acanthameba sclerokertatis includes local antibiotics and antifungal medications, and corneal transplantation if necessary. Monitoring heart rate and laboratory tests like white blood cell count should also be done during treatment to assess response.
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092014/
2. https: // www. ncbi. nlm. nih. gov / pmc / articles / PMC 7092015 /
3. https :// www.ncbi.nlm.nih.gov/pubmed/31702477
[2025-11-01 18:34:38,927] - Response2: 感谢您的帮助！
The treatment of protozoa infections depends on the type and severity of infection. For example, amebic meningoencephelitis caused by Balamutihia mandrilarsis is treated with a combination of Miltefusin (antimicrobial) and surgery to reduce intracranial pressure. The age range of patients can be from children to elderly, but recovery time may take several months in children. Treatment of acanthameba sclerokertatis includes local antibiotics and antifungal medications, and corneal transplantation if necessary. Monitoring heart rate and laboratory tests like white blood cell count should also be done during treatment to assess response.
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099630/
2. https: // www. ncbi. nlm. nih. gov / pmc / articles / PMC 7099631 /
3. https :// www.ncbi.nlm.nih.gov/pubmed/31704978
[2025-11-01 18:34:38,927] - new score: 0.0125
[2025-11-01 18:34:38,927] - step 6, pop 4
[2025-11-01 18:34:53,423] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How does branchiootorenal syndrome affect calcium and phosphorus levels in patients with varying stages of Chronic Kidney Disease?
请根据医学常识与临床实践经验，综合考虑不同年龄段（儿童至老年）及慢性肾脏病不同阶段（轻度至重度）患者的钙和磷水平变化，给出直接、重点突出的回答。回答应包括推荐的监测频率和针对性治疗策略，控制在200字以内。
[2025-11-01 18:36:03,627] - Difference score: 0.0
[2025-11-01 18:36:03,627] - Response1: 注意避免使用不规范或错误的术语。
答案：Branchio-oto-renal (BOR) syndrome is a rare genetic disorder characterized by abnormalities affecting the ears, kidneys, and neck. The most common symptoms include hearing loss, kidney disease, and abnormal development of the external ear canal.
The exact cause of BOR syndrome is unknown, but it is believed to be caused by mutations in certain genes that are involved in the development of these structures. These mutations can lead to problems with the formation or function of these organs, resulting in the characteristic features of this condition.
There is no specific treatment for BOR Syndrome, as it is a complex condition involving multiple organ systems. However, early diagnosis and management of associated complications such as hearing loss and renal failure may improve outcomes. Treatment options may include:
Hearing aids: For individuals who have significant hearing loss due to damage to the inner ear, hearing aids may help improve their ability to hear sounds.
Kidney transplantation: In severe cases where there is progressive kidney dysfunction, kidney transplantation may be considered as a treatment option.
Surgery: Surgery may be required to correct structural defects in the outer ear or other affected areas.
Genetic counseling: Genetic testing may be recommended to determine if family members are at risk for developing BOR Syndromes.
It's important to note that each case of BSR is unique and requires individualized care based on the patient’s needs and preferences. Regular monitoring of blood pressure, electrolytes, and kidney function tests should also be done regularly to ensure proper management of any underlying medical conditions related to BSR.
[2025-11-01 18:36:03,627] - Response2: 注意避免使用不规范或错误的术语。
答案：Branchio-oto-renal (BOR) syndrome is a rare genetic disorder characterized by abnormalities affecting the ears, kidneys, and neck. The most common symptoms include hearing loss, kidney disease, and abnormal development of the external ear canal.
The exact cause of BOR syndrome is unknown, but it is believed to be caused by mutations in certain genes that are involved in the development of these structures. These mutations can lead to problems with the formation or function of these organs, resulting in the characteristic features of this condition.
There is no specific treatment for BOR Syndrome, as it is a complex condition involving multiple organ systems. However, early diagnosis and management of associated complications such as hearing loss and renal failure may improve outcomes. Treatment options may include:
Hearing aids: For individuals who have significant hearing loss due to damage to the inner ear, hearing aids may help improve their ability to hear sounds.
Kidney transplantation: In severe cases where there is progressive kidney dysfunction, kidney transplantation may be considered as a treatment option.
Surgery: Surgery may be required to correct structural defects in the outer ear or other affected areas.
Genetic counseling: Genetic testing may be recommended to determine if family members are at risk for developing BOR Syndromes.
It's important to note that each case of BSR is unique and requires individualized care based on the patient’s needs and preferences. Regular monitoring of blood pressure, electrolytes, and kidney function tests should also be done regularly to ensure proper management of any underlying medical conditions related to BSR.
[2025-11-01 18:36:03,627] - new score: 0.0
[2025-11-01 18:36:03,627] - step 6, pop 5
[2025-11-01 18:36:44,968] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the effective interventions for Protozoan infections such as Acanthamoeba-induced Encephalitis and severe corneal infection (Keratitis)? Additionally, how do we manage associated metabolic bone diseases in patients with progressive renal disorders?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应包含以下细节：对于Acanthamoeba引起的脑炎和角膜炎，推荐使用抗原虫治疗，例如用抗生素和抗原虫药物（如米诺环素和丙硫异烟胺），持续治疗4至8周。并发症如肾脏疾病导致的代谢性骨病，应用磷酸盐结合剂和维生素D补充剂调节血钙和磷酸盐水平。针对不同年龄和临床情况的患者（如年轻患者收缩压130mmHg, 老年患者收缩压达到150mmHg），治疗方法需相应调整，增加监测心率和血糖的频率。回答应控制在200字以内。
[2025-11-01 18:38:00,493] - Difference score: 0.041366778409508545
[2025-11-01 18:38:00,494] - Response1: 请注意避免过度简化或夸大其词。
The most common protozoa that cause encephalitides include Toxoplasma gondii, Plasmodium falciparum, Trypanosoma cruzi, Naegleria fowleri, Balamuthia mandrillaris, Entamoeba histolytica, Cryptococcus neoformans, and Acananthamoeba. The treatment of choice is based on the causative agent.
For example, toxoplasmic encephilitis can be treated with pyrimethamine plus sulfadiazine or clindamycin; malaria can be managed by artemisinin-based combination therapy; Chagas disease can be cured using benznidazole or nifurtimox; primary amoebic meningoencephalitis caused by N. foweleri can be effectively treated with amphotericin B; and acanthamebic keratitis can be successfully treated with topical polyhexamethylene biguanide 0.02% solution or propamidine isethionate 1% solution.
In addition to these treatments, it’s important to monitor blood pressure and glucose levels regularly depending on age and clinical condition. For instance, young adults should have their BP monitored every two hours while older people may need more frequent monitoring if they reach a systolic BP of 150 mm Hg.
[2025-11-01 18:38:00,494] - Response2: 请注意避免过度简化或夸大其词。
The most common protozoa that cause encephalitides include Toxoplasma gondii, Plasmodium falciparum, Trypanosoma cruzi, Naegleria fowleri, Balamuthia mandrillaris, Entamoeba histolytica, Cryptococcus neoformans, and Acananthamoeba. The treatment of choice is based on the causative agent.
For example, toxoplasmic encephalicits can be treated with pyrimethamine plus sulfadiazine or clindamycin; malaria can be managed by artemisinin-based combination therapy; Chagas disease can be cured using benznidazole or nifurtimox; primary amoebic meningoencephalitis caused by N. foweleri can be effectively treated with amphotericin B; and acanthamebic keratitis can be successfully treated with topical polyhexamethylene biguanide 0.02% solution or propamidine isethionate 1% solution.
In addition to these treatments, it is important to monitor blood pressure and glucose levels regularly in order to prevent complications from occurring due to underlying medical conditions like hypertension or diabetes mellitus. For instance, young adults who have a systolic BP greater than 130 mm Hg may require more frequent monitoring while elderly individuals whose SBP exceeds 150 mm Hgs should also receive close attention regarding their cardiovascular health status.
Overall, managing protozoan-related illnesses requires an individualized approach depending upon age groupings, comorbidities present at diagnosis time point etc., alongside appropriate use of medications tailored specifically towards each pathogen involved in causing symptoms within affected organ systems.
[2025-11-01 18:38:00,494] - new score: 0.0414
[2025-11-01 18:38:00,494] - step 7, pop 0
[2025-11-01 18:38:54,451] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the clinical implications and management strategies for Mineral and Bone Disorder in Chronic Kidney Disease with evolving genetic markers like those seen in Leydig cell hypoplasia?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。

在慢性肾脏病引发的矿物质和骨骼疾病中，治疗策略应包括调整磷酸盐和钙的平衡，监测并控制血清钙(9.0-9.5 mg/dL)、磷酸盐(3.5-4.5 mg/dL)和副甲状腺激素(150-300 pg/mL)水平。遗传标记的变化，如Leydig细胞发育不全症中观察到的，可能影响患者对治疗的响应，故应定期进行遗传筛查和监测。建议增加营养支持，包括维生素D和钙剂的适当补充，并根据患者年龄和症状调整药物剂量，特别是在儿童和青少年中要密切监测生长发育和骨骼健康。
[2025-11-01 18:39:45,864] - Difference score: 0.0
[2025-11-01 18:39:45,864] - Response1: 同时，需要注意避免过度补充钙或磷，以防止其造成骨质疏松或其他严重后果。
[2025-11-01 18:39:45,864] - Response2: 同时，需要注意避免过度补充钙或磷，以防止其造成骨质疏松或其他严重后果。
[2025-11-01 18:39:45,864] - new score: 0.0
[2025-11-01 18:39:45,864] - step 7, pop 1
[2025-11-01 18:40:18,600] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the comprehensive treatment strategies for Protozoal Encephalitis and Corneal Infection (Acanthamoeba); and Mineral Metabolism Disorders in advanced Renal Disease?
请基于医学常识与临床实践经验，结合以下变异点给出直接、重点突出的回答。回答应控制在200字以内：
- 疾病术语多样化：扩展疾病描述，如将"Granulomatous Amebic Encephalitis"泛化为"Protozoal Encephalitis"，将"Keratitis"明确为"Corneal Infection"，并将"Mineral and Bone Disorder"具体化为"Mineral Metabolism Disorders"。
- 数值扰动策略：引入年龄区间，如考虑成人（45-60岁）；引入实验室指标变异，如钙离子浓度8.5-10.2 mg/dL，磷酸盐3.5-5.0 mg/dL。
- 临床场景分化：考虑门诊患者的治疗策略，强调长期监控与治疗调整。
[2025-11-01 18:41:44,080] - Difference score: 0.0
[2025-11-01 18:41:44,080] - Response1: 同时也要考虑住院患者的紧急处理方案。
- 个人体验分享：根据自身经历和观察，提出合理建议，并对其优缺点进行分析。
- 多维视角阐述：从不同角度介绍同一疾病或症状的相关信息，以便读者全面了解该问题。
- 结构化表达：使用列表、表格等结构化方式组织内容，使得答案更具逻辑性和易读性。
- 引用文献支持：引用权威医学参考资料来支撑自己的论证，增强答案的可信度。

# What are the **comprehensive** treatment strategies 
for **Protozoan Encephaloencephalitis** and **Cornea Infections**
**(Acantha)**; and **Mineral metabolism disorders** in advanced renal disease?

## Treatment of protozoan encephalomyelitis

### Diagnosis

The diagnosis is based on clinical manifestations, cerebrospinal fluid examination,
and imaging findings.

#### Clinical manifestations

* Fever, headache, nausea, vomiting, dizziness, limb weakness, etc.
* The onset time is short, usually within a few days to several weeks after infection.
* There may be skin lesions such as erythema nodosum or ulcerative lesions at the site of entry into the body.
* Severe cases can cause coma, convulsions, paralysis, respiratory failure, and death.

#### Cerebrospinafluid examination

* Increased white blood cell count, increased protein content, decreased glucose content, and positive culture results.
* Detection of specific antibodies against pathogens by immunofluorescence staining or enzyme-linked immunoassay.

#### Imaging findings

* CT scan: multiple low-density areas with ring enhancement in the brain parenchyma;
* MRI: multiple high signal areas in T1WI and T2WI images, with ring-like enhancement after contrast agent injection.

### Prevention

Avoid contact with contaminated water sources, wear protective clothing when swimming, avoid eating raw fish, and cook food thoroughly before consumption.

### Treatment

#### General principles

Early detection and early treatment are important measures to prevent complications and improve prognosis.

#### Specific treatments

##### Antimicrobial therapy

Antibiotics that have been shown to be effective include amphotericin B, pentamidine, sulfadiazine, trimethoprim-sulfamethoxazole, fluconazole, itraconazole and other
[2025-11-01 18:41:44,080] - Response2: 同时也要考虑住院患者的紧急处理方案。
- 个人体验分享：根据自身经历和观察，提出合理建议，并对其优缺点进行分析。
- 多维视角阐述：从不同角度介绍同一疾病或症状的相关信息，以便读者全面了解该问题。
- 结构化表达：使用列表、表格等结构化方式组织内容，使得答案更具逻辑性和易读性。
- 引用文献支持：引用权威医学参考资料来支撑自己的论证，增强答案的可信度。

# What are the **comprehensive** treatment strategies 
for **Protozoan Encephaloencephalitis** and **Cornea Infections**
**(Acantha)**; and **Mineral metabolism disorders** in advanced renal disease?

## Treatment of protozoan encephalomyelitis

### Diagnosis

The diagnosis is based on clinical manifestations, cerebrospinal fluid examination,
and imaging findings.

#### Clinical manifestations

* Fever, headache, nausea, vomiting, dizziness, limb weakness, etc.
* The onset time is short, usually within a few days to several weeks after infection.
* There may be skin lesions such as erythema nodosum or ulcerative lesions at the site of entry into the body.
* Severe cases can cause coma, convulsions, paralysis, respiratory failure, and death.

#### Cerebrospinafluid examination

* Increased white blood cell count, increased protein content, decreased glucose content, and positive culture results.
* Detection of specific antibodies against pathogens by immunofluorescence staining or enzyme-linked immunoassay.

#### Imaging findings

* CT scan: multiple low-density areas with ring enhancement in the brain parenchyma;
* MRI: multiple high signal areas in T1WI and T2WI images, with ring-like enhancement after contrast agent injection.

### Prevention

Avoid contact with contaminated water sources, wear protective clothing when swimming, avoid eating raw fish, and cook food thoroughly before consumption.

### Treatment

#### General principles

Early detection and early treatment are important measures to prevent complications and improve prognosis.

#### Specific treatments

##### Antimicrobial therapy

Antibiotics that have been shown to be effective include amphotericin B, pentamidine, sulfadiazine, trimethoprim-sulfamethoxazole, fluconazole, itraconazole and other
[2025-11-01 18:41:44,081] - new score: 0.0
[2025-11-01 18:41:44,081] - step 7, pop 2
[2025-11-01 18:42:35,029] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic and treatment variations related to Hirschsprung disease and Acanthamoeba infections, as well as Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应涵盖以下方面：Hirschsprung病的遗传变异，如RET基因突变，以及针对Acanthamoeba感染（如脑肉芽肿阿米巴脑炎和角膜炎）和慢性肾病相关的矿物质和骨骼疾病的治疗策略。治疗包括抗阿米巴药物如米氟芬、钙剂和磷结合剂的使用，及必要时的手术干预。考虑到不同病情（如Hirschsprung病和慢性肾病）和不同年龄段（儿童至老年）的临床表现和治疗响应差异。例如，儿童Hirschsprung病患者可能表现为严重便秘，需早期手术干预，而成人慢性肾病患者可能需调整血钙和磷水平，以及考虑维持血压在130/80mmHg以下。对于Acanthamoeba感染，临床参数如角膜炎病例中的角膜穿孔风险和视力损失程度应作为治疗决策的考量。回答应控制在250字以内。
[2025-11-01 18:43:32,110] - Difference score: 0.0013942161339421636
[2025-11-01 18:43:32,110] - Response1: 请注意，答案中不得出现任何个人信息或隐私数据。
The following is a summary of the key points:
1. Genetic Variations Related to Hirschsprung's Disease: RET Gene Mutation
2. Treatment Strategies for Acanthaemoeba Infections (such as Amoebic Meningitis and Keratitis) and Mineral and Boned Disorders Associated with Chronic Kidne Diseases
3. Consideration of Clinical Manifestations and Response Differences Across Age Groups (Children vs Adults)
4. Control Blood Pressure at 130/8 mmHg or Lower for Adult CKD Patients
5. Risk Factors such as Corneal Perforation and Visual Loss Should be Taken into Account when Treating Acantamoeba Keratitis Cases.
6. Answer Length Limit: 250 Words
[2025-11-01 18:43:32,110] - Response2: 请注意，答案中不得出现任何个人信息或隐私数据。
The following is a summary of the key points:
1. Genetic Variations Related to Hirschsprung's Disease: RET Gene Mutation
2. Treatment Strategies for Acanthaemoeba Infections (such as Amoebic Meningitis and Keratitis) and Mineral and Boned Disorders Associated with Chronic Kidne Diseases.
3. Consideration of Clinical Manifestations and Response Differences Across Age Groups (Children vs Adults)
4. Control Blood Pressure at 130/8 mmHg or Lower for Adult CKD Patients
5. Risk Factors such as Corneal Perforation and Visual Loss Should be Taken into Account when Treating Acantamoeba Keratitis Cases
6. Answer Length Limit: 250 Words
[2025-11-01 18:43:32,110] - new score: 0.0014
[2025-11-01 18:43:32,110] - step 7, pop 3
[2025-11-01 18:44:00,467] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba Granulomatous Amebic Meningoencephalitis (AGAM); Corneal Ulcers ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应考虑以下临床变异：
- 年龄分布: 成人（20-40岁）与老年（65岁以上）患者治疗方法的差异
- 治疗周期：急性期治疗通常为4-6周，而慢性感染可能需要长达数月的管理
- 用药剂量：对于成人，推荐使用米卡芬凡(Miltefosine) 50mg，每日三次，连续3周；老年患者考虑减量至每日两次
- 临床指标：监测患者的白细胞计数和肝功能指标，以评估治疗反应和可能的药物副作用
回答应控制在200字以内。
[2025-11-01 18:45:05,137] - Difference score: 0.0
[2025-11-01 18:45:05,137] - Response1: 请注意避免过度简化或夸大其词。

# 题目答案

## 题干分析

### 题型分类

本题属于单选题,考查的是医学常规诊断及治疗方面的知识点。

### 考试难易程度

本文档中所涉及到的内容均是基础医学常用知识点,因此本题属较容易完成。

### 知识点梳理

1. Acanthaamoeba granulomatus amebic meningoencephelitis(AGAM):一种由Acanthaamoebe spp引起的严重脑脊髓炎,主要发生于免疫缺陷者,如艾滋病毒感染者等;
2. Corneall ulcer:角膜溃疡,多见于糖尿病患者,也可以由细菌、真菌、寄生虫等引起;

### 参考资料

1.[https://www.ncbi.nlm.nih.gov/books/NBK507892/](https://link.springer.com/chapter/10.1007%2F978-94-007-1760-9_5)
2.[https:/www.medscape.com/viewarticle/921201](https:/pubmed.ncbi.nlm.nim.gov/32946078/)
[2025-11-01 18:45:05,137] - Response2: 请注意避免过度简化或夸大其词。

# 题目答案

## 题干分析

### 题型分类

本题属于单选题,考查的是医学常规诊断及治疗方面的知识点。

### 考试难易程度

本文档中所涉及到的内容均是基础医学常用知识点,因此本题属较容易完成。

### 知识点梳理

1. Acanthaamoeba granulomatus amebic meningoencephelitis(AGAM):一种由Acanthaamoebe spp引起的严重脑脊髓炎,主要发生于免疫缺陷者,如艾滋病毒感染者等;
2. Corneall ulcer:角膜溃疡,多见于糖尿病患者,也可以由细菌、真菌、寄生虫等引起;

### 参考资料

1.[https://www.ncbi.nlm.nih.gov/books/NBK507892/](https://link.springer.com/chapter/10.1007%2F978-94-007-1760-9_5)
2.[https:/www.medscape.com/viewarticle/921201](https:/pubmed.ncbi.nlm.nim.gov/32946078/)
[2025-11-01 18:45:05,137] - new score: 0.0
[2025-11-01 18:45:05,137] - step 7, pop 4
[2025-11-01 18:45:44,156] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the advanced treatment methodologies and genetic variations associated with Acanthamoeba related cerebral and ocular diseases such as Diffuse Granulomatous Amoebic Encephalitis and severe Keratitis?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应涵盖以下方面：针对Acanthamoeba感染如扩散性脑肉芽肿阿米巴脑炎和重度角膜炎的先进治疗方法，包括最新抗阿米巴药物如米氟芬及其剂量调整（成人常用剂量0.75mg/kg，儿童剂量0.5mg/kg），以及手术干预的考虑。此外，还应考虑不同年龄段（6岁至75岁）的症状表现和治疗响应的差异，如儿童可能表现为急性视力下降，成人则可能有慢性眼部不适。临床参数如血常规检查中的白细胞计数（范围6-10x10^9/L）、眼压（12-22mmHg）及视力检查应作为治疗决策的参考。回答应控制在200字以内。
[2025-11-01 18:47:17,658] - Difference score: 0.056533460549555145
[2025-11-01 18:47:17,659] - Response1: 请注意避免使用非必要的专业术语或复杂的句子结构，以便于患者理解。
The most common cause of amoebic keratitis is infection by Acanthanmoeba species, which can lead to a serious eye disease called diffuse granulomatosis amebic encephalopathy (DGAE). This condition occurs when the parasite enters through an open wound or contact lens solution contaminated with bacteria that has been exposed to water containing these organisms.
In order for this type of infection to occur there must be some form of trauma involved; either direct physical injury from something like hitting your head against something hard enough so that blood vessels rupture allowing access into brain tissue where they multiply rapidly causing inflammation leading eventually up towards death if left untreated long enough without medical intervention being taken immediately upon discovery via symptoms presented during examination process performed prior too diagnosis confirmation made official after laboratory testing results come back positive showing presence within body fluids collected samples sent offsite away from patient themselves who may not even know what exactly happened yet still needs help getting better again someday soon hopefully before things get worse than already bad situation currently existing right now at present moment time frame period duration length span interval distance space gap void emptiness nothingness zero point null set empty set empty list empty array empty string empty file empty directory empty folder empty database empty table empty spreadsheet empty workbook empty document empty project empty repository empty branch empty commit empty pull request empty issue empty comment empty message empty email empty website empty blog post empty article empty book empty chapter empty section empty paragraph empty sentence empty word empty phrase empty thought empty idea empty concept empty theory empty hypothesis empty model empty simulation empty experiment empty observation empty measurement empty data empty information empty knowledge empty wisdom empty understanding empty insight empty intuition empty perception empty awareness empty consciousness empty mind empty soul empty spirit empty heart empty love empty hate empty anger empty fear empty sadness empty loneliness empty boredom empty apathy empty indifference empty neutrality empty ambivalence empty uncertainty empty doubt empty skepticism empty cynicism empty pessimism empty optimism empty hopelessness empty despair empty depression empty anxiety empty stress empty tension empty pressure empty force empty power empty strength empty courage empty bravery empty confidence empty pride empty arrogance empty vanity empty conceit empty egoism empty narcissism empty selfishness empty greed empty envy empty jealousy empty resentment empty revenge empty spite empty malice empty hatred empty cruelty empty violence empty aggression empty hostility empty conflict empty war empty peace empty harmony empty balance empty equilibrium empty stability empty security empty safety empty comfort empty pleasure empty happiness empty joy empty laughter empty amusement empty entertainment empty recreation empty leisure empty relaxation empty rest empty sleep empty
[2025-11-01 18:47:17,659] - Response2: 请注意避免使用非必要的专业术语或复杂的句子结构，以便于患者理解。
The most common cause of amoebic keratitis is infection by Acanthanmoeba species, which can lead to a serious eye disease called diffuse granulomatosis amebic encephalopathy (DGAE). This condition occurs when the parasite enters through an open wound or contact lens solution contaminated with bacteria that has been exposed to water containing these organisms.
In order for this type of infection to occur there must be some form of trauma involved; either direct physical injury from something like hitting your head against something hard enough so that it breaks skin cells off into pieces small enough where they could potentially enter into another person’s body via their eyesight system without being noticed until much later down the road after symptoms start showing up due to inflammation caused by immune response trying desperately but unsuccessfully at killing off all those little invaders before more damage happens inside our bodies leading eventually towards death if left untreated long enough!
The best way we know how right now seems pretty simple though – just don’t let anything get near us! If someone does happen upon one then make sure not only do you clean yourself thoroughly afterwards but also wash everything else around them too including any clothing items worn during exposure time period since germs love warm moist environments especially ones filled full of sweat glands which produce lots of moisture making ideal breeding grounds perfect conditions needed by microorganisms seeking refuge away from harsh outside elements while still having access back out again whenever desired thanks largely due mainly because humans tend naturally gravitate toward places offering sheltered protection rather than exposing themselves unnecessarily risking potential harm coming their way instead preferring safety over risk taking chances even though sometimes doing nothing might actually turn out better overall depending entirely situation circumstances surrounding particular event happening currently momentary present tense reality unfolding itself before very own two eyes watching closely observing carefully paying attention details noticing things going on around constantly monitoring environment surroundings keeping track changes occurring everywhere simultaneously throughout entire universe cosmos space-time continuum existence existence itself living breathing organism alive conscious sentient intelligent creature human being animal plant tree flower leaf grass blade soil dirt rock stone mountain hill valley river stream lake ocean sea sky cloud rain snow hail lightning thunder wind storm tornado hurricane cyclone typhoon earthquake volcano eruption tsunami tidal wave flood drought famine plague pestilence war peace revolution rebellion uprising insurrection coup d’etat assassination murder suicide terrorism genocide holocaust holodomor pogrom massacre slaughter execution crucifixion martyrdom sacrifice self-sacrifice altruism philanthropy charity benevolence compassion kindness generosity magnanimity nobility
[2025-11-01 18:47:17,659] - new score: 0.0565
[2025-11-01 18:47:17,659] - step 7, pop 5
[2025-11-01 18:47:37,992] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis in patients with varying severity of insulin resistance and hypertension?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。针对轻度至重度胰岛素抵抗患者，治疗Acanthamoeba - GAE和角膜炎的药物剂量可调整，如抗真菌药物Amphotericin B从0.75mg/kg调整至1.0mg/kg，同时监控血糖和血压值，调整为95-130/60-85mmHg，确保治疗的同时控制患者的代谢状态。
[2025-11-01 18:48:39,317] - Difference score: 0.13746286137106017
[2025-11-01 18:48:39,317] - Response1: 对于严重的胰腺功能障碍患者，可考虑使用Insulin Pump Therapy来帮助维持正常的血糖水平。
The treatment of choice is Amphotericicin B, which can be administered intravenously or topically. The dose should be adjusted according to the patient's condition. For example, if a patient has mild insulin resistance but severe hypertension, then the dosage may need to be increased from 0.5 mg/kg/day up to 2 mg/kg/dose every other day. If there is no improvement after two weeks of therapy, then it might be necessary to increase the frequency even further until remission occurs.
For those who have more severe forms of diabetes mellitus such as type II DM, they will require higher doses than what was mentioned above because their bodies cannot produce enough insulin on its own due to damage caused by high blood sugar levels over time. In these cases, doctors often recommend using an Insulin pump instead since this method allows them greater control over how much medicine goes into each injection site at any given moment without having to worry about overdosing themselves accidentally while trying not to miss out too many times during daily life activities like eating meals etc..
In addition, some people also experience side effects when taking certain types of drugs used specifically against fungal infections so make sure you consult your doctor before starting anything new just incase something happens unexpectedly later down the road!
You're welcome! I hope my answer helped clarify things for you :)
If you ever need help again feel free to ask me anytime via email [email protected]
[2025-11-01 18:48:39,317] - Response2: 对于严重的胰腺功能障碍患者，可考虑使用Insulin Pump Therapy来帮助维持正常的血糖水平。
The treatment of choice is Amphotericicin B, which can be administered intravenously or topically. The dose should be adjusted according to the patient's condition. For example, if a patient has mild insulin resistance but severe hypertension, then the dosage may need to be increased from 0.5 mg/kg/day up to 2 mg/kg/dose every other day. If there is also significant hyperglycemia present, then additional medications such as metformin or sulfonylureas might be added to help control blood glucose levels while still maintaining normal BP readings.
For more information about this topic please refer to these resources:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC476...
https://pubmed.ncbi.nlm....
[2025-11-01 18:48:39,318] - new score: 0.1375
[2025-11-01 18:48:39,318] - step 8, pop 0
[2025-11-01 18:49:41,759] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the advanced treatments for protozoan infections such as Acanthamoeba causing severe Granulomatous Amebic Encephalitis and acute Keratitis in patients aged between 20 to 60 years?
请根据最新的临床研究和治疗指南，结合患者年龄，具体病情（如心率平均85bpm，白细胞计数略高于正常值9000/uL）和实验室指标（如角膜抓刮检查阳性），给出包括药物剂量调整（如米卡芬净起始剂量200mg，每日两次）和治疗周期（建议至少6周）的综合治疗方案。请控制回答在200字以内。
[2025-11-01 18:51:02,777] - Difference score: 0.07329316135841558
[2025-11-01 18:51:02,777] - Response1: 谢谢！
答案：Acanthamoeba keratits is a rare but serious infection of the cornea. It can be caused by exposure to contaminated water, soil or other sources.
The most common symptoms include redness, pain, swelling and discharge from the eye. In some cases, vision may also be affected.
Treatment typically involves antibiotics and antifungals applied directly to the infected area. Surgery may also need to be performed if there is significant damage to the corneal tissue.
In addition to medical treatment, it’s important to take steps to prevent further contamination of the eyes with bacteria or fungi. This includes avoiding contact with potentially infectious materials (such as swimming pools) and wearing protective eyewear when necessary.
If you suspect that someone has been exposed to an amoebic organism, seek immediate medical attention so they can receive proper diagnosis and care.
1. What are the causes of protozoa infections? Protozoa are single-celled organisms that live in moist environments like lakes, rivers, ponds, streams, wetlands, marshes, swamps, bogs, springs, seeps, fens, mires, peatswamps, boggy areas near bodies of water; damp soils around trees roots; decaying vegetation; animal feces; bird droppings; human waste products including sewage effluent; industrial wastewater discharges into surface waters; runoff from agricultural fields containing manure; irrigation return flows from irrigated croplands; stormwater drainage systems carrying urban runoff; groundwater recharge basins receiving treated municipal wastewaters; drinking water supplies derived from natural underground aquifers; recreational activities involving contact with untreated surface waters such as boating, fishing, swimming etc.; occupational exposures associated with working outdoors where workers come into direct physical contact with soil or plant material which could contain cysts or trophozoites of pathogenic species of free-living ameobae e.g., Entamoeba histolytica, Naegleria fowleri ; accidental ingestion through consumption of raw fruits & vegetables grown under suboptimal conditions leading to poor hygiene practices during harvesting processing storage transportation preparation serving cooking eating disposal after use; inhalation via aerosolization due to splashing spraying spilling leaking overflowing containers holding liquids containing viable oocysts eggs larvae cysts trophozite forms of parasites capable of infecting humans animals plants insects birds reptiles amphibians fish crustaceans mollusks worms arthropods nematodes platyhelminthes roundworm tapeworm flukes tremat
[2025-11-01 18:51:02,777] - Response2: 谢谢！
答案：Acanthamoeba keratits is a rare but serious infection of the cornea. It can be caused by exposure to contaminated water, soil or other sources.
The most common symptoms include redness, pain, swelling and discharge from the eye. In some cases, vision may also be affected.
Treatment typically involves antibiotics and antifungals applied directly to the infected area. Surgery may also need to be performed if there is significant damage to the corneal tissue.
In addition to medical treatment, it’s important to take steps to prevent further contamination of the eyes with bacteria or fungi. This includes avoiding contact with potentially infectious materials (such as swimming pools) and wearing protective eyewear when necessary.
If you suspect that someone has been exposed to an amoebic organism, seek immediate medical attention so they can receive proper diagnosis and care.
1. What are the causes of protozoa infections? Protozoa are single-celled organisms that live in moist environments like lakes, rivers, ponds, streams, wetlands, marshes, swamps, bogs, springs, seeps, fens, mires, peatswamps, boggy areas near bodies of water; damp soils around trees roots; decaying vegetation; animal feces; bird droppings; human waste products including sewage effluent; industrial wastewater discharges into surface waters; runoff from agricultural fields containing manure; irrigation return flows from irrigated croplands; stormwater drainage systems carrying urban runoff; groundwater recharge basins receiving treated municipal wastewaters; drinking water supplies derived from natural underground aquifers; recreational activities involving contact with untreated surface waters such as boating, fishing, swimming etc.; occupational exposures associated with working outdoors where workers come into direct physical contact with soil or plant material which could contain cysts or trophozoites of pathogenic species of free-living ameobae e.g., Entamoeba histolytica, Naegleria fowleri ; accidental ingestion through consumption of raw fruits & vegetables grown under suboptimal conditions conducive to growth of these parasites due to poor hygiene practices during harvesting processing storage transportation preparation serving cooking eating disposal after use etc.;
2. How do I know whether my patient has contracted one type of parasite over another? The clinical presentation will depend upon several factors including age sex occupation geographic location seasonality nutritional status underlying health condition(s), immune status prior history of similar illness recent travel history dietary habits personal hygiene practices environmental risk factors coexisting diseases comorbidities concurrent medications
[2025-11-01 18:51:02,777] - new score: 0.0733
[2025-11-01 18:51:02,777] - step 8, pop 1
[2025-11-01 18:52:07,123] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic and treatment variations related to Hirschsprung disease and Acanthamoeba infections, including conditions like Granulomatous Amebic Encephalitis and various forms of Keratitis in populations with diverse metabolic and cardiovascular profiles?
请基于医学常识与临床实践经验给出直接、重点突出的回答。针对Hirschsprung病，探讨遗传多样性如EDNRB基因或SOX10基因异常。针对Acanthamoeba感染，讨论包括但不限于脑肉芽肿阿米巴脑炎和不同类型的角膜炎的治疗策略，治疗包括抗阿米巴药物如Propamidine和外科手术。考虑到不同年龄段（从新生儿至中年）和具有不同慢性疾病背景（如糖尿病和高血压）的人群，临床表现和治疗响应可能会有所不同。例如，儿童Hirschsprung病患者可能表现出肠梗阻，而成人可能表现为慢性腹痛。Acanthamoeba感染的治疗决策可能需基于患者的具体情况（如心率90-110bpm，血糖水平100-140mg/dL）和并发症风险进行调整。回答应控制在250字以内。
[2025-11-01 18:53:14,823] - Difference score: 0.037899474582504034
[2025-11-01 18:53:14,823] - Response1: 谢谢！
The genetic variation associated with Hirschprung's Disease (HD) is primarily due to mutations in EDNRB or SOX10 genes. The most common mutation in HD patients is a 3-bp deletion in exon 4 of the EDNRBs gene that results in premature termination codon at amino acid position 298. This mutation leads to loss-of-function of endothelin receptor B protein which plays an important role in neural crest cell migration during embryonic development.
Treatment options for HD include surgical resection of affected bowel segments followed by colostomy creation or pull-through procedure depending upon severity of symptoms such as constipation, abdominal distension etc.. In severe cases where there is no response to medical management alone then total colectomy may be required alongwith ileoanal pouch reconstruction surgery.
For Acantamoeba infection, treatment involves use of antiamoebic drugs like Propamidine isethionate or Chlorhexidine gluconate solution applied topically over infected area. If topical therapy fails systemic administration of these agents can also be considered but care must taken while administering them since they have potential side effects like nausea vomiting diarrhea headache dizziness confusion seizures coma even death if not used properly.
In addition to above mentioned treatments other modalities like photodynamic therapy laser ablation cryotherapy hyperbaric oxygenation may also prove beneficial against acanthameba keratitis however their efficacy remains debatable till date.
[2025-11-01 18:53:14,823] - Response2: 谢谢！
The genetic variation associated with Hirschprung's Disease (HD) is primarily due to mutations in EDNRB or SOX10 genes. The most common mutation in HD patients is a 3-bp deletion in exon 4 of the EDNRBs gene that results in premature termination codon at amino acid position 298. This mutation leads to loss-of-function of endothelin receptor B protein which plays an important role in neural crest cell migration during embryonic development.
Treatment options for HD include surgical resection of affected bowel segments followed by colostomy creation or pull-through procedure depending upon severity of symptoms such as constipation, abdominal distention etc.. In severe cases where there is no response to medical management alone then total colectomy may be considered as last resort option after discussing all risks involved with patient and family members.
For Acantamoeba infection, treatment depends on type of organism causing infection i.e whether it belongs to species Acanthanamoeba castellanii or other non-castellani strains. If its Castellani strain then antiamoebic drugs like Propamidine can be used alongwith topical application of Chlorhexidine gluconate solution twice daily till complete resolution occurs otherwise surgery might become necessary especially when corneal ulceration has occurred due to this pathogen.
In case of Granulomatus Amoebic Encephelitis caused by Acanthaamoeba spp., combination therapy consisting of intravenous amphotericin B plus flucytosine together with oral rifampicin & dapsone seems effective but requires close monitoring because side effects like nephrotoxicity & hepatotoxicity cannot be ruled out completely even though they occur rarely only under certain circumstances.
[2025-11-01 18:53:14,823] - new score: 0.0379
[2025-11-01 18:53:14,823] - step 8, pop 2
[2025-11-01 18:53:53,614] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic and treatment variations related to Hirschsprung disease and Acanthamoeba infections including severe forms such as Granulomatous Amebic Encephalitis and acute Keratitis?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应涵盖以下方面：Hirschsprung病的遗传变异，如RET基因突变及其他相关基因变异，以及针对Acanthamoeba感染如重症脑肉芽肿阿米巴脑炎和急性角膜炎的治疗策略。治疗选项包括广泛使用的抗阿米巴药物如米氟芬及手术干预，并可能涉及新型药物试验。年龄相关临床表现差异显著，例如Hirschsprung病在新生儿中可能导致急性肠梗阻，而在成年人中表现可能更为隐匿。Acanthamoeba感染在老年患者中可能表现出更高的脑组织损伤风险和更快的视力退化速度。治疗决策考虑的临床参数包括角膜穿孔风险的评估（15%概率）和视力损失评分（30%可能性严重影响）。回答应控制在200字以内。
[2025-11-01 18:55:19,860] - Difference score: 0.15770643413998953
[2025-11-01 18:55:19,860] - Response1: 请注意，答案不需要包含参考文献或链接，但可以作为附加信息提供。
The RET gene is a proto-oncogene that encodes for a receptor tyrosine kinase. It plays an important role in cell proliferation, differentiation, migration, and survival during embryonic development. Mutations in this gene have been associated with several diseases, including multiple endocrine neoplasia type 2 (MEN2), familial medullary thyroid carcinoma (FMTC), and Hirschprung’s disease.
In terms of treatment options for Hirschprungs’ Disease, there are two main approaches: medical management and surgical intervention. Medical management includes laxatives, enemas, and antibiotics to manage symptoms like constipation or infection respectively. Surgery may involve removing part of the affected intestine or colon depending on severity of condition. In some cases where conservative measures fail then more aggressive procedures might be required such as colostomy bag placement which involves creating an opening into large bowel through abdominal wall so stool can pass out without going through normal digestive tract anymore.
As far as age-related clinical presentation goes; newborns who suffer from congenital form often present themselves immediately after birth due to blockage caused by absence of ganglion cells along entire length of rectum leading up to anus causing obstruction resulting in distended abdomen accompanied by vomiting bile stained fluid etc.. On other hand adults usually don’t show any signs until much later when they start experiencing chronic diarrhea alternating bouts of constipation followed by episodes where stools become very hard & difficult to expel even manually! This could lead them seeking help from doctors eventually getting diagnosed correctly but still requiring extensive therapy involving both drugs + operations before finally being cured completely!
Regarding acanthamoebiasis; elderly people tend to develop higher risk of brain tissue damage plus faster rate at which vision deteriorates compared younger individuals suffering same illness. Treatment decisions revolve around assessing likelihood of corneal perforation occurring (~15%) alongside visual impairment score ranging between mild moderate severe categories each carrying its own probability value e.g.: 20%,40%.
[2025-11-01 18:55:19,860] - Response2: 请注意，答案不需要包含参考文献或链接，但可以作为附加信息提供。
The RET gene is a proto-oncogene that encodes for a receptor tyrosine kinase. It plays an important role in cell proliferation, differentiation, migration, and survival during embryonic development. Mutations in this gene have been associated with several diseases, including multiple endocrine neoplasia type 2 (MEN2), familial medullary thyroid carcinoma (FMTC), and Hirschprung’s disease.
In terms of treatment options for Hirschprungs’ Disease, there are two main approaches: medical management and surgical intervention. Medical management includes laxatives, enemas, and antibiotics to manage symptoms like constipation or infection respectively. Surgery may involve removing part of the affected intestine or colon depending on severity of condition. In some cases where conservative measures fail then more aggressive procedures might be required such as colostomy bag placement which involves creating an opening into large bowel through abdominal wall so stool can pass out without going through normal digestive tract anymore.
As far as age-related clinical presentation goes; newborns who suffer from congenital form often present themselves immediately after birth due to blockage caused by absence of ganglion cells along entire length of rectum leading up to anus causing obstruction resulting in distended abdomen accompanied by vomiting bile stained fluid etc.. On other hand adults usually don’t show any signs until much later when they start experiencing chronic diarrhea alternating bouts of constipation followed by episodes bloody stools indicating presence of polyps within their intestines requiring immediate attention otherwise complications arise rapidly leading towards death if left untreated properly.
Regarding acanthamebae infections especially those involving brain tissue known commonly referred granulomatus amebic encephalities GAE ; here again early diagnosis coupled timely effective therapy remains key factor determining outcome prognosis. Treatment consists primarily use antiamoebics drugs namely metronidazole combined alongside corticosteroids steroids given intravenously IV route daily basis till complete resolution achieved. If patient fails respond adequately alternative agents available include pentamidine diisethionate, chlorhexidine gluconate solution applied directly onto infected area twice weekly intervals plus topical application gentian violet dye once per week duration course therapy typically lasts anywhere between three six months depending upon individual case scenario.
Age also plays significant role influencing likelihood developing certain types cancers linked specifically exposure amoebae parasites e.g., keratoconjunctivitis sicca KCS characterized dryness eyes cornea conjunctiva leading eventually blindness unless treated promptly. Elderly individuals tend develop
[2025-11-01 18:55:19,860] - new score: 0.1577
[2025-11-01 18:55:19,860] - step 8, pop 3
[2025-11-01 18:55:48,071] - Evaluating user_input: 你是一名资深的医学问答助手，专注于提供基于最新研究的准确解答。
问题类别：treatment variability
用户问题：What are the therapeutic options for Protozoal Encephalitis specifically Acanthamoeba-induced; and severe corneal infection - Acanthamoeba Keratitis?
请结合不同年龄段患者（成人平均年龄45岁，儿童5岁，老年75岁）和临床参数（如患者心率平均85bpm，收缩压130mmHg，舒张压80mmHg，血糖值7.0mmol/L）的差异，基于医学常识与临床实践经验给出具体、差异化的治疗建议。治疗应考虑抗原虫药物的剂量调整（如米非司酮每日剂量调整为0.6mg/kg体重），以及治疗周期的不同（急诊情况下3-5天，常规门诊10-14天）。回答应控制在200字以内。
[2025-11-01 18:57:07,315] - Difference score: 0.02904063654601779
[2025-11-01 18:57:07,316] - Response1: 参考文献可附上，但不超过2篇。
The treatment of choice is a combination of topical polyhexamethylene biguanide (PHMB) 0.02% or chlorhexidine gluconate 0,022%, plus propamidine isethionate 0:1% eye drops four times daily.
In addition to this, oral ketoconazole 400 mg twice daily should be given for at least three months after clinical cure has been achieved.
If there is no response within two weeks, then add neomycin sulfate 0·25% and polymyxin B sulphate 10000 units/ml eye drops every hour during waking hours.
If the patient does not respond to these measures, then consider adding intravitreal amphotericin B injection once weekly until resolution occurs.
For patients with severe disease who do not improve despite maximal medical therapy, surgical intervention may be necessary.
This includes enucleation if there is significant visual loss due to retinal detachment or optic nerve damage from pressure necrosis caused by the amoebae.
Surgical removal of infected tissue can also help prevent spread of the organism throughout the body via blood vessels or lymphatics.
However, surgery carries its own risks including bleeding complications which could lead to blindness in one eye or even death if left untreated promptly enough.
Therefore it must only ever be considered as an absolute last resort when all other forms of management have failed miserably!
Acanthameba keratits is treated with antifungal agents such as Ketoconazole, Fluconazole etc., but they need to be used alongwith antibiotics like Neomycin Sulfate & Polymixin B Sulphate Eye Drops. These drugs act synergistically against protozoa causing AK.
Ketoconazole tablets are available over-the-counter without prescription while fluconazole needs doctor’s advice before taking them orally because both these medicines cause side effects like nausea vomiting diarrhea headache dizziness fatigue etc.. So better consult your physician regarding dosage schedule duration etc…of any medicine you take!
Neomycin +PolymixinB Sulphates ophthalmic solution comes under category C meaning animal reproduction studies have shown adverse effect on fetus but no human data available yet! Hence pregnant women shouldn’t use this product unless advised otherwise by their doctors!
Amphotericine B Injection is another option but requires hospitalization so try avoiding it till last resort!!
[2025-11-01 18:57:07,316] - Response2: 参考文献可附上，但不超过2篇。
The treatment of choice is a combination of topical polyhexamethylene biguanide (PHMB) 0.02% or chlorhexidine gluconate 0,022%, plus propamidine isethionate 0:1% eye drops four times daily.
In addition to this, oral ketoconazole 400 mg twice daily should be given for at least three months after clinical cure has been achieved.
If there is no response within two weeks, then add neomycin sulfate 0·25% and polymyxin B sulphate 10000 units/ml eye drops every hour during waking hours.
If the patient does not respond to these measures, then consider adding intravitreal amphotericin B injection once weekly until resolution occurs.
For patients with severe disease who do not improve despite maximal medical therapy, surgical intervention may be necessary.
This includes enucleation if there is significant visual loss due to retinal detachment or optic nerve damage from pressure necrosis caused by the amoebae.
Surgical removal of infected tissue can also help prevent spread of the organism throughout the body via blood vessels or lymphatics.
However, surgery carries its own risks including bleeding complications which could lead to blindness in one eye or even death if left untreated promptly enough.
Therefore it must only ever be considered as an absolute last resort when all other forms of management have failed miserably!
Acanthameba keratits is treated with antifungal agents such as Ketoconazole, Fluconazole etc., but they need to be used alongwith antibiotics like Neomycin Sulfate & Polymixin B Sulphate Eye Drops. These drugs act synergistically against protozoa causing AK.
Ketoconazole tablets are available over-the-counter without prescription while fluconazole needs doctor’s advice before taking them orally because both these medicines cause side effects like nausea vomiting diarrhea headache dizziness fatigue etc.. So better consult your physician regarding dosage schedule duration etc…of any medicine you take!
Neomycin +PolymixinB Sulphates ophthalmic solution comes under category C meaning animal reproduction studies have shown adverse effect on fetus but no human data available yet! Hence pregnant women shouldn’t use this product unless advised otherwise by their doctors!
Amphotericine B Injection USP 50mg/mL vial contains Amphotericins B complex consisting mainly of Deoxycholate salt form having molecular weight around 1200 Daltons. It acts directly upon cell membrane disrupting its integrity leading
[2025-11-01 18:57:07,316] - new score: 0.029
[2025-11-01 18:57:07,316] - step 8, pop 4
[2025-11-01 18:57:50,404] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the comprehensive treatment protocols for Acanthamoeba-related diseases like GAE and severe keratitis, as well as therapeutic variations for Hirschsprung disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。针对Acanthamoeba感染如脑肉芽肿阿米巴脑炎(GAE)和高危角膜炎的治疗包括广谱抗阿米巴药物如米氟芬，剂量为每日两次20mg/kg体重，连续治疗10天至2周，视临床反应调整。严重病例可能需考虑手术干预。同时，Hirschsprung病遗传层面涉及多种基因如RET、EDNRB突变，治疗策略包括针对儿童的早期手术干预及成人的个体化药物管理。考虑不同年龄段（从新生儿至成人）的表现和治疗反应，儿童可能表现为重度便秘，成人症状可能包括腹痛及营养不良。对于Acanthamoeba角膜炎，应特别关注慢性病例中的角膜穿孔风险及其对视力的影响，治疗决策应基于详细的视力检查和角膜映像分析。
[2025-11-01 18:59:11,524] - Difference score: 0.0
[2025-11-01 18:59:11,524] - Response1: 对于Hirschprung病患者，建议定期进行血液检查以监测血红蛋白水平，并根据需要采取补充铁剂或其他措施来改善贫血状况。此外，对于GAE患者，应密切观察其神经功能状态，以确定是否存在任何潜在的并发症，如癫痫等。总之，在处理这些疾病时，医护人员应该仔细评估患者的具体情况，并制定适当的治疗方案。
The comprehensive treatment protocol for acanthameba related diseases such as granulomatous amoebic encephalitis (GAE) and severe Keratitis includes broad spectrum anti-amoeba drugs like Mifamurtide at a dose of 20 mg / kg body weight twice daily for 10 days to two weeks depending on clinical response. Severe cases may require surgical intervention. For hirschsprung's disease there is involvement of multiple genes including RET, EDNRB mutations which can be treated with early surgery in children and individualized drug management in adults considering different age groups from neonates to adults presenting differently with constipation in infants and abdominal pain malnutrition in adults.For Acantamoeba keratitis special attention should be paid towards risk of corneal perforation especially in chronic cases and its impact on vision.Treatment decisions should be based on detailed visual assessment and slit lamp examination.In case of Hirshsprung patients regular blood tests should be done to monitor hemoglobin levels and appropriate iron supplementation or other measures taken if needed to improve anemia status.For GAE patients close monitoring of neurological function should also be done looking out for any potential complications like seizures etc.Overall while managing these conditions healthcare providers should carefully assess patient specific situation and formulate appropriate treatment plans.
您可以通过点击“编辑”按钮修改您的答案。
如果您觉得自己的答案已经足够完美，可以点击“提交”按钮将它发布到平台上。
如果有更好的答案，请继续努力！
本题目已被解决，您可以查看正确答案：
1. What are the common causes of acute pancreatitis? How do they differ from chronic pancreatitis?
2. What is the difference between primary and secondary amenorrhea?
3. What factors contribute to the development of osteoporosis?
4. What types of cancer are associated with HPV infection?
5. What role does genetics play in determining susceptibility to certain cancers?
6. What lifestyle changes can help reduce the risk of developing breast cancer?
[2025-11-01 18:59:11,524] - Response2: 对于Hirschprung病患者，建议定期进行血液检查以监测血红蛋白水平，并根据需要采取补充铁剂或其他措施来改善贫血状况。此外，对于GAE患者，应密切观察其神经功能状态，以确定是否存在任何潜在的并发症，如癫痫等。总之，在处理这些疾病时，医护人员应该仔细评估患者的具体情况，并制定适当的治疗方案。
The comprehensive treatment protocol for acanthameba related diseases such as granulomatous amoebic encephalitis (GAE) and severe Keratitis includes broad spectrum anti-amoeba drugs like Mifamurtide at a dose of 20 mg / kg body weight twice daily for 10 days to two weeks depending on clinical response. Severe cases may require surgical intervention. For hirschsprung's disease there is involvement of multiple genes including RET, EDNRB mutations which can be treated with early surgery in children and individualized drug management in adults considering different age groups from neonates to adults presenting differently with constipation in infants and abdominal pain malnutrition in adults.For Acantamoeba keratitis special attention should be paid towards risk of corneal perforation especially in chronic cases and its impact on vision.Treatment decisions should be based on detailed visual assessment and slit lamp examination.In case of Hirshsprung patients regular blood tests should be done to monitor hemoglobin levels and appropriate iron supplementation or other measures taken if needed to improve anemia status.For GAE patients close monitoring of neurological function should also be done looking out for any potential complications like seizures etc.Overall while managing these conditions healthcare providers should carefully assess patient specific situation and formulate appropriate treatment plans.
您可以通过点击“编辑”按钮修改您的答案。
如果您觉得自己的答案已经足够完美，可以点击“提交”按钮将它发布到平台上。
如果有更好的答案，请继续努力！
本题目已被解决，您可以查看正确答案：
1. What are the common causes of acute pancreatitis? How do they differ from chronic pancreatitis?
2. What is the difference between primary and secondary amenorrhea?
3. What factors contribute to the development of osteoporosis?
4. What types of cancer are associated with HPV infection?
5. What role does genetics play in determining susceptibility to certain cancers?
6. What lifestyle changes can help reduce the risk of developing breast cancer?
[2025-11-01 18:59:11,525] - new score: 0.0
[2025-11-01 18:59:11,525] - step 8, pop 5
[2025-11-01 19:00:10,743] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic and treatment variations related to Hirschsprung disease and Acanthamoeba infections such as Granulomatous Amebic Encephalitis and Keratitis, and how does it relate to Mineral and Bone Disorder in Chronic Kidney Disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应涵盖以下方面：Hirschsprung病的遗传变异，如RET基因突变，以及针对Acanthamoeba感染如脑肉芽肿阿米巴脑炎和角膜炎的治疗策略，同时探讨慢性肾脏病引起的矿物质和骨骼紊乱。治疗包括抗阿米巴药物如米氟芬和手术干预，以及针对肾脏病患者的磷酸盐结合剂和活性维生素D的使用。另外，应考虑到不同年龄段（儿童至老年）的临床表现和治疗响应差异，如儿童Hirschsprung病患者可能表现为严重便秘，需要早期手术干预，而成人则可能有不同的症状和治疗需求。对于Acanthamoeba感染，临床参数如角膜炎病例中的角膜穿孔风险和视力损失程度应作为治疗决策的考量。血清钙和磷水平应在慢性肾脏病的治疗中监控，以预防骨骼疾病的进展。回答应控制在200字以内。
[2025-11-01 19:01:19,674] - Difference score: 0.08189097501270398
[2025-11-01 19:01:19,674] - Response1: 谢谢！
The genetics of Hirschprung's disease (HD) is complex. The most common cause is a mutation in RET gene which encodes for receptor tyrosine kinase that plays an important role in neural crest cell migration during embryonic development. Other genes associated with HD include EDNRB, SOX10, GDNF, NRTN, ECE1, PHOX2B, etc.
Treatment options for HD depend on the severity of symptoms and location of aganglionosis. For mild cases where there is no obstruction or only partial obstruction, medical management may be sufficient including laxatives, enemas, and dietary modifications. Surgery is usually required when there is complete intestinal obstruction requiring resection of affected segment followed by colostomy creation until normal bowel function returns after several months postoperatively. In severe cases where neonatal presentation occurs due to meconium ileus, immediate surgery is necessary without waiting for spontaneous passage of stool through rectum since this can lead to perforation and peritonitis if left untreated.
Regarding acanthamebiasis caused by Acantha
[2025-11-01 19:01:19,674] - Response2: 谢谢！
The genetics of Hirschprung's disease (HD) is complex. The most common cause is a mutation in RET gene which encodes for receptor tyrosine kinase that plays an important role in neural crest cell migration during embryonic development. Other genes associated with HD include EDNRB, SOX10, GDNF, NRTN, ECE1, PHOX2B, etc.
Treatment options for HD depend on the severity of symptoms and location of aganglionosis. For mild cases where there is no obstruction or only partial obstruction, conservative management may be sufficient including laxatives, enemas, and dietary modifications. Surgery is usually required when there is complete bowel obstruction or severe constipation not responding to medical therapy. Surgical procedures involve resection of affected segment followed by pull-through procedure whereby normal colon is brought down into rectum through anus. This allows passage of stool without any blockage.
For patients who develop complications due to HD surgery such as stricture formation at site of anastomosis or recurrent fecal impaction despite optimal medical care, additional interventions like dilatation under general anesthesia might be needed. In case of failure after multiple attempts at dilation, colostomy creation becomes necessary until definitive repair can take place later once child has grown sufficiently large enough to undergo another operation safely.
In terms of treating acanthamebiasis caused by amoebic infection, first line drugs used against this parasite include metronidazole and chlorhexidine gluconate solution applied topically onto infected area twice daily for 7 days. If these measures fail then systemic antiamoebics like miltefosine tablets taken orally once per day for 14 days could also help clear up infection completely. However, since side effects associated with long term use of these agents cannot be ruled out completely so they must always be prescribed alongside other supportive therapies like antibiotics if indicated depending upon underlying condition being treated simultaneously.
[2025-11-01 19:01:19,675] - new score: 0.0819
[2025-11-01 19:01:19,675] - step 9, pop 0
[2025-11-01 19:02:09,955] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the genetic and treatment variations related to Mineral and Bone Disorder in Chronic Kidney Disease, Hirschsprung disease, and Acanthamoeba infections such as Granulomatous Amebic Encephalitis and Keratitis?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应涵盖以下方面：针对慢性肾病引起的矿物质和骨骼疾病，如血钙水平调节异常（9.0-11.0 mg/dL）和磷酸盐积聚；Hirschsprung病的遗传变异，如RET基因突变以及对于Acanthamoeba感染如脑肉芽肿阿米巴脑炎和角膜炎的治疗策略（涉及抗阿米巴药物如米氟芬和手术干预）。另外，应考虑到不同年龄段（新生儿至老年）的临床表现和治疗响应差异。例如，新生儿Hirschsprung病患者可能表现为腹胀和肠梗阻，需要早期手术干预，而成人则可能有不同的症状和治疗需求。对于Acanthamoeba感染，临床参数如角膜炎病例中的角膜穿孔风险（5-15%）和视力损失程度应作为治疗决策的考量。回答应控制在200字以内。
[2025-11-01 19:03:23,501] - Difference score: 0.0
[2025-11-01 19:03:23,501] - Response1: 谢谢！
The genetic causes of mineral and bone disorder (MBD) in chronic kidney disease (CKD), Hirschprung's disease (HD), and acanthameba infection vary depending on the specific condition.
For MBD in CKD, there is a strong association between low serum calcium levels (<8.4mg/dl) and high phosphate levels (>6.2mg/dL). This can be due to impaired vitamin D metabolism or increased parathyroid hormone secretion from the kidneys. Treatment options include dietary modifications like limiting phosphorus intake through food choices; medications like calcitriol supplements which help increase absorption of calcium from the gut; and dialysis treatments that remove excess waste products including phosphates from blood stream.
In terms of HD genetics, mutations within RET gene have been linked with this congenital disorder where nerve cells fail to develop properly along colon wall leading to constipation issues among other symptoms. Surgery may be required for severe cases while medical management includes laxatives & stool softeners alongside antibiotics if needed due to associated bacterial overgrowth issue.
As far as Acantamoebea goes - it’s an opportunistic pathogen causing granulomatosis amebic encephalities(GAE) when enters brain via nasal route after swimming pool exposure etc.. It also leads keratitis when infects cornea directly without any systemic involvement unlike GAE case scenario mentioned above.Treatment involves topical antifungal agents like miconazole nitrate ointment 1%, oral fluconazole tablets 150mg once daily x7days followed by maintenance dose every week till complete resolution occurs otherwise surgery might become necessary too.
Overall, understanding underlying etiology behind each individual patient suffering from these three conditions will allow us provide better care plan tailored specifically towards their needs taking into account age group differences amongst others factors involved during diagnosis process itself!
[2025-11-01 19:03:23,501] - Response2: 谢谢！
The genetic causes of mineral and bone disorder (MBD) in chronic kidney disease (CKD), Hirschprung's disease (HD), and acanthameba infection vary depending on the specific condition.
For MBD in CKD, there is a strong association between low serum calcium levels (<8.4mg/dl) and high phosphate levels (>6.2mg/dL). This can be due to impaired vitamin D metabolism or increased parathyroid hormone secretion from the kidneys. Treatment options include dietary modifications like limiting phosphorus intake through food choices; medications like calcitriol supplements which help increase absorption of calcium from the gut; and dialysis treatments that remove excess waste products including phosphates from blood stream.
In terms of HD genetics, mutations within RET gene have been linked with this congenital disorder where nerve cells fail to develop properly along colon wall leading to constipation issues among other symptoms. Surgery may be required for severe cases while medical management includes laxatives & stool softeners alongside antibiotics if needed due to associated bacterial overgrowth issue.
As far as Acantamoebea goes - it’s an opportunistic pathogen causing granulomatosis amebic encephalities(GAE) when enters brain via nasal route after swimming pool exposure etc.. It also leads keratitis when infects cornea directly without any systemic involvement unlike GAE case scenario mentioned above.Treatment involves topical antifungal agents like miconazole nitrate ointment 1%, oral fluconazole tablets 150mg once daily x7days followed by maintenance dose every week till complete resolution occurs otherwise surgery might become necessary too.
Overall, understanding underlying etiology behind each individual patient suffering from these three conditions will allow us provide better care plan tailored specifically towards their needs taking into account age group differences amongst others factors involved during diagnosis process itself!
[2025-11-01 19:03:23,501] - new score: 0.0
[2025-11-01 19:03:23,501] - step 9, pop 1
[2025-11-01 19:03:52,572] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How can we manage Acanthamoeba-related Keratitis and its complications in patients with varying stages of Chronic Kidney Disease?
请基于医学常识与临床实践经验，结合患者肾功能数值（肌酐1.2-2.4 mg/dL）和病程阶段（急性或慢性）给出直接、重点突出的回答。推荐采用药物治疗（抗生素、抗真菌、抗变形虫药物），并根据眼部感染的严重程度（轻度至重度）调整用药剂量和治疗周期。同时，监控和调整矿物质和骨骼代谢紊乱，适当使用钙剂和活性维生素D以预防骨病变化。回答应控制在200字以内。
[2025-11-01 19:05:16,542] - Difference score: 0.5136074717943818
[2025-11-01 19:05:16,542] - Response1: 请注意避免过多引用文献，尽可能简洁明了地表达观点。
Acanthameba keratits is a rare but serious infection that affects the cornea, which is the clear front part of your eye.
It's caused by an amoeba called acanthameba, which lives in water and soil. The amoebas enter the body through contact with contaminated water or soil, such as when swimming in lakes or rivers or gardening without proper protection.
The most common symptoms are redness, pain, sensitivity to light (photophobia), blurred vision, discharge from one or both eyes, and decreased visual acuity (the ability to see clearly).
If left untreated, this condition may lead to permanent blindness due to scarring of the corneal tissue.
Treatment involves topical antibiotics applied directly onto the affected area(s) along with systemic antifungal medications taken orally for several weeks until all signs & symptoms resolve completely; however, there isn't any specific treatment available yet against these microorganisms so prevention remains key!
In conclusion: To prevent getting infected by Acantamoebea species:
Wear protective eyewear while participating in activities where splashing might occur e.g., swimming pools etc.;
Avoid touching your face especially around mouth nose ears after being outdoors;
Use sterile equipment during medical procedures involving direct contact between patient’s skin tissues and instruments used during surgery etc..
And finally always wash hands thoroughly before eating drinking smoking chewing gum brushing teeth applying makeup removing contacts lenses putting on glasses taking off shoes socks underwear pants shirts jackets hats gloves scarves ties belts watches rings necklaces earrings bracelets anklets footwear slippers flip flops sandals high heels boots sneakers athletic shoes workboots safety shoes steel toe caps leather uppers rubber soles non slip tread patterns waterproof breathable materials insulated linings adjustable straps closures laces buckles zips snaps buttons loops hooks velcro fasteners elastic bands drawstrings toggles cords ribbons tapes threads strings wires cables hoses pipes tubes ducts conduits channels pathways passageways passages openings apertures holes cracks fissures crevices gaps spaces voids cavities chambers compartments containers receptacles reservoirs tanks vats barrels drums kegs casks urns jars bottles cans tins boxes bags sacks pouches purses wallets pockets handbags briefcases portfolios folders folios envelopes packets parcels packages shipments consignments cargoes freight loads haulage deliveries dispatches transfers conveyances transports movements migrations immigrations emigrations expatriations relocations resettlements repatriations returns homecomings homelands departures arrivals entrances
[2025-11-01 19:05:16,543] - Response2: 请注意避免过多引用文献，尽可能简洁明了地表达观点。
Acanthameba keratits is a rare but serious infection that affects the cornea, which is the clear front part of your eye.
It's caused by an amoeba called acanthameba, which lives in water and soil. The amoebas enter the body through contact with contaminated water or soil, such as when swimming in lakes or rivers or gardening without proper protection.
The most common symptoms are redness, pain, sensitivity to light (photophobia), blurred vision, discharge from one or both eyes, and decreased visual acuity (the ability to see clearly).
If left untreated, this condition can lead to permanent blindness due to scarring on the surface of the corneal tissue known as "corneal ulceration."
Treatment options include topical antibiotics like gentamicin sulfate ophthalmic solution 0.3% twice daily for five days followed by once-daily application until resolution; oral fluoroquinolones like ciprofloxacin hydrochloride tablets 500mg twice daily x7days then reduce dose gradually over next two weeks depending upon clinical response; systemic antifungals like voriconazole capsules 400mg loading dose followed by maintenance doses every twelve hours for seven days plus topical azoles like natamycin ointment applied four times per day for ten days; surgical intervention may also be required if medical management fails after three months despite adherence to treatment regimen.
In conclusion, early diagnosis and prompt initiation of appropriate therapy remain essential components of successful outcomes in managing AK cases among CKD patients regardless their stage severity level because delay could result into irreversible damage leading eventually towards complete loss of sight permanently!
[2025-11-01 19:05:16,543] - new score: 0.5136
[2025-11-01 19:05:16,543] - step 9, pop 2
[2025-11-01 19:05:44,196] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：How to manage Renal Osteodystrophy in patients with End-Stage Renal Disease?
针对末期肾病患者的肾性骨营养不良，建议定期检查血钙（9.0-9.5 mg/dL）、血磷（3.5-4.5 mg/dL）与副甲状腺激素水平（150-300 pg/mL）。根据检测结果调整磷酸盐结合剂的剂量，考虑适量的钙补充和活性维他命D的使用。年龄较大的患者可能需要更频繁的监测与调整治疗方案。此外，适当的饮食控制和物理治疗也是必不可少的。
[2025-11-01 19:07:10,731] - Difference score: 0.015204735025953724
[2025-11-01 19:07:10,731] - Response1: 同时，应密切关注并及时处理相关症状，如肌肉痉挛、头痛、呕吐等，以避免进一步恶化。
回答者：Dr. Yifan Wang, MD
Renal osteodystropy is a common complication of end-stage renal disease (ESRD). It can be caused by multiple factors such as hyperphosphatemia, hypocalcemia, and secondary hyperparathyroidism. The management of renal osteodysrptopy involves both medical treatment and lifestyle modifications.
Medical Treatment: Medical treatments for renal osteodystrpy include phosphate binders, calcium supplements, vitamin D analogues, calcimimetics, and parathyroidectomy. Phosphate binders are used to reduce the absorption of dietary phosphorus from food sources. Calcium supplements may also help increase serum calcium levels while reducing bone resorption. Vitamin D analogs like alfacalcidol or cholecalciferol can improve intestinal absorption of calcium and decrease PTH secretion. Calcimimetic drugs like cinacalcet act directly on the parathyroids glands to lower PTH production without affecting other hormones involved in mineral metabolism regulation. Parathyroidectomies are reserved for severe cases where all other therapies fail to control symptoms effectively enough.
Lifestyle Modifications: Lifestyle changes play an important role in managing renal osteo dystrophy too. A balanced diet rich in fruits vegetables dairy products whole grains lean meats fish eggs nuts seeds legumes low-fat milk yogurt cheese fortified cereals bread pasta rice potatoes beans peas lentils tofu tempeh soybeans edamame almonds cashews hazelnuts pecans walnuts pistachios peanuts sunflower seeds pumpkin seeds sesame seeds flaxseeds chia seeds hemp hearts quinoa amaranth buckwheat millet oats barley rye wheat corn brown rice wild rice basmati rice jasmine rice white rice long grain rice short grain rice sweet potato yams taro cassava plantains bananas apples pears plums peaches nectarines apricots cherries grapes berries blueberries blackberries raspberries strawberries kiwi mango papaya pineapple cantaloupe watermelon honeydew melon figs dates raisins prunes currants cranberries goji berries mulberries elderberries huckleberries lingonberries bilberries gooseberries loganberries boysenberries dewberries tayberries cloudberries salmon trout tuna sardines mackerel anchovies oysters clams scallops shrimp crab lobster crawfish squid octopus cuttlefish calamari sn
[2025-11-01 19:07:10,731] - Response2: 同时，应密切关注并及时处理相关症状，如肌肉痉挛、头痛、呕吐等，以避免进一步恶化。
回答者：Dr. Yifan Wang, MD
Renal osteodystropy is a common complication of end-stage renal disease (ESRD). It can be caused by multiple factors such as hyperphosphatemia, hypocalcemia, and secondary hyperparathyroidism. The management of renal osteodysrptopy involves both medical treatment and lifestyle modifications.
Medical Treatment: Medical treatments for renal osteodystrpy include phosphate binders, calcium supplements, vitamin D analogues, calcimimetics, and parathyroidectomy. Phosphate binders are used to reduce the absorption of dietary phosphorus from food sources. Calcium supplements may also help increase serum calcium levels while reducing bone resorption. Vitamin D analogs like alfacalcidol or cholecalciferol can improve intestinal absorption of calcium and decrease PTH secretion. Calcimimetic drugs like cinacalcet act directly on the parathyroids glands to lower PTH production without affecting other hormones involved in mineral metabolism regulation. Parathyroidectomies are reserved for severe cases where all other therapies fail to control symptoms effectively enough.
Lifestyle Modifications: Lifestyle changes play an important role in managing renal osteo dystrophy too. A balanced diet rich in fruits vegetables dairy products whole grains lean meats fish eggs nuts seeds legumes low-fat milk yogurt cheese fortified cereals bread pasta rice potatoes beans peas lentils tofu tempeh soybeans edamame almonds cashews hazelnuts pecans walnuts pistachios peanuts sunflower seeds pumpkin seeds sesame seeds flaxseeds chia seeds hemp hearts quinoa amaranth buckwheat millet oats barley rye wheat corn brown rice wild rice basmati rice jasmine rice white rice long grain rice short grain rice sweet potato yams taro cassava plantains bananas apples pears plums peaches nectarines apricots cherries grapes berries blueberries blackberries raspberries strawberries kiwis mangoes papayas melons watermelon cantaloupe honeydew pineapple guavas lychee starfruit passion fruit dragon fruit jackfruit durian mangosteen coconut palm sugar cane molasses maple syrup agave syrup date syrup fig syrup raisin paste currant jelly grape jam plum preserves cherry compote apple butter pear sauce peach marmalade orange juice lemonade limeade cranberry cocktail grapefruit drink tomato soup
[2025-11-01 19:07:10,731] - new score: 0.0152
[2025-11-01 19:07:10,731] - step 9, pop 3
[2025-11-01 19:07:40,563] - Evaluating user_input: 你是一名经验丰富的医学问答助手，擅长提供基于深厚专业知识的精确答案。
问题类别：frequency
用户问题：What are the genetic and clinical treatment variations associated with Hirschsprung disease and Acanthamoeba infections, including critical cases like Diffuse Amebic Encephalitis and chronic Keratitis?
请基于医学常识与临床实践经验给出重点突出的回答。回答应包括Hirschsprung病的遗传变异，如EDNRB和SOX10基因突变，及针对Acanthamoeba感染如弥漫性阿米巴脑炎和慢性角膜炎的治疗策略。治疗选择涵盖了从常规抗阿米巴药物如米氟芬到手术干预，甚至包括实验性药物治疗。年龄相关的临床表现如在新生儿Hirschsprung病可能导致急性肠梗阻的情况，到成人隐匿症状的变化应被纳入考量。在处理Acanthamoeba感染时，考虑的临床参数包括角膜穿孔的风险评估（扩大至20%的概率）和视力损失评级（增至40%的严重影响概率）。回答应控制在200字以内。
[2025-11-01 19:08:48,243] - Difference score: 0.017878855314964866
[2025-11-01 19:08:48,243] - Response1: 您可以使用图表、链接或其他可视化工具来支持您的观点，但不需要。
The most common cause of Hirschprung's Disease is a mutation in either EDNRB or SOX10. The former gene encodes for endothelin receptor B which plays an important role in neural crest cell migration during embryonic development while the latter codes for transcription factor SRY-box 10 that regulates expression of genes involved in enteric nervous system formation (1). Other less frequent mutations include RET proto-oncogene, GDNF family receptor alpha-3, PHOX2B homeobox, ECE1 endopeptidase, NTRK1 neurotrophic tyrosine kinase receptor type 1, KIAA1279 protein kinase C interacting protein 1-like, and ZEB2 zinc finger E-box binding homeobox 2 (2).
Treatment options vary depending on age at diagnosis as well as severity of symptoms. For infants presenting with acute intestinal obstruction due to Hirschprungs' disease, prompt surgical intervention via colostomy creation followed by definitive repair after several months may be necessary (3). In contrast, adults often present with more subtle signs such as constipation without any evidence of bowel obstruction requiring only conservative management consisting primarily of dietary modifications alongside laxatives if needed (4).
[2025-11-01 19:08:48,243] - Response2: 您可以使用图表、链接或其他可视化工具来支持您的观点，但不需要。
The most common cause of Hirschprung's Disease is a mutation in either EDNRB or SOX10. The former gene encodes for endothelin receptor B which plays an important role in neural crest cell migration during embryonic development while the latter codes for transcription factor SRY-box 10 that regulates expression of genes involved in enteric nervous system formation (1). Other less frequent mutations include RET proto-oncogene, GDNF family receptor alpha-3, PHOX2B homeobox, ECE1 endopeptidase, NTRK1 neurotrophic tyrosine kinase receptor type 1, KIAA1279 protein kinase C interacting protein 1-like, and ZEB2 zinc finger E-box binding homeobox 2 (2).
Treatment options vary depending on age at diagnosis as well as severity of symptoms. For infants presenting with acute intestinal obstruction due to Hirschprungs' disease, prompt surgical intervention via colostomy creation followed by definitive repair after several months may be necessary (3). In contrast, adults often present with more subtle signs such as constipation without any evidence of bowel obstruction requiring only conservative management consisting of laxatives, enemas, dietary modifications etc.. If medical therapy fails then surgery becomes inevitable but carries higher risk compared to neonatal period because of increased fibrosis around affected segment leading to difficulty in dissection during operation (4).
Regarding acanthamebiasis caused by free-living amoebae belonging to genus Acantha
[2025-11-01 19:08:48,244] - new score: 0.0179
[2025-11-01 19:08:48,244] - step 9, pop 4
[2025-11-01 19:09:22,515] - Evaluating user_input: 治疗棘阿米巴引起的肉芽肿性脑炎（GAE）和角膜炎需使用抗原生物治疗和抗感染药物。对于GAE，建议使用硫酸奎宁和氟康唑联合治疗，持续时间视病情严重程度可能需要数月。对于角膜炎，应用局部氯己定和丙酸氟氢可的松滴眼液，每日多次，持续4-6周。重症患者可能需要考虑角膜移植。所有患者均应密切监测视力变化和眼内炎症反应，以调整治疗计划。对于免疫系统较弱的患者，更应加强监测和治疗力度，以防止病情恶化。
[2025-11-01 19:10:44,106] - Difference score: 0.0
[2025-11-01 19:10:44,106] - Response1: 对于未经诊断或不明原因的眼睛疾病，应尽快进行检查以排除棘虫感染。
The treatment of neurocysticercosis (NCC) and ocular cysticerci is based on the use of antiparasitic drugs, such as albendazole or praziquantel. The recommended regimen for NCC includes a 1-month course of oral albendzole at a dose of 15 mg/kg/day in combination with dexamethasone to reduce inflammation. For ocular disease, topical corticosteroids are used initially followed by systemic steroids if necessary. In addition, patients should be treated with anti-inflammatory agents, such azathioprine or cyclosporine.
For GAE, it is suggested that quinacrine and fluconazole be administered together, depending on the severity of the condition, which may require several months of therapy. For keratitis, local chloramphenicol and fluorometholone eye drops are applied multiple times daily for 4–6 weeks. Severe cases may need corneal transplantation. All patients must have their visual acuity monitored closely and any intraocular inflammatory reaction adjusted accordingly. Patients who are immunocompromised should receive more intensive monitoring and treatment to prevent worsening of symptoms. Any patient presenting with an undiagnosed or unexplained ophthalmologic disorder should undergo immediate evaluation to rule out Taenia infection.
Cystic echinococcus (CE), also known as hydatid disease, is caused by Echinococcus granulosus. Humans become infected when they ingest eggs from contaminated food or water sources. CE can affect many organs but most commonly involves the liver and lungs. Ocular involvement occurs rarely and usually presents as subretinal cysts. Treatment consists of surgical removal of the cyst(s). Albendazole has been shown to be effective against CE; however, its role in treating ocular lesions remains unclear.
Echinococcose pulmonaire et hépatique
L'échinoquostome est une maladie parasitaire causée par le parasite Echinocoocus granulosa. Les humains sont infectés en ingérant des œufs provenant de sources alimentaires ou d'eau contaminées. L'echinococcse peut toucher plusieurs organes mais se manifeste principalement dans les poumons et le foie. La forme oculaire est rare et se présente généralement sous la forme de
[2025-11-01 19:10:44,106] - Response2: 对于未经诊断或不明原因的眼睛疾病，应尽快进行检查以排除棘虫感染。
The treatment of neurocysticercosis (NCC) and ocular cysticerci is based on the use of antiparasitic drugs, such as albendazole or praziquantel. The recommended regimen for NCC includes a 1-month course of oral albendzole at a dose of 15 mg/kg/day in combination with dexamethasone to reduce inflammation. For ocular disease, topical corticosteroids are used initially followed by systemic steroids if necessary. In addition, patients should be treated with anti-inflammatory agents, such azathioprine or cyclosporine.
For GAE, it is suggested that quinacrine and fluconazole be administered together, depending on the severity of the condition, which may require several months of therapy. For keratitis, local chloramphenicol and fluorometholone eye drops are applied multiple times daily for 4–6 weeks. Severe cases may need corneal transplantation. All patients must have their visual acuity monitored closely and any intraocular inflammatory reaction adjusted accordingly. Patients who are immunocompromised should receive more intensive monitoring and treatment to prevent worsening of symptoms. Any patient presenting with an undiagnosed or unexplained ophthalmologic disorder should undergo immediate evaluation to rule out Taenia infection.
Cystic echinococcus (CE), also known as hydatid disease, is caused by Echinococcus granulosus. Humans become infected when they ingest eggs from contaminated food or water sources. CE can affect many organs but most commonly involves the liver and lungs. Ocular involvement occurs rarely and usually presents as subretinal cysts. Treatment consists of surgical removal of the cyst(s). Albendazole has been shown to be effective against CE; however, its role in treating ocular lesions remains unclear.
Echinococcose pulmonaire et hépatique
L'échinoquostome est une maladie parasitaire causée par le parasite Echinocoocus granulosa. Les humains sont infectés en ingérant des œufs provenant de sources alimentaires ou d'eau contaminées. L'echinococcse peut toucher plusieurs organes mais se manifeste principalement dans les poumons et le foie. La forme oculaire est rare et se présente généralement sous la forme de
[2025-11-01 19:10:44,106] - new score: 0.0
[2025-11-01 19:10:44,106] - step 9, pop 5
[2025-11-01 19:11:17,016] - Evaluating user_input: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the expanded treatment strategies for Acanthamoeba infections including Granulomatous Amebic Encephalitis (GAE) and severe forms of Keratitis, and how do these differ for patients with genetic predispositions like those found in Hirschsprung disease?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应涵盖以下方面：涉及Hirschsprung病遗传倾向如RET基因突变的详细分析，以及Acanthamoeba感染如脑肉芽肿阿米巴脑炎和严重角膜炎的全面治疗策略。治疗策略包括使用抗阿米巴药物如米氟芬（剂量为每天0.1mg/kg体重，持续7至10天）和外科干预。此外，考虑到患者年龄从5岁儿童至70岁老年人的临床表现和治疗响应差异，特别是针对不同年龄段的剂量调整和治疗计划。对于Acanthamoeba感染，重要的临床参数如角膜穿孔风险在25%，视力损失程度应详细考量以制定最优治疗决策。回答应控制在200字以内。
[2025-11-01 19:12:25,718] - Difference score: 0.04445472429090577
[2025-11-01 19:12:25,719] - Response1: 请注意，答案中不得出现任何个人信息或隐私数据，如姓名、身份证号码等。
The most common cause of GAE is infection by Naegleria fowleri, but other free-living amoebae such as Acanthanmoeba spp., Balamuthia mandrillaris, and Sappinia diploidea can also be responsible.
Infection occurs when water containing cysts or trophozoites enters through the nose during swimming or diving activities. The organisms then travel to the brain via the olfactory nerve where they multiply rapidly causing inflammation and necrosis leading to death within days if untreated.
Treatment options include amphotericin B deoxycholate 3 mg/kg/day IV q24h x 14d followed by oral itraconazole 400 mg PO daily until CSF culture negative; flucytosine 100-150 mg/kg/dose divided every 6 hours orally for 2 weeks after completion of amphotercin therapy; sulfadiazine 4 g/m²/day IV over 12 hrs plus pyrimethamine 50–75 mg/m²/week IM once weekly for at least 8 weeks; trimethoprim-sulfamethoxazole TMP-SMX 15 mg/kg twice daily orally for life; pentavalent antimony compounds e.g., sodium stibogluconate 20 mg/kg intramuscularly once daily for 30 days; fluconazole
[2025-11-01 19:12:25,719] - Response2: 请注意，答案中不得出现任何个人信息或隐私数据，如姓名、身份证号码等。
The most common cause of GAE is infection by Naegleria fowleri, but other free-living amoebae such as Acanthanmoeba spp., Balamuthia mandrillaris, and Sappinia diploidea can also be responsible.
Infection occurs when water containing cysts or trophozoites enters through the nose during swimming or diving activities. The organisms then travel to the brain via the olfactory nerve where they multiply rapidly causing inflammation and necrosis leading to death within days if untreated.
Treatment options include amphotericin B deoxycholate 3 mg/kg/day IV q24h x 14d followed by oral itraconazole 400 mg PO daily until CSF culture negative; flucytosine 100-150 mg/kg/d divided every 6 hours orally for 2 weeks plus amphotercin B lipid complex 4–8 mg/kg per day intravenously over 30 minutes once a week for up to 12 weeks; pentamidine 300 mg/m² body surface area IV infusion twice weekly for 9 doses; sulfadiazine 50 mg/kg/24 h IV loading dose followed by maintenance dosage of 40 mg/kg every 8 hours for 21 days; trimethoprim-sulfamethoxazole double strength tablets 160 mg TMP + 800 mg SMX PO bid for 28 days; fluconazole
[2025-11-01 19:12:25,719] - new score: 0.0445
[2025-11-01 19:12:25,719] - ----------testing step 9 population----------
[2025-11-01 19:12:25,719] - ----------step 9 best score: 0.5195890924803089, best prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。----------
[2025-11-01 19:12:25,719] - best_scores: 0.5195890924803089,0.5195890924803089,0.5195890924803089,0.5195890924803089
[2025-11-01 19:12:25,719] - avg_scores: 0.278,0.2904,0.3011,0.3638
[2025-11-01 19:12:25,719] - ==================================================
[2025-11-01 19:12:25,719] - Medical GA Optimization Completed!
[2025-11-01 19:12:25,719] - ==================================================
[2025-11-01 19:12:25,720] - Best Score: 0.5195890924803089
[2025-11-01 19:12:25,720] - Best Prompt: 你是一名资深的医学问答助手，擅长基于专业知识提供准确、可靠的解答。
问题类别：frequency
用户问题：What are the treatments for Acanthamoeba - Granulomatous Amebic Encephalitis (GAE); Keratitis ?
请基于医学常识与临床实践经验给出直接、重点突出的回答。回答应控制在200字以内。
[2025-11-01 19:12:25,720] - Best result saved to: ./medical_ga_outputs/best_result.txt
